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Parkinson’s disease (PD) is the second most common neurodegenerative 
disease with ≈ 145,000 people in the UK living with the disease. Most cases 
are idiopathic, with only 10-15% of cases having a known familial cause. PD 
patients are more likely to get melanoma compared to the general population. 
The mechanisms linking these diseases are not understood. LRRK2 is a 
serine/threonine kinase and is the most commonly mutated gene in familial 
PD. Hyperactivating mutations in LRRK2 cause defects in a number of 
pathways including the endolysosomal system and mitophagy. In this body of 
work, I aimed to investigate the cell biology of LRRK2 in the context of 
melanocytes and melanoma cells which express high levels of LRRK2. I have 
shown that LRRK2 is inversely related to pigmentation markers in melanoma 
cells and is upregulated in cell lines with high invasive potential. MLi-2 is a 
highly specific, commercially available inhibitor for LRRK2 kinase activity. I 
found that LRRK2 inhibition increases pigmentation in melanocytes and 
melanoma cells, suggesting that LRRK2 functions to negatively regulate 
melanogenesis. I present data showing acute LRRK2 inhibition induces rapid 
acidification of organelles in melanocytes and pigmented melanoma cells. This 
was coupled with a change in the morphology of melanosomes which is 
resolved after 24 hours of LRRK2 inhibition, at which point an increase in late 
stage pigmented melanosomes was observed. Collectively the data indicate 
that LRRK2 acts at early acidic melanosomes and late stage pigmented 
melanosomes. In addition to effects on pigmentation, I have shown LRRK2 
inhibition decreases cell mobility of non-pigmented, invasive melanoma cells. 
I also found by EM that LRRK2 inhibition increases ER-mitochondrial contact 
sites in melanocytes. 
Mutations in the retromer component VPS35 cause an autosomal dominant 
form of PD. The [D620N] mutation in VPS35 has been shown to hyperactivate 
LRRK2, indicating they operate in the same pathway. LRRK2 hyperactivation 
has been shown by others to induce a disrupted trans-golgi network (TGN). I 
have shown that the VPS35 [D620N] mutation also induces a dispersed TGN, 
further supporting a role for LRRK2 and VPS35 in common pathways. Both 
VPS35 and LRRK2 have been shown to negatively regulate Rab7, however, 
it is not known if these effects are through a common pathway or two separate 
pathways. I have generated inducible VPS35 WT and [D620N] RPE1 Flp-In 
cells, as well as pools of these Flp-In cells transduced with lentiviral constructs 
expressing wild type, hyperactive and kinase dead forms of LRRK2. I also set 
up an already established assay to measure Rab7 activity. I have generated 
and characterised these tools in detail, which provide a platform to answer 
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REPs Rab escort complex proteins  
RHEB Ras homolog enriched in brain 
RICTOR Rapamycin-independent companion of mTOR 
RILP Rab interacting lysosomal protein 
ROC-
COR Ras of complex-C-terminal of ROC 
ROS Reactive oxidative species  
SH3 SRC Homology 3 
SNARE SNAP Receptor 
SNCA Alpha-synuclein  
SNpc Substantia nigra pars compacta 
SNpr Substantia nigra pars reticular  
SVs Synaptic vesicles  
SYNJ1 Synaptojanin 1 
TFEB Transcription factor EB 
TGN Trans-Golgi network  
TIMM Trans-inner mitochondrial membrane 
TM Trans-membrane 
TOMM Trans-outer mitochondrial membrane  
TSC Tuberous sclerosis complex 
TYRP1 Tyrosinase related protein 1 
TYRP2 Tyrosinase related protein 2 
UBL Ubiquitin like  
ULK1/2 Unc-51 like autophagy activating kinase 1/2 
UPS Ubiquitin proteasome system  
UV Ultraviolet  
UVRAG UV radiation resistance-associated gene  
v-ATPase Vaculoar ATPase 
VAMP7 Vesicle associated membrane protein 7  
VARP VPS9-ankyrin-repeat protein 




WIP1 Wild-type p53-induced phosphatase 1  
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1. Chapter 1 Introduction 
1.1. Membrane Trafficking  
Membrane traffic is the complex set of processes which establish the dynamic 
membrane bound subcellular compartments which are required for normal cell 
maintenance and homeostasis. Compartmentalisation within the cell allows 
separation of various cellular activities which can be controlled by a web of 
signals and pathways. This network requires cross talk and the ability to confer 
identity to and recognise specific compartments. These trafficking events can 
facilitate the general maintenance of the cell, or drive cell type specific 
functions. Examples of the latter include the generation of melanosomes in 
melanocytes or the transport of synaptic vesicles in neuronal cells. Specific 
pathways are also integral to the cell’s ability to respond to and adapt to 
changes in the environment such as nutrient availability (e.g. GLUT4 
trafficking). 
 
One of the key principles of membrane traffic is the budding or formation of 
vesicles to transport cargos from one compartment to another, and the 
subsequent fusion with the target membrane. This requires a number of 
processes such as inducing membrane curvature to form the vesicle bud from 
the donor membrane, organisation of correct cargo to be transported, scission 
of the bud membrane to release the vesicle from the donor membrane and 
recognition of the donor membrane by the target membrane. This process is 
tightly controlled by a number of sequential events which ensures correct and 
effective trafficking of cargos (Chiang et al., 1989; Kaushik and Cuervo, 2012; 
Rothman, 1994).  
 
1.1.1. Vesicle Coat formation 
The formation of a vesicle bud requires the manipulation of the lipid bilayers 
that make up eukaryotic cell membranes. The forces acting on these 
membranes make them resistant to bending, and therefore proteins which 




(McMahon and Boucrot, 2015). It is usually a combined effort of multiple 
proteins and interactions that results in successful bud formation. 
Transmembrane proteins with a conical structure can induce curvature by 
clustering together at one site. Some proteins (e.g. Arf proteins and Sar1) can 
also insert a hydrophobic motif into the lipid bilayer between lipid head groups, 
creating a wedge which induces bending. If multiple insertions are made in 
close proximity, this can induce membrane curvature (Pucadyil and Schmid, 
2009).  
 
Coat proteins such as clathrin or coatomer components polymerise to form a 
coat around an emerging bud to induce and stabilise membrane curvature. 
Different coat proteins are associated with different trafficking routes. COPI 
coated vesicles transport cargo from the cis-Golgi to the endoplasmic 
reticulum (ER) and retrograde transport from Golgi cisternae. COPII coated 
vesicles shuttle between the ER and the Golgi. Finally, clathrin coated vesicles 
mediate endocytosis from the plasma membrane to the endosomal network 
and from the trans-Golgi network (TGN) to endosomes. Coat proteins cannot 
directly interact with the membrane but instead bind via adaptor proteins 
(Kirchhausen, 2000; Pucadyil and Schmid, 2009; McMahon and Boucrot, 
2015).  
 
1.1.2. Vesicle release and coat disassembly 
Once formed the bud must separate itself from the donor organelle, and the 
coat must be lost from the resulting vesicle. This process differs between 
vesicle types. In the case of CCVs this process requires the protein Dynamin 
(Lafer, 2002). Dynamin is a GTPase associated with CCVs. Dynamin can bind 
to membranes via a PH domain and binds to the SH3 domain of accessory 
proteins at the membrane (Pucadyil and Schmid, 2009). Dynamin GTPase 
polymerises around the neck of the vesicle before hydrolysing GTP. This 
hydrolysis drives the scission of the vesicle from the parent membrane (Takei 
et al., 1995; Marks et al., 2001; Schmid et al., 1998). Once pinched off, the 




disassembly of the clathrin coat (Ungewickell et al., 1995). Dynamin is not 
required for the scission of COPI or COPII coated vesicles. The release of the 
bud and the energy required for scission is provided by the coat polymer itself 
(Bonifacino and Glick, 2004; Kirchhausen, 2000). 
 
1.1.3. Vesicle Fusion and SNARE proteins 
SNARE [soluble NSF (N-ethylmaleimide-sensitive fusion protein) attachment 
protein receptor] proteins are a family of receptor proteins involved in vesicle 
fusion events. Originally SNARE proteins were subdivided into v-SNAREs, 
which are present on the trafficking vesicle, and t-SNAREs present on the 
target membrane. In the original model, recognition of a v-SNARE and t-
SNARE on two cognate membranes brings them within close enough 
proximity to fuse by forming a trans-SNARE complex with a 1:3 ratio of helices. 
(Fasshauer et al., 2002; Hanson et al., 1997; Lin and Scheller, 1997; Söllner 
et al., 1993). We now have better understanding of SNARE proteins and their 
interactions, and they are now divided into the subcategories Qa-, Qb-, Qc- 
and R-SNAREs. Classification is based on the residue at the position of the 
zero ionic layer of the 4-helical bundle. R-SNAREs have an Arg/R residue, 
whilst Q-SNAREs have a Gln/Q residue. The Q-SNAREs are further 
subdivided based on the amino acid sequence of their SNARE motif (Clague 
and Urbé, 2020; Jahn and Scheller, 2006; Fasshauer et al., 1998).  
 
SNARE proteins are first trafficked to the relevant compartments. Most 
SNARE proteins have a C-terminal transmembrane domain, a SNARE motif, 
and a N-terminal domain which varies between the subsets of SNARE proteins 
(Hong, 2005; Jahn and Scheller, 2006). In many (but not all) cases, when not 
in complex, SNARE motifs are unstructured. The two membranes to be fused 
are first brought together by tethering complexes. These proteins, or multi-
subunit complexes, can provide some specificity to membrane trafficking. 
Early endosome antigen 1 (EEA1) acts as a tethering complex for the 
homotypic fusion of early endosomes. It binds to Rab5 and PI3P present on 




al., 2001; Christoforidis et al., 1999). Similarly, in the fusion of endosomes with 
lysosomes, the  homotypic fusion and vacuole protein sorting (HOPS) 
tethering complex binds Rab7 on late endosomes and Arl8b on lysosomes to 
bring the two membranes into close proximity (Balderhaar and Ungermann, 
2013; Khatter et al., 2015). Finally, the exocyst complex tethers secretory 
vesicles to the plasma membrane prior to fusion (Mei and Guo, 2018) and has 
also been linked to melanosome secretion (Moreiras et al., 2020). 
 
SNARE proteins mediate membrane fusion by forming a spontaneous 
complex. The SNARE motifs associate in a four-helical bundle which is highly 
stable and formed from one of each of the subcategories of SNAREs (Yoon 
and Munson, 2018; Chen and Scheller, 2001; Hong, 2005; Jahn and Scheller, 
2006; Bonifacino and Glick, 2004). The highly stable tetra-helical complex 
helps overcome the energy barrier created by the hydrophobic forces of the 
opposing membranes. Thus, the formation of this complex may be sufficient 
to drive vesicle fusion (Yoon and Munson, 2018). Following fusion, the SNARE 
complex remains intact in the target compartment. This then disassembles by 
the combined action of NSF and SNAP proteins, which free the v-SNARE to 
recycle back for future rounds of fusion, whilst the t-SNARE remains in the 
target membrane (Bonifacino and Glick, 2004; Jahn and Scheller, 2006; Hong, 
2005; Chen and Scheller, 2001; Yoon and Munson, 2018; Morgan and 
Burgoyne, 1995). SNARE proteins belong to one of two major families which 
account for specificity in trafficking and the fusion of vesicles. For example, 
SNAP-25, synaptobrevin and syntaxin-1 form the SNARE complex involved in 
fusion of synaptic vesicles with the plasma membrane in neurons. The other 
family are the Rab proteins. Additionally, tethering complexes dock specific 
organelles to their target membranes to add additional control to trafficking 
pathways.  
 
1.1.4. Rab proteins  
Rab GTPases are a family of proteins integral to membrane trafficking. They 




number of interactors to mediate trafficking events (Zerial and McBride, 2001). 
They facilitate vesicle motility, docking and fusion with the appropriate 
membrane compartment. They were first discovered in yeast, with a major 
finding coming when Novick and Schekman identified the SEC genes 
responsible for progression through the secretory pathway in the 1980s 
(Novick et al., 1980). They discovered that Sec4 protein was a Ras like 
GTPase protein which was essential for secretion (Salminen and Novick, 
1987). This marked the identification of the first Rab protein.  Following this 
discovery, Tavitian and Zerial started cloning the mammalian homologues 
(Zahraouis et al., 1989; Chavrier et al., 1990) which were numbered in the 
order they were sequenced. Zerial later showed that different Rab proteins 
localised to different membrane compartments (Chavrier et al., 1990) (Figure 
1.1). Their discovery provided the first set of organelle specific membrane 
markers. There are 11 Rab proteins expressed in yeast and over 60 Rab family 
members identified in mammalian cells (Bock et al., 2001). This increase in 
family members is reflective of the increase in complexity, and need for more 






Figure 1.1 Localisation of Rab proteins across the 
endolysosomal system 
Rab proteins localise to distinct subcellular compartments and 
can act as organelle markers. Created with BioRender.com. 
 
1.1.5. The Rab cycle 
Like other GTPases, Rab proteins (Rabs) cycle between their active (GTP 
bound) and inactive (GDP bound) forms through cycles of GTP binding and 
hydrolysis (Figure 1.2A). A variety of proteins interact with Rabs as they go 
through this cycle. A general schematic of the Rab cycle is depicted in Figure 
1.2B. Newly formed Rabs are geranylgeranylated at their C-terminus- a 
process carried out by the Rab escort complex proteins (REPs) together with 
a geranylgeranyltransferase (GGTase). They interact non-specifically to 
modify Rab proteins, allowing their insertion into their target membrane in their 
GDP bound form (Desnoyers et al., 1996; Wu et al., 2007; Alexandrov et al., 
1994; Seabra, 1996). Once within their target membrane, Rabs can interact 
with their specific guanine nucleotide exchange factor (GEF). Rab proteins 
bind GTP and GDP with similar high affinity. Consequently, there is a low basal 
rate of dissociation. GEFs accelerate this process by changing the nucleotide 
binding site leading to dissociation of the bound GDP and the rebinding of a 
new nucleotide. Although Rab proteins have similar affinities for GDP and GTP, 




meaning GDP is replaced with GTP. (Bos et al., 2007). The binding of GTP 
causes a conformational change in the Rab protein which enables interaction 
with effector proteins to carry out downstream functions (Zerial and McBride, 
2001).  
 
Effector protein interactions are tailored to individual Rabs based on the 
functional needs of the associated organelle and trafficking events. For 
example, EEA1 is an effector for early endosome associated Rab5 (Simonsen 
et al., 1998). Inactivation of a Rab protein requires the hydrolysis of the bound 
GTP to GDP. The basal rate of GTP hydrolysis by Rab proteins is very slow. 
Therefore, hydrolysis requires interaction of Rab proteins with their respective 
GTPase activating proteins (GAPs). These can catalyse conversion of GTP to 
GDP returning the Rab to its inactive conformation (Figure 1.2A) (Bos et al., 
2007). Chaperone proteins known as GDP dissociation inhibitors (GDIs) can 
then extract the inactive membrane bound Rab protein which can then re-enter 
the cycle for further rounds of GTP binding and hydrolysis (Figure 1.2B) (Araki 
et al., 1990; Pfeffer et al., 1995). The presence of Rab proteins on distinct 
membranes allows for specificity in trafficking of cargos from one compartment 
to another. Rabs can bind to effector proteins which act to relocate vesicles to 
new parts of the cell by binding to microtubules (e.g. Rab7 effector RILP in the 
positioning of late endosomes to lysosomes). Other effectors such as tethering 
factors, bring two membranes into close proximity (e.g. the Rab7 effector 
HOPS complex in the fusion of late endosomes to lysosomes, Rab11 and the 
exocyst in the docking of secretory vesicles at the plasma membrane, or the 
Rab5 effector EEA1 in the homotypic fusion of early endosomes) (Rubino et 
al., 2000; Lin et al., 2014; Jordens et al., 2001; Van Der Kant et al., 2013). 
Once Rab proteins have docked a vesicle to its appropriate target membrane 
(acceptor membrane) SNARE proteins facilitate vesicle fusion with the 
acceptor membrane (Yoon and Munson, 2018; Chen and Scheller, 2001; Jahn 





1.1.6. Rab cascades 
Rab proteins can act in cascades, which coordinate trafficking events, 
organelle maturation and give some pathways (like the endolysosomal 
pathway) directionality. One well studied example is the progression of early 
to late endosomes in the endolysosomal system. Rab5 is a well-established 
marker for early endosomes, whereas Rab7 is localised to the late endosome. 
(Chavrier et al., 1990; Poteryaev et al., 2010). This indicates that there must 
be a so called “Rab conversion”, where the Rab identity of an organelle is 
changed during the maturation process. Two possible mechanisms were 
considered. In the first, cargos destined for lysosomal degradation were 
trafficked from a Rab5 positive compartment to a Rab7 positive compartment. 
In the second model, early endosomes exchange their Rab5 molecules for 
Rab7 in an organelle maturation step. It is now widely believed that Rab5 and 
Rab7 operate in a cascade reaction where Rab7 is recruited by active Rab5 
and activated Rab7 can switch off Rab5 activity (Rink et al., 2005). This 
cascade ensures the polarity of the endolysosomal system.  
 
1.1.7. Recruitment and activation of Rab7 in the 
endolysosomal system 
Rab7 is one of the best studied Rab proteins and is well known to localise to 
the late endosomal compartment (Bucci et al., 2000). Research has found that 
Rab7 has key roles in late endosome maturation, late endosome-lysosome 
fusion events as well as lysosome positioning through a number of effector 
proteins (Bucci et al., 2000; Guerra and Bucci, 2016). On early endosomes 
Rab5 is activated by its GEF Rabex-5. Activation of Rab5 recruits the 
phosphoinositide 3-kinase (PI3 kinase) VPS34, which exclusively generates 
PI3P. This increases the recruitment of Rab5 effector proteins such as EEA1, 
which can recruit further Rab5 molecules, generating a positive feedback 
mechanism (Mills et al., 1999; Poteryaev et al., 2010; Rojas et al., 2008; 
Rubino et al., 2000). This positive feedback loop can be interrupted by 
recruitment of another Rab5 effector, the Mon1/CCZ1 complex (Rink et al., 




activation of Rab5. Rab7 is recruited to the endosomal compartment by Mon1 
complex which also acts as a Rab7 GEF (Balderhaar and Ungermann, 2013; 
Poteryaev et al., 2010). Activated Rab7 can now bind to its effectors which 
include the HOPS complex, VPS35 and Rab interacting lysosomal protein 
(RILP) (Balderhaar and Ungermann, 2013; Rojas et al., 2008; Cantalupo et al., 
2001; Jordens et al., 2001; Stenmark, 2009). Rab7 can also recruit RabGAP-
5 which inactivates Rab5 by activating GTP hydrolysis to GDP. This targets 
Rab5 for extraction by GDI proteins, thus leaving active Rab7 alone at the late 
endosomal membrane (Del Conte-Zerial et al., 2008; Haas et al., 2005).  This 
concomitant inactivation of Rab5 and activation of Rab7 ensures the polarity 
of the endosomal pathway and is one example of how Rab proteins act in 







Figure 1.2 Rab GTPases are molecular switches which 
undergo a tightly controlled cycle of nucleotide exchange 
and hydrolysis.  
A Rab proteins cycle between their inactive GDP-bound form and 
active GTP-bound form in a cycle which requires the action of 
GEFs for exchange of GDP to GTP and GAPs for the hydrolysis 
of GTP to GDP. B Newly synthesised GDP bound Rab proteins 
are geranylgeranylated by the Rab escort complex and 
geranylgeranyl transferase before being inserted into their target 
membrane. Here they interact with a GEF which promotes 
nucleotide exchange for GTP leading to Rab activation. Active 
Rab proteins interact with effector proteins to carry out their roles 
in membrane traffic. Rab GAPs catalyse the hydrolysis of GTP to 
GDP leaving Rabs in an inactive state. Rab GDIs can extract 





1.2. The Endolysosomal system  
The endolysosomal system is a dynamic tubulo-vesicular network which 
participates in a wide array of cell functions including signalling, cell 
homeostasis, protein degradation and recycling, nutrient uptake and endocytic 
cargo control. The success of such a network is dependent on the coordinated 
action of proteins and signals which overlap and maintain distinct organelles 
and their subdomains.  
 
The pathway begins with early endosomes- membrane bound organelles 
which undergo a maturation process which is defined by distinct stages. Early 
endosomes can be operationally defined using pulse chase experiments, or 
as organelles which are slightly acidic and enriched in Rab5, Rab11 and EEA1 
(Clague, 1998). The maturation of endosomes is characterised by the number 
of intraluminal vesicles, the intraluminal pH, the transport from the cell 
periphery to the microtubule organising centre (MTOC) and the Rab proteins 
present (Hu et al., 2015; Huotari and Helenius, 2011; Helenius et al., 1983; 
Hopkins et al., 1990; Futter et al., 1996).  Early endosomes gradually undergo 
maturation to late endosomes before finally fusing with the lysosome (Hu et 
al., 2015; Jovic et al., 2010; Futter et al., 1996). 
 
1.2.1. Endocytosis  
Endocytosis is the internalisation of cargo or cargoes from outside of the cell 
in vesicles which enter into the endosomal system (Roth and Porter, 1964). 
Endocytosis can largely be split into four categories- phagocytosis, pinocytosis, 
caveolae and receptor mediated endocytosis. Internalisation typically occurs 
by an invagination of the plasma membrane which contains the desired cargo. 
This forms the beginning of a vesicle which eventually is pinched off into the 
cell’s cytoplasm (Schmid et al., 2014). The resulting endocytic vesicle can then 
join the endolysosomal system by fusion with an early endosome (Jovic et al., 





1.2.2. Early endosomes 
Early endosomes provide a sorting hub for the cell, determining the fate of 
proteins targeted to the endolysosomal system. Proteins within this pathway 
are either delivered to the lysosome for degradation, or can be recycled back 
to the plasma membrane or the TGN by retrograde transport (Jovic et al., 2010; 
Hu et al., 2015). Early endosomes have a different morphology compared with 
the later compartments of the pathway. They have tubular structures which 
extend out from the vacuolar body of the vesicle which form the basis of the 
recycling elements. These can bud off from early endosomes and traffic back 
to the TGN or the plasma membrane (Jovic et al., 2010; Naslavsky and Caplan, 
2018; Zerial and McBride, 2001; Mukherjee et al., 1997). Over time early 
endosomes increase in size as they undergo homotypic fusion and fusion 
events with endocytic vesicles. Rab proteins on early endosomes such as 
Rab5, Rab4, Rab21 and Rab11 localise to distinct microdomains which govern 
the sorting of cargos for different fates (Naslavsky and Caplan, 2018).  As early 
endosomes mature, invaginations of the membrane occur which bud off into 
the lumen to form internal vesicles. Increasing numbers of these luminal 
vesicles marks the formation of multivesicular bodies (MVBs) or late 
endosomes (Futter et al., 1996; Hopkins et al., 1990) 
 
1.2.3. Late endosomes 
As early endosomes mature into late endosomes, the complex sorting-events 
that maintain this pathway continue recycling proteins through retrograde 
transport, whilst proteins that remain in late endosomes will be degraded after 
fusion with the lysosome (Huotari and Helenius, 2011; Mukherjee et al., 1997; 
Helenius et al., 1983). The transition from early to late endosome is marked 
by a Rab switch from Rab5 to Rab7 (see section 1.1.7). Additionally, as 
vesicles progress through the endosomal pathway, they become progressively 
more acidic due to the action of vacuolar ATPase (v-ATPase), which 
establishes an acidic environment in late endosomes (Maxfield and McGraw, 
2004; Mukherjee et al., 1997)(Section 1.2.7). This reduction is integral to the 




see section 1.2.5) (Brown et al., 1986). The CIMPR is able to bind mannose-
6-phosphate (M6P) residues at the more neutral pH of the TGN and early 
endosomes (approx. 6.5). As the endosomal pathway becomes more acidic, 
the binding affinity decreases and CIMPR releases the M6P residue at pH <6. 
Therefore, by the time these vesicles arrive at late endosomes the lysosomal 
proteins are released and will continue along the endosomal pathway to the 
lysosome. Meanwhile, the CIMPR is recycled back from the late endosomal 
compartment to the TGN where it can bind another round of lysosomal 
proteins (Brown et al., 1986; Kornfeld and Mellman, 1989; Hirst et al., 1998). 
Lysosomal membrane proteins remain in the membrane of late endosomes, 
whereas trans-membrane (TM) cargos for degradation are sorted into internal 
vesicles. Late endosomes progress through the endosomal pathway until they 
reach and fuse with the lysosomal compartment. Fusion of a late endosome 
with a lysosome leads to lysosomal membrane proteins being integrated into 
the lysosome membrane, whilst vesicles and their contents to be degraded 
are released into the lysosome lumen (De Duve and Wattiaux, 1966; De Duve 
et al., 1955; Ciechanover, 2005; Futter et al., 1996). 
 
1.2.4. Lysosomes 
Lysosomes are the terminal compartment of the endolysosomal system, as 
well as the autophagy pathway. The lysosome was first discovered by 
Christian De Duve using centrifugation techniques separating a granule 
organelle containing hydrolase enzymes from mitochondria and microsomes 
(De Duve et al., 1953, 1955). The lysosome acts as the mammalian equivalent 
of the vacuole in yeast. The lysosomal system represents one of two major 
pathways by which proteins are degraded and cell homeostasis is maintained- 
the other being the ubiquitin-proteasome system (UPS) (Tanaka et al., 1983; 
Hough et al., 1986; Ciechanover, 2005; Clague and Urbé, 2020).  
Lysosomes are classically regarded as acidic organelles which contain a 
variety of proteolytic enzymes, including hydrolases, which non-selectively 
degrade proteins and organelles (Haider and Segal, 1972; De Duve et al., 




and that not all lysosomes are acidic (Bright et al., 2016; Johnson et al., 2016). 
The acidic environment of the lysosome is established and maintained by the 
v-ATPase proton pump which maintains a pH of around 4 (Schneider, 1981) 
(Section 1.2.7). Cargos destined for degradation are delivered to the lumen 
of the lysosome by the endosomal or autophagy pathways where they are 
digested by resident acid-dependent proteases. This pathway processes a 
range of cargos and serves a variety of functions to maintain the homeostasis 
of the cell and adaptation to the cellular environment. This includes degrading 
receptors taken up by endocytosis (such as epidermal growth factor receptor 
(EGFR)), misfolded or unwanted proteins within the cell, and damaged 
organelles (Futter et al., 1996; Maxfield and McGraw, 2004). Damaged 
organelles can be taken up by selective autophagy (e.g. in the case of 
damaged mitochondria-mitophagy) and the subsequent autophagosome 
fuses with the lysosome for degradation (Xie and Klionsky, 2007).  
 
In the case of cellular stress (e.g. nutrient deprivation) the lysosome can be 
used in conjunction with autophagy to ensure cell survival (Martina et al., 2012; 
Settembre and Ballabio, 2011). Organelles and proteins are enveloped non-
selectively by the autophagy machinery into autophagosomes which are then 
delivered to and fuse with the lysosome. The cargo are then degraded and 
amino acid permeases in the lysosomal membrane transfer free amino acids 
back to the cytoplasm for use in synthesis of new proteins (Yorimitsu and 
Klionsky, 2005; Xie and Klionsky, 2007). The lysosome is also a hub for mTOR 
signalling which will be discussed in more detail in section 1.2.15. 
 
1.2.5. Selective activity and delivery of lysosomal enzymes 
Because the role of lysosomal enzymes is to degrade proteins non-specifically, 
it is of great importance that they are selectively delivered to the lysosome and 
only become activated once they reach the lysosome lumen. Therefore, these 
proteins are not released into the cytoplasm but are instead trafficked in 
vesicles which join the endolysosomal system. Lysosomal hydrolases exist in 




sequence is removed and the enzymes become activated (Cooper and 
Stevens, 1996). Soluble lysosomal proteins are targeted to the lysosome by 
the CIMPR and sorting receptor sortilin (Petersen et al., 1997; Seaman, 2004). 
In the case of CIMPR, the relevant proteins are modified in the cis-Golgi 
network leaving the carbohydrate molecule mannose-6-phosphate (M6P) 
attached. In the TGN these modifications can bind the CIMPR tightly and 
specifically (Cooper and Stevens, 1996). This interaction is maintained as 
these proteins bud off into vesicles from the TGN which eventually fuse with 
endosomal compartments. The CIMPR interaction is lost in the acidic 
environment of the MVBs and is recycled back to the TGN for further rounds 
of traffic (Hirst et al., 1998). Once delivered to the lysosome the hydrolases 
are converted to their active form following a cleavage event (Gieselmann et 
al., 1985). This protects the endosomal pathway machinery as well as other 
proteins in the late endosomal compartments from being degraded until they 
have reached the lumen of the lysosome.  
 
1.2.6. The retromer complex 
The retromer complex was first discovered in yeast and was found to be 
integral to the retrograde traffic of the yeast CIMPR homolog-Vps10. Three 
members of the VPS proteins form a heterotrimeric complex which forms the 
scaffold for a number of accessory factors (Seaman et al., 1997, 1998). The 
retromer is highly conserved in higher eukaryotes and in mammalian cells the 
heterotrimeric core is made up of: VPS35, VPS26 and VPS29 (Swarbrick et 
al., 2011; Seaman, 2012). A number of other accessory proteins form transient 
interactions with the core of the retromer complex, including SNX-BAR 
proteins which are integral for the correct sorting of cargos (Seaman, 2012).  
One major function of the retromer complex is retrograde sorting and transport 
of proteins from the late endosome back to the TGN or the plasma membrane. 
As we have seen above, the recycling of the CIMPR is integral to the 
homeostasis of the lysosome in ensuring continual delivery of its functional 
enzymes. Similarly, receptors and their ligands internalised by endocytosis 




2009). Receptors are sorted for either degradation, or recycled back to the 
plasma membrane, depending on the signalling needs of the cell. The 
retromer complex is recruited to the endosomal network by Rab7 and acts as 
a Rab7 effector (Rojas et al., 2008; Seaman, 2012). The core retromer 
complex is key to sorting cargos via its interaction with the SNX proteins and 
helps to deform the endosomal membranes in the initiation and formation of 
carriers (Temkin et al., 2011; Harterink et al., 2011; Wassmer et al., 2009, 
2007).  The retromer can also recruit the WASH complex. WASH is an actin 
polymerising complex which drives the formation of subdomains at early 
endosomes, important for sorting of cargos for different fates (Gomez and 
Billadeau, 2009; Derivery et al., 2009). The core retromer complex also 
interacts with TBC1D5, a Rab7 GAP  (Seaman et al., 2009). Furthermore, as 
well as being a Rab7 effector, the retromer can also act as a Rab7 regulator. 
Retromer associated TBC1D5 can catalyse the hydrolysis of GTP to GDP, 
switching off Rab7. This is supported by data which shows knockout of VPS35 




Acidification is integral to certain membrane trafficking events and organelle 
functions. The process of acidification is carried out by the v-ATPase (Maxson 
and Grinstein, 2014). The v-ATPases are multi-subunit complexes which can 
be split into two domains, the V0 and V1 domains. In all isoforms the V0 domain 
is made up of 6 subunits and functions to translocate protons across the 
membrane. The V1 domain is composed of 8 subunits which are able to 
hydrolyse ATP (Toei et al., 2010). The energy harnessed from ATP hydrolysis 
is used to drive protons across the membrane against the proton gradient. The 
different isoforms are targeted to different organelles.  The a1 subunit has 
been implicated in the endolysosomal pathway. This is perhaps the best 
characterised acidification pathway with pH being important for both effective 
retrograde transport and lysosomal hydrolase activity (discussed in section 




undergo acidification. Melanosomes are lysosome related organelles which 
undergo a 4-stage maturation process. (Section 1.3.2). Early-stage 
melanosomes are acidified by a v-ATPase isoform containing the a3 subunit, 
however, the later stages require a neutral pH consequent to loss of the v-
ATPase (Toei et al., 2010; Tabata et al., 2008; Ancans et al., 2001).  
 
Control of the v-ATPase is central in regulating the luminal pH of organelles 
and is thought to occur at multiple levels. Dissociation of the V0 and V1 subunits 
has been reported in some organelles, which is a rapid way of regulating v-
ATPase function (Kane, 2006; Forgac, 2007). The efficiency of the v-ATPase 
at pumping protons across the membrane has been reported to vary between 
organelles and is likely isoform specific (Toei et al., 2010; Maxson and 
Grinstein, 2014). Finally, transcriptional and protein stability control of v-
ATPase can regulate the levels present in the cell and therefore its activity. v-
ATPase is under the transcriptional control of TFEB (Section 1.2.13) and is 
up regulated in response to cellular stress. The levels of RILP protein within 
the cell has also been reported to affect the recruitment and stability of the v-
ATPase (Maxson and Grinstein, 2014).  
 
Counterion channels are essential to the effective acidification. The pumping 
of protons across the membrane by the v-ATPase will increase the positive 
charge within the organelle, creating an electrochemical gradient as well as a 
pH gradient (Mills et al., 2001; Paroutis et al., 2004a; Forgac, 1998a). This 
accumulation impedes the further flux of protons and increases the leak of 
protons back across the membrane. Therefore, chloride channels are used to 
give counterions which balance out this electrochemical gradient and allow for 
further transport of protons across the membrane by the v-ATPase (Mills et al., 
2001; Paroutis et al., 2004b; Forgac, 1998b).  
 
Lysosomal acidification is essential to effective lysosomal function (Section 
1.2.5). There is a growing body of evidence implicating function of the v-
ATPase in neurodegenerative disease. Neurons are more sensitive to defects 




ATPase function have been linked to Alzheimer’s, PD and lysosomal storage 
diseases (Song et al., 2020). In particular, PD related protein LRRK2 (Section 
1.4.7) has been shown to directly interact with the a1 subunit of the v-ATPase. 
Pathogenic mutation in LRRK2 has been shown to induce a decrease in 
protein levels of the a1 subunit as well as mis-localisation (Wallings et al., 
2019a). 
 
1.2.8. Rab7 and lysosome fusion 
One of Rab7’s key functions is to mediate the fusion of late endosomes with 
the lysosome. This is a function actioned by the HOPS complex which acts as 
a downstream Rab7 effector through its associated proteins. The HOPS 
machinery and its function was first identified in yeast as a multimeric protein 
complex which acts as a tethering factor (Balderhaar and Ungermann, 2013). 
In yeast the HOPS complex binds to two Rab7 molecules (Ypt7 in yeast)- one 
on the late endosome and one on the vacuole (the yeast equivalent of the 
lysosome). In this model, Rab7 and the HOPS complex together tether the late 
endosome and lysosome (Bröcker et al., 2012)- a precursor step required for 
fusion. In yeast the HOPS complex also recruits the relevant SNARE proteins 
responsible for the actual fusion event (Lürick et al., 2015; Behrmann et al., 
2014). Although this process is still being defined in mammalian cells, there 
are some key differences from the process in yeast. The HOPS complex binds 
to a Rab7-RILP complex on late endosomes (Lin et al., 2014; Van Der Kant et 
al., 2015, 2013). RILP is a Rab7 effector, crucial for Rab7’s role in lysosome 
positioning, discussed in more detail below (Sun et al., 2009; Guerra and Bucci, 
2016; Cantalupo et al., 2001; Jordens et al., 2001). HOPS binds Arl8b GTPase 
on the lysosome to bring these two compartments into close proximity (Khatter 
et al., 2015) and allows for their subsequent fusion.  
 
1.2.9. Rab7 and lysosomal positioning 
Typically, most lysosomes are localised primarily to the microtubule organising 
centre (MTOC), although lysosomes can be found dispersed through the 




through interaction with its effector RILP. RILP can interact with the dynein-
dynactin complex (Van Der Kant et al., 2013, 2015). Cytoplasmic dynein (from 
here referred to as Dynein) is a cytoskeletal motor protein that moves along 
the microtubules. It is responsible for the retrograde transport of lysosomes 
from the cell periphery towards the cell centre (from plus to minus end of 
microtubules). Dynein interacts with dynactin, a multimeric protein complex 
made up of more than 20 components (Pu et al., 2016). Activated Rab7 on 
late endosomes and lysosomes recruits dynein-dynactin via RILP, to tether 
organelles to the cytoskeleton for their transport. (Van Der Kant et al., 2013; 
Pu et al., 2016; Jordens et al., 2001).  
 
1.2.10.  Activation of Lysosome biogenesis 
The formation of lysosomes is a tightly controlled process which can be 
upregulated depending on the degradative needs of the cell. For example, in 
cellular stress, the pathway is activated to increase the degradative capacity 
of the cell to produce more amino acids for synthesis of new proteins. This 
controlled activation requires selective transcription of lysosomal genes. Many 
of these genes are under the transcriptional control of transcription factor EB 
(TFEB) (Napolitano and Ballabio, 2016).  
 
1.2.11.  Autophagy 
Autophagy is a recycling pathway where cells digest their own proteins and 
organelles to generate building blocks for further protein synthesis and 
organelle biogenesis. Autophagy can be subdivided into macro-autophagy, 
micro-autophagy and chaperone mediated autophagy (CMA). In addition to 
these broad non-specific forms of autophagy there are also organelle specific 
forms of autophagy such as mitophagy. The terminal compartment for all 
forms of autophagy is the degradative lysosomal compartment (Klionsky, 2005; 
Wang and Klionsky, 2003; Glick et al., 2010; Dikic and Elazar, 2018).  
 
Originally, autophagy was defined by De Duve when double membrane 




1966; De Duve et al., 1953). It was subsequently shown that the degradation 
of cargo by the autophagy pathway was distinct from the endocytosis pathway 
for degradation (Essner and Novikoff, 1961; Klionsky, 2008; Kanki and 
Klionsky, 2008). At steady state, a baseline of autophagy is required to 
maintain protein and organelle homeostasis. In times of cellular stress and 
nutrient deprivation the cell responds by increasing this catabolic activity, non-
specifically digesting portions of itself. In macro-autophagy, this is done by the 
engulfment of part of the cytosol by a double membrane forming a vesicle 
called an autophagosome. Autophagosomes are trafficked to the lysosomal 
compartment where fusion of an autophagosome with a lysosome generates 
an autolysosome. Cargo delivered here is degraded by the hydrolase 
enzymes in the lysosome. In micro-autophagy, the lysosomal membrane 
generates invaginations which directly take up cytosol for degradation (Yim 
and Mizushima, 2020) (Figure 1.3).  
 
Figure 1.3 Macro and micro-autophagy pathways 
Macro-autophagy: the non-selective engulfment of cell contents 
within an isolation membrane which are delivered to the 
lysosome for degradation. Micro-autophagy: The direct 
engulfment of cellular contents by the lysosome for degradation. 





In macro-autophagy the initiating steps require the nucleation of the engulfing 
curved membrane known as a phagophore (also known as an isolation 
membrane) (Essner and Novikoff, 1961; Réz G; Meldolesi, 1980). The 
elongation of this membrane results in the formation of a spherical vesicle- the 
final step of formation being the fusion of either end of the membrane. Any 
cytosolic proteins or other materials which are captured within the 
autophagosome are trafficked along the microtubules to the lysosome (Seglen 
and Bohley, 1992). Fusion with the lysosomal membrane releases these 
components into the lysosomal lumen where degradative enzymes break 
them down (Lamb et al., 2013; Stolz et al., 2014; Mizushima et al., 2011). 
Lysosomal permeases and other transporters export amino acids and other 
degradation products out of the lysosome into the cytoplasm, where they can 
be used as building blocks for new macromolecules or for metabolism (Glick 
et al., 2010; Dikic and Elazar, 2018).  
 
An advancement in our understanding of autophagy came when work from 
Ohsumi’s group discovered the autophagy related genes (ATG) proteins in 
yeast (Tsukada and Ohsumi, 1993). These were determined to be the key 
proteins required for autophagy. Importantly, many of the ATG genes 
discovered in yeast are highly conserved in humans. There is significant 
interest in understanding this pathway, as dysfunction in autophagy genes and 
autophagic flux have been linked to diseases including cancer and 
neurodegenerative diseases (Nixon, 2013; Jiang et al., 2019; Mizushima and 
Levine, 2010; Liang et al., 1999; Kuma et al., 2004).  
 
1.2.12. Regulation of autophagy 
As mentioned above, autophagy is always operating in some capacity within 
the cell. The level of autophagic flux is linked to several factors, especially the 
availability of nutrients within the cell. Therefore, there must be a system which 
activates the autophagic pathway when nutrients are depleted and stems 
autophagy when the cell is fed. A major player in this regulatory pathway is 




mTORC1 and mTORC2 which play 2 different roles (Figure 1.4). Components 
common to both complexes are mammalian lethal with SEC13 protein 8 
(mLST8) and DEP domain-containing mTOR-interacting protein (DEPTOR) 
which act as positive and negative regulators of the complexes respectively. 
In addition to these common components there are also subunits which are 
unique to each complex. mTORC1 also contains the scaffold protein, 
regulatory associated protein of mTOR (RAPTOR) and negative regulator, 
PRAS40/AKTIS1. mTORC2 contains a different scaffold protein called 
rapamycin-independent companion of mTOR (RICTOR) and regulator 
subunits PROTOR1/2 and mSIN1/MAPKAP1 (Loewith et al., 2002; Zoncu et 
al., 2011b).  
 
Figure 1.4 Components of the mTORC1 and mTORC2 
complexes 
mTORC1 and mTORC2 complexes share some core 
components but have different effector proteins which give rise 
to distinct functions. Created with BioRender.com. 
 
When nutrients in the cell are in good supply, mTORC1 is recruited to the 
lysosome membrane (Rogala et al., 2019; Condon and Sabatini, 2019; Wyant 
et al., 2017). In a fed state the cell activates the PI3K pathway via growth factor 
and insulin receptors (White, 1998). This generates PtdIns3,4,5-P3 which in 
turn activates the phosphoinositide-dependent kinase 1 (PDK1) kinase and 
mTORC2 complex. Both are able to phosphorylate and activate protein kinase 




Activated AKT/PKB can then phosphorylate tuberous sclerosis (TSC1/2) 
complex which acts as a GAP protein for Ras homolog enriched in brain 
(RHEB) GTPase (Yang et al., 2006; Zoncu et al., 2011b). Phosphorylation of 
TSC1/2 inhibits its GAP activity preventing the hydrolysis of GTP by RHEB. 
Active RHEB promotes the activity of mTOR in a nutrient fed state. In addition 
to RHEB GTPase the Rag GTPases also play a role in the regulation of 
autophagy. Rag GTPases form heterodimers of either RagA or RagB with 
RagC or RagD. When the cell is fed, RagA or RagB in the heterodimer is GTP 
bound, whilst the RagC or RagD component is GDP bound. In this 
conformation the heterodimer interacts with RAPTOR and recruits the 
mTORC1 complex to the lysosome or late endosome where RHEB can 
promote mTOR activity (Sancak et al., 2008, 2010; Sancak and Sabatini, 2009; 
Liu and Sabatini, 2020; Shen et al., 2017). The effect of mTORC1 on 
regulating autophagy is through the hyperphosphorylation of Unc-51 like 
autophagy activating kinase (ULK)1/2 and ATG13 which prevents the 
formation of a complex between the two (Kim et al., 2011b; Kamada et al., 
2010).  
 
When nutrients are depleted, and the cell no longer activates the PI3K 
pathway, this results in the inactivation of AKT/PKB. This subsequently leads 
to the activation of 5’-AMP activating protein kinase (AMPK) by liver kinase B1 
(LKB1) leading to the activation of the TSC1/2 complex and the hydrolysis of 
GTP to GDP by RHEB (Sancak et al., 2008). Additionally, the Rag GTPases 
switch to their inactive conformation where the composite GTPases switch 
their nucleotide binding state (Sancak and Sabatini, 2009). The combined 
results of the changes to these 2 GTPase cycles results in the inactivation of 
mTORC1 which results in the formation of a complex between ULK1/2 and 
ATG13, ATG101 and FIP100 which promotes the nucleation of autophagic 





Figure 1.5 Nutrient availability regulates the activation of the 
mTORC1 pathway 
At steady state mTORC1 is active and inhibits the activation of 
autophagy via Rag GTPases. In starved conditions, mTORC1 is 







TFEB is a member of the Microphthalmia/TFE (MiT) family of transcription 
factors- a distinct set of bHLH-Zip transcriptions factors. The family also 
contains MITF (section 1.3.15) as well as TFEC and TFE3 (Figure 1.6). TFEB 
activates the transcription of lysosomal genes by binding to a recognition 
sequence in their promotor known as a Coordinated Lysosomal Expression 
and Recognition (CLEAR) element. TFEB binding to the promoter activates 
transcription and therefore upregulation of these lysosomal proteins to drive 
lysosomal biogenesis (Sardiello et al., 2009). TFEB is known to regulate the 
expression of a variety of lysosomal proteins including hydrolase enzymes for 
degradation, lysosomal membrane proteins, and components of the v-ATPase 
acidification pump. Overexpression of TFEB results in an increase in the 
number of lysosomes in cells (Palmieri et al., 2011; Sardiello et al., 2009). As 
well as being a regulator of lysosomal genes, TFEB has also been found to 
regulate genes which are key to related processes, such as autophagy and 
lysosome exocytosis (Palmieri et al., 2011; Napolitano and Ballabio, 2016). 
 
1.2.14. Post-translational control of TFEB 
Under steady state, nutrient rich conditions, TFEB is inactive and maintains a 
diffuse localisation throughout the cytoplasm. Translocation to the nucleus is 
prevented by phosphorylation of two serine residues, Ser142 and Ser211 
(Martina et al., 2012; Roczniak-Ferguson et al., 2012; Settembre et al., 2012; 
Settembre and Ballabio, 2011). Phosphorylation of TFEB at Ser211 promotes 
its binding to 14-3-3 chaperone protein which sequesters TFEB in the cytosol-
likely through masking its nuclear localisation signal (NLS) (Martina et al., 
2012; Roczniak-Ferguson et al., 2012). There has been some debate about 
the kinases which phosphorylate TFEB, however, mTORC1 and extracellular-
signal related kinase 2 (ERK2) have been reported to phosphorylate TFEB at 
the significant sites for its regulation (Martina et al., 2012; Roczniak-Ferguson 






Figure 1.6 MITF and TFEB drive the biogenesis of two 
related organelles 
MITF and TFEB are two transcription factors from the MiT 
transcription factor family. They drive the biogenesis of 
melanosomes and lysosomes respectively. Both organelles 
originate from the early endosome compartment. They are also 
both acidified via the action of the v-ATPase throughout their 




1.2.15. mTORC1 nutrient sensing and regulation of TFEB 
At steady state, in nutrient rich conditions, TFEB is phosphorylated by 
mTORC1 and is retained in the cytosol (Martina et al., 2012; Roczniak-
Ferguson et al., 2012; Settembre and Ballabio, 2011; Settembre et al., 2012). 
Under starvation conditions this modification must be reversed to allow TFEB 
to translocate to the nucleus (Palmieri et al., 2011; Sardiello et al., 2009). 
Regulation of TFEB by mTORC1 occurs at the lysosomal membrane 
(Jimenez -Orgaz et al., 2018). The lysosomal v-ATPase is key for the 




driven signalling. Where nutrients are rich, v-ATPase recruits the Rag-GTPase 
proteins to the cytoplasmic surface of the lysosome via interactions with the 
scaffolding complex Ragulator. Active Rag-GTPases recruit mTORC1 to the 
lysosomal surface where it can phosphorylate TFEB (Sancak et al., 2010; 
Settembre et al., 2012; Zoncu et al., 2011a).  
 
Under conditions of cellular stress or starvation, v-ATPase no longer interacts 
with Ragulator and the Rag-GTPases are inactivated. This results in mTORC1 
complex being released into the cytosol preventing further phosphorylation of 
TFEB (Zoncu et al., 2011a; Sancak et al., 2010). In addition to this, cell 
starvation also results in calcium efflux from the lysosome through Ca2+ 
channel mucolipin 1 (MCOLN1). This flux activates phosphatase calcineurin, 
which can dephosphorylate TFEB, allowing it to translocate to the nucleus and 











Figure 1.7 mTORC1 regulation of TFEB 
TFEB is a transcription factor under the control of mTORC1. At 
steady state, TFEB is phosphorylated by mTORC1 and bound by 
the 14-3-3 chaperone protein. This sequesters TFEB in the 
cytoplasm and prevents transcription of its target genes. In nutrient 
starvation, TFEB is dephosphorylated by calcineurin which 
releases TFEB from the 14-3-3 chaperone and TFEB  translocates 
to the nucleus. TFEB activates transcription of a number of 
lysosome and autophagy related genes by binding to CLEAR 

















1.3. Melanoma  
According to Cancer Research UK, melanoma is the 5th most common type 
of cancer in the UK with 16,200 people being diagnosed per year in 2020 
(www.cancerresearchuk.org).  Melanoma is a form of skin cancer which 
results from the transformation of melanocytes- cells located between the 
dermis and the skin epidermis. The main environmental risk factor for 
melanoma is UV radiation from the sun or the use of sunbeds. Other factors 
which affect the risk of developing melanoma include hair colour, skin type, 
some genetic risk factors and the number of melanocytic nevi (BERAL et al., 
1983). The rising number of melanoma cases could be attributed to the 
increase in awareness, surveillance and detection of cases, alongside the 
increased trend in sun tanning and the use of sunbeds. According to the 
American cancer society, the key to a good melanoma prognosis is early 
detection, with the most significant factor in outcome prediction being 
Breslow’s tumour thickness. Later metastatic forms of melanoma are generally 
associated with a poor prognosis (www.cancer.org). 
 
1.3.1. Melanocytes 
Melanocytes are skin cells which are located at the base of the skin epidermis 
where it meets the dermis (Figure 1.8). They produce the pigment melanin 
which is packaged into pigment granules called melanosomes through a 
process termed melanogenesis. Melanosomes, once formed, are transferred 
to neighbouring cells where they form a nuclear protective cap which serves 
to protect nuclear DNA from UV damage. The number of melanocytes does 
not vary between skin types, but rather the amount of UV-protective melanin 
pigments produced, which accounts for the increased risk of melanoma in 





Figure 1.8 Localisation of Melanocytes 
Melanocytes are pigment granule producing cells which lie in the 
base of the skin epidermis. They are in contact with around 40 
keratinocytes. Once pigment granules (melanosomes) are 
formed they are transferred to the neighbouring keratinocytes 
where they form a nuclear protective cap.  
 
1.3.2. Melanogenesis 
Melanosomes are specialised lysosome related organelles. They derive from 
early endosomes and go through a 4-stage maturation process termed 
melanogenesis resulting in pigmented, mature melanosomes (Raposo and 
Marks, 2007). This process is termed melanogenesis (Figure 1.10). 
Melanosomes appear as round or ovoid organelles with a diameter of 
approximately 500 nm (Birbeck et al., 1956; Raposo and Marks, 2007; SEIJI 
et al., 1961). The 4-stage development can be defined by distinct markers at 
each stage (SEIJI et al., 1963). Stage I melanosomes are derived from early 
endosomes and resemble multi-vesicular bodies (MVBs) containing intra-
luminal vesicles (Raposo et al., 2001). Stage II melanosomes contain a fibril 
network which distorts the shape of melanosomes to an ellipsoid. A 




deposited onto the fibril network. Stage IV melanosomes are fully pigmented, 
mature melanosomes which are ready for transport onto neighbouring 
keratinocytes (SEIJI et al., 1963).  
 
1.3.3. Stage I melanosomes 
Stage I and II melanosomes are defined by a fibril network which is made up 
of pre-melanosomal protein (PMEL, also known as Pmel17). PMEL is an 
amyloid protein which is different to other pathogenic amyloids in that it serves 
a known biological function (Hurbain et al., 2008). Stage I melanosomes can 
be characterised by the presence of a clathrin coat as well as pools of PMEL 
protein localised to the limiting melanosome membrane and intra-luminal 
vesicles (Hurbain et al., 2008; Raposo and Marks, 2007). PMEL is trafficked 
to the early melanosomes following synthesis in the ER, after which it is further 
modified in the Golgi apparatus to target it to the plasma membrane (PM). 
PMEL is then internalised and transported to early-stage melanosomes. PMEL 
has two functional roles in early melanosomes. It forms the fibril network onto 
which melanin is deposited (Berson et al., 2001; McGlinchey et al., 2009), and 
it sequesters reactive oxidative species (ROS) generated during melanin 
synthesis (Watt et al., 2013). The latter function is essential in protecting 
melanocytes from toxic by-products of melanosome formation.  
 
1.3.4. Stage II melanosomes 
Once at the early melanosomes, PMEL undergoes a number of cleavage 
processing steps by proteases accompanied by sorting to intraluminal vesicles 
(ILVs) for nucleation of fibrils (Berson et al., 2003; Rochin et al., 2013; Berson 
et al., 2001; McGlinchey et al., 2009). Unlike canonical ESCRT machinery-
dependent ILV sorting, PMEL sorting is mediated via apolipoprotein E (ApoE) 
and cluster of differentiation 63 (CD63) (van Niel et al., 2015, 2011). 
Nucleation and extension of PMEL fibrils into PMEL sheets that span across 
melanosomes results in the ellipsoidal shape of stage II melanosomes. These 






Figure 1.9 Early and late-stage melanosomes 
Melan-a cells fixed and processed for EM were imaged using a 
TEM microscope. A early-stage melanosome. B late-stage 
melanosome. 
 
1.3.5. Stage III melanosomes 
Stage III melanosomes are characterised by the initiation of the synthesis of 
melanin which is subsequently deposited onto the established PMEL fibril 
network. This requires the delivery of melanin synthesising proteins such as 
tyrosinase, tyrosinase related protein 1 (TYRP1) and TYRP2 (Raper, 1927; 
Aroca et al., 1991; Del Marmol and Beermann, 1996). These enzymes are 
delivered specifically to maturing melanosomes following fibril formation 
(Sitaram and Marks, 2012).  
 
1.3.6. Stage IV melanosomes 
Once melanin synthesis is complete and a melanosome is fully pigmented, it 
is then transferred onto a neighbouring keratinocyte where it performs its role 
as a nuclear protective cap around the keratinocyte nucleus. An electron 







Figure 1.10 Biogenesis of melanosomes 
Melanosomes are lysosome related organelles (LRO) which derive 
from early endosomes. In early-stage pre-melanosomes (stages I 
and II) PMEL is cleaved to form fibrils. Melanogenic enzymes such 
as tyrosinase, TYRP1, TYRP2 and MART-1 synthesise the 
pigment melanin, which is deposited onto the fully formed PMEL 
fibrils in stage III melanosomes. Stage IV melanosomes are fully 
pigmented mature melanosomes which are transported along 
melanocyte dendrites for transport to neighbouring keratinocytes. 





1.3.7. Melanin Synthesis 
Melanin, derived from tyrosine, is a cocktail of pigments. In humans, two 
melanins are produced, eumelanin, which is a brown/black pigment, and 
pheomelanin, which is a yellow/red pigment. Both pigments share the common 
precursor dopaquinone, which is derived from the tyrosinase dependent 
oxidation of L-tyrosine. Dopaquinone is transformed into dopachrome which is 
oxidoreduced into dihydroxindole (DHI) and DHI carboxylic acid (DHICA) 
which can polymerise into eumelanin. For pheomelanin, there must be 
sufficient cysteine present at the conversion of dopaquinone. In this case, 
cysteinyldopa is generated which can be converted to pheomelanin (Hearing, 
2011; Wakamatsu and Ito, 2002). Melanin functions as a protective shield for 
nuclei in keratinocytes in the skin and protects cells from UV damage via anti-
oxidant properties and the scavenging of free radicals (Meredith and Sarna, 
2006).  
 
1.3.8. Tyrosinase related proteins 
The maturation of melanosomes requires the action of enzymes called 
tyrosinase related proteins (TYRPs). There are three members: Tyrosinase 
TYRP1 and TYRP2 (also known as DCT). TYRPs are transmembrane 
Cu++/Zn++ metalloenzymes which also contain 2 characteristic cysteine rich 
regions. All family members share over 80% homology (Kwon et al., 1987) and 
contain two copper binding sites essential for enzymatic activity (Wang and 
Hebert, 2006). The TYRPs are glycoproteins and thus are synthesised and 
modified via the ER and Golgi apparatus where they undergo glycosylation 
(Jackson et al., 1992; Liu et al., 2001b; Mikami et al., 2013). Delivery of TYRPs 
to maturing melanosomes must be timed after the formation of the PMEL fibrils 
in early melanosomes. The mechanism for this scheduled delivery is known to 






Tyrosinase was the first of the TYRPs to be identified. It is responsible for 
catalysing the rate limiting step of melanin synthesis. In the ER it is bound by 
chaperones which is essential for the correct folding and the binding of copper 
to tyrosinase (Branza-Nichita et al., 1999). Tyrosinase can form homo or 
heterodimers in the ER before being trafficked to the Golgi. From the ER, 
tyrosinase is trafficked to the Golgi in COPII coated vesicles. At the Golgi the 
glycosylation modifications on tyrosinase are further modified and some 
evidence suggests that the Golgi is the site of copper binding (Wang and 
Hebert, 2006; Setty et al., 2008). Tyrosinase is trafficked from the Golgi to 
melanosomes in an adaptor protein complex 3 (AP-3)-dependent mechanism. 
AP-3 can recognise Tyrosinase via a dileucine repeat within its cytoplasmic 
tail. AP-3 colocalises with tyrosinase at buds at the early endosome thought 
to be essential to sorting from endosomes to melanosomes (Theos et al., 2005; 
Höning et al., 1998; Raposo and Marks, 2007).  A small pool of tyrosinase can 
colocalise with AP-1 at early endosomal buds, which are distinct from the AP-
3 positive buds. This pool increases with AP-3 depletion indicating that this is 
a distinct trafficking pathway which may try to compensate for the loss of AP-
3 trafficking (Theos et al., 2005). In AP-3 deficient melanocytes tyrosinase is 
mis-localised to the early endosome and to MVBs. Despite this defect, these 
cells are still able to produce some melanosomes indicating an AP-3-
independent pathway for tyrosinase trafficking. Once at melanosomes 
tyrosinase catalyses the hydroxylation of tyrosine to dihydroxyphenylalanine 
(DOPA) and the subsequent oxidation of DOPA to DOPAquinone as well as 
DHI and DHICA into melanin precursors (Körner and Pawelek, 1982).  
 
1.3.10. TYRP1 
TYRP1 (also known as gp 75) is a transmembrane glycoprotein (Ghanem and 
Fabrice, 2011). Like tyrosinase it is trafficked to the Golgi from the ER before 
being sorted to melanosomes (Chen et al., 2001; Liu et al., 2001a; Jimbow et 
al., 1997). Of all the TYRPs, TYRP1’s catalytic activity in the melanogenesis 




catalase and DHIA oxidase activity (Kobayashi 1994, 1994). TYRP1 serves a 
function in stabilising tyrosinase by forming heterodimers which appear to be 
crucial to the correct trafficking of these enzymes and therefore crucial to 
melanogenesis. TYRP1 is bound by AP-1 via its di-leucine sorting sequence 
and is mis-sorted in AP-1 deficient mice, but not in AP-3 deficient mice, 
indicating two distinct delivery mechanisms (Raposo and Marks, 2007; Theos 
et al., 2005). TYRP1 delivery to melanosomes has been found to be via 
recycling endosome tubular carriers. This process is thought to be dependent 
on biogenesis of lysosome-related organelle complex 1 (BLOC-1) 
(Dell’Angelica, 2004). AP-1 can bind kinesin motor KIF13A which helps 
promote the elongation of the endosomal tubule (Delevoye et al., 2009). AP-1 
functions to organise melanosomal proteins into these tubules via their 
recognition motifs. Following the formation of these tubules, they are then 
brought into proximity with maturing melanosomes where they are then able 
to make contact and deliver melanogenic enzymes via fusion with the 
melanosome membrane (Delevoye et al., 2009).  
 
1.3.11. BLOC Complexes 
BLOC-1 is one of 3 BLOC complexes found to have a role in melanogenesis. 
BLOC-1 is the largest with 8 subunits and thought to operate in the formation 
of endosome carriers (Dell’Angelica, 2004). BLOC-1 is required for the 
delivery of copper transporter ATP7A, a cofactor for tyrosinase activity, to 
melanosomes (Setty et al., 2008, 2007). Loss of BLOC-1 does not affect 
tyrosinase localisation to melanosomes but results in a loss of tyrosinase 
activity. This is due to a mislocalisation of ATP7A and leads to a significant 
pigmentation defect. BLOC-1 colocalises to the tubule carriers for early 
melanosomes and functions to transport TYRP1 carriers so may function with 
AP-1 and KIF13A (Setty et al., 2008, 2007).  
 
BLOC-2 is the second largest BLOC complex with 3 subunits and functions 
downstream of BLOC-1. BLOC-2 defects result in a phenotype where the 




contacts with melanosomes, resulting in less efficient delivery of melanogenic 
enzymes (Dennis et al., 2015). As a result, BLOC-2 deficient mice exhibit a 
pigmentation defect that is less severe than the defect seen with loss of BLOC-
1 (Dell’Angelica, 2004). These results indicate that BLOC-2 promotes 
tethering of the tubule carriers to melanosomes to promote fusion.  
 
BLOC-3 complex is composed of only 2 subunits and is the least well 
characterised of the BLOC complexes. In mice BLOC-3 deficiency leads to 
only a mild coat colour change but leads to an extreme skin hypopigmentation 
defect (Nguyen and Wei, 2007). BLOC-3 can act as a GEF for Rab32 and 
Rab38 (discussed below in section 1.3.12) and activates their activity 
(Gerondopoulos et al., 2012). The significance of this activity remains 
unknown. BLOC-3 has also been implicated in the recycling of components 
from melanosomes including the SNARE protein VAMP7 (Dennis et al., 2016). 
VAMP7 is exported from melanosomes via tubular structures which extend 
from the melanosome body. Rab38 and its effector VARP are also present at 
these recycling tubules. VAMP7 is the SNARE protein required for the fusion 
of BLOC-1 mediated endosomal carriers with melanosomes for the delivery of 
melanogenic enzymes (Dennis et al., 2016). The model proposed in this study 
suggests that VAMP7 is bound by VARP which locks it in an inactive state and 
prevents its function while it is recycled (Schäfer et al., 2012). They suggest 
that VAMP7 is recycled from melanosomes back to the endosome so it can 
carry out further rounds of fusion and delivery of melanogenic enzymes 
(Dennis et al., 2016).   
 
1.3.12. Other melanogenesis proteins 
Rab proteins Rab32 and Rab38 have specialised roles in cell types which 
generate lysosome related organelles (LROs) such as melanocytes. These 
Rab proteins have been found to mediate the selective delivery of tyrosinase 
and TYRP1 to melanosomes, although the mechanism of this delivery remains 





Rab6 has been linked to the trafficking of TYRP1 and melanoma antigen 
recognised by T cells (MART-1) to melanosomes. Vesicular carriers 
containing these proteins are derived from the TGN via the action of Rab6 
which then transports and targets the delivery of these vesicles to 
melanosomes (Patwardhan et al., 2017). The SNARE protein VAMP-7 is 
thought to be essential for the fusion of carriers from endosomes with 
melanosomes for the delivery of TYRP1 (Dennis et al., 2016). In addition, 
SNARE protein STX13 and Rab protein Rab9 have been linked to the 
trafficking of melanogenesis enzymes via recycling endosome carriers 
(Mahanty et al., 2016; Jani et al., 2015). Rab7 has also been linked to 
melanogenesis. Gomez and colleagues showed that Rab7 could colocalise 
with TYRP1 positive vesicles and suggested a role for Rab7 in the transport 
of melanogenic enzymes (Gomez et al., 2001). Neefjes’ group published 
evidence that Rab7 works in concert with Rab27a for melanosome transport 
(Jordens et al., 2006). 
 
1.3.13. Transport of melanosomes  
Following maturation of melanosomes, they then must be transported from 
their site of development to the cell periphery so they can be transported along 
the melanocyte projections ready for transport to neighbouring keratinocytes. 
First, melanosomes are transported the extended distance from the 
perinuclear area to the cell periphery by kinesins and microtubule networks 
(Hume and Seabra, 2011). Melanosomes are then docked at the actin 
cytoskeleton at the plasma membrane. This is mediated by Rab27a. Rab27a 
is recruited in its active form to mature melanosomes where it binds its effector 
melanophilin (Wu et al., 2001; Hume et al., 2001). Melanophilin can recruit and 
activate motor Myosin Va. This heterotrimeric complex can then stimulate the 
release of melanosomes from the microtubule network and the subsequent 
transport along the melanocyte projections (Wu et al., 2001, 2005; Hume and 
Seabra, 2011; Li et al., 2005). In the retinal pigment epithelium (RPE), 
melanosomes are transported to the apical region and have a similar system 




appear to mediate the docking of melanosomes in the apical processes (Lopes 
et al., 2007b).  
 
1.3.14. Secretion of melanosomes 
Once fully matured, melanosomes must be transported to neighbouring 
keratinocytes. This process is not well understood, and more than one model 
has been proposed. One proposes that melanosomes are secreted by 
exocytosis and are subsequently engulfed by keratinocytes. Another suggests 
that melanosomes are grouped into membrane bound vesicles which either 
fuse with the plasma membrane of keratinocytes, or are taken up by 
phagocytosis. Alternatively, it is possible that keratinocytes are able to take up 
part of the dendritic tip of melanocytes via phagocytosis. Or finally it has been 
proposed that melanosomes are transferred via a direct fusion of the plasma 
membrane of both cells creating a direct transfer from one cell to another (Van 
Den Bossche et al., 2006). More recent studies lean towards a model where 
melanosomes are in some way first secreted and the taken up by neighbouring 
keratinocytes. Rab11b has been implicated in this process, with recent work 
implicating the exocyst complex as an effector for Rab11 in the melanosome 
secretion process (Tarafder et al., 2014; Moreiras et al., 2020). 
 
1.3.15. Microphthalmia transcription factor 
Microphthalmia transcription factor (MITF) is one of four members of the MiT 
transcription factor family. MITF is a bHLH-leu-ZIP transcription factor which 
binds to lineage-specific targets in cells such as melanocytes and osteoclasts. 
It recognises E-Box and M-Box sequences in the promotor regions of genes 
and is the major transcription factor driving melanogenesis (Napolitano and 
Ballabio, 2016). Hence, MITF is an integral part of melanocyte development 
(Figure 1.6). As well as driving melanogenesis, MITF is able to drive other 
processes including cell proliferation, migration and senescence (Hartman and 
Czyz, 2015). Binding of MITF to the M-Box in the promoter regions of several 
melanogenesis related genes drives their transcription. This promotes 




enzymes Tyrosinase, TYRP1 and TYRP2 (Hah et al., 2012; Hemesath et al., 
1994a; Sitaram and Marks, 2012). MITF is also responsible for the 
transcriptional control of Rab27a, the Rab protein responsible for transporting 
mature melanosomes along the projections of melanocyte cells so that they 
may be transferred to neighbouring keratinocytes (Chiaverini et al., 2008). 
MITF binds to DNA either as a homodimer or heterodimer with another 
member of the MiT transcription family members (Hemesath et al., 1994b). 
The regulation of MITF is controlled at multiple levels including transcriptional 
activation, repression, phosphorylation and SUMOylation (Hartman and Czyz, 
2015).   
 
1.3.16. MITF and Melanoma  
Alterations in MITF expression and transcriptional activity have been linked to 
melanoma. As well as activating genes required for melanogenesis, it also has 
a number of pro-tumorigenic targets which have roles in cell death, DNA 
replication and proliferative pathway. Targets of MITF include CDKN2a 
(tumour suppressor) and BCL-2 (anti-apoptosis). Studies have shown that 
MITF is amplified in a subset of melanomas and is commonly upregulated in 
melanomas harbouring the BRAF (V600E) mutation. Additionally, data 
suggests that upregulation of MITF promotes cell survival and confers drug 
resistance to melanomas (Garraway et al., 2005).   
 
Melanoma cells undergo what is known as “phenotypic switching”. This 
process is reminiscent of the well characterised epithelial-mesenchymal 
transition (EMT) which is observed in many cancers when gaining metastatic 
potential (Li et al., 2015). In melanoma there are additional lineage specific 
gene sets which are altered between the core tumour and invading metastatic 
cells. MITF is one of the identified markers of melanoma phenotypic switching 
(Li et al., 2015; Vandamme and Berx, 2014; Hartman and Czyz, 2015). 
Differential expression of MITF can confer different benefits to different stages 
of melanoma. Early-stage melanomas have higher MITF activity levels which 




advantageous to primary tumour formation and would work collaboratively with 
other common melanoma mutations in genes such as BRAF and N-RAS 
(Carreira et al., 2006). Later stages of melanoma have a tendency to down 
regulate MITF expression, which promotes cell invasiveness beneficial to later 
stage cancer progression (Carreira et al., 2006). Understanding the 
expression profiles across this phenotypic switching is of great interest as 
early-stage disease is very treatable and has a good prognosis. Later stages 
of disease where metastasis has occurred have a poor prognosis. Therefore 
prognosis can be better or worse, depending on the expression profile of 
certain genes, with many genes conferring therapy resistance (Li et al., 2015; 
Vandamme and Berx, 2014).  
 
1.3.17. Rab7 and melanoma 
Rab7 has also been found to have a differential expression pattern in different 
stages of melanoma. Alonso-Curbelo and colleagues showed that melanoma 
cells rewire the endolysosomal system to benefit melanoma progression 
(Alonso-Curbelo et al., 2014). Their study showed that depletion of Rab7 in 
melanoma cells reduced cell proliferation and colony formation suggesting that 
enhanced Rab7 expression and activity is beneficial for early-stage melanoma. 
In contrast they showed that depletion of Rab7 in melanoma cells increased 
cell invasion, and that cell lines which have high invasive potential in culture 
had lower basal Rab7 levels. Furthermore, they looked at Rab7 expression 
across cross sections of melanomas from various stages of disease. They 
found that melanoma cells had higher levels of expression compared to 
normal tissue, consistent with a role for Rab7 in melanoma initiation. They also 
found that Rab7 expression was not consistent across all stages, and that 
Rab7 expression was decreased at the transition stage where melanoma cells 
gain invasive potential (Alonso-Curbelo et al., 2014). This data supports Rab7 
as a marker for phenotypic switching in melanoma cells, although this study 
indicated that this effect was independent of the pigmentation status and 





1.4. Parkinson’s disease (PD) 
Parkinson’s disease is the second most common neurodegenerative disease 
after Alzheimer’s disease (Tysnes and Storstein, 2017). The substantia nigra 
pars compacta (SNpc) is the initial site of neuronal loss in PD (Figure 1.11). 
The SNpc forms one of two regions of the substantia nigra in the midbrain- the 
other being the substantia nigra pars reticular (SNpr). The major function of 
the SNpc is to operate the motor control of the body; hence defects in motor 
control in PD patients (Armstrong and Okun, 2020; Fearnley and Lees, 1991; 
Dickson et al., 2009). Symptoms of PD include (but are not limited to) tremor 
at rest, bradykinesia (slowness of movement) and muscle stiffness. Post-
mortem analysis of brain tissues show pathology arises from a 
neurodegeneration of the dopaminergic neurons in the SNpc (Fearnley and 
Lees, 1991; Dickson et al., 2009; Ma et al., 1997; Kordower et al., 2013). 
These neurons contain the pigment neuromelanin and thus post-mortem 
tissues show a characteristic loss of this pigmented region of the brain. The 
remaining neurons routinely contain protein inclusions called “Lewy bodies” 
(LB). These protein inclusions are protein aggregates which are enriched for 
the protein a-synuclein (Spillantini et al., 1997, 1998; Lees et al., 2009; Reeve 
et al., 2014).  
 
Dopaminergic neurons produce the neurotransmitter dopamine (DA) which is 
released into the striatum to help maintain projections within other parts of the 
basal ganglia. DA is a catecholamine neurotransmitter which is responsible for 
motor control, motivation, reinforcement and reward (Barbeau, 1962). As PD 
results from a loss of the neurons which produce DA, it was hypothesised that 
by administering DA to PD patients, the progression of the disease could be 
slowed or stopped. Administering DA is unsuccessful in treating PD as it is 
unable to cross the blood brain barrier (BBB). DA precursor, levodopa (L-
DOPA), is able to cross the BBB, and once entered into the central nervous 
system, can be converted to DA by the enzyme L-DOPA decarboxylase 
(Hornykiewicz, 2017; Dorszewska et al., 2014; Hornykiewicz, 2006). Thus, L-
DOPA is used to increase the neurological DA levels in PD patients. Although 




of this treatment decreases over time and produces substantial adverse side 
effects (Hornykiewicz, 2017; Dorszewska et al., 2014).  Due to the nature of 
the disease and its progression, there are no conclusive tests to diagnose PD. 
Instead, a diagnosis is made based on symptom presentation. Additionally, 
there’s currently no cure for PD, only treatments which can lessen the 
symptoms of patients. Hence there are a large number of clinical trials 
searching for preventative and more effective treatments (Armstrong and 
Okun, 2020). Although there is much interest in the field, clinical trials provide 
a significant challenge as they are both costly and difficult to manage. The lack 






Figure 1.11 Substantia Nigra Pars Compacta (SNpc) 
The substantia nigra is a region of the midbrain which is split in 
to two regions. The substantia nigra pars reticular (SNpr) and the 
substantia nigra pars compacta (SNpc). The SNpc is the region 
of the brain associated with the initial loss of neurons in PD. 
 
1.4.1. Aetiology of PD 
The majority of PD cases are idiopathic, with only around 10-15% of cases 
having a familial link (Armstrong and Okun, 2020). There are a number of 




penetrance associated with them (Blauwendraat et al., 2020). These genes 
appear to broadly fall into two categories- mitophagy dysfunction and 
endolysosomal trafficking defects- two pathways we know have substantial 
crosstalk (Armstrong and Okun, 2020). Although only a small percentage of 
PD cases have a known genetic cause, studying these cases helps to 
understand the overall disease pathology and may shine some light on the 
aetiology of “sporadic” cases. One of the greatest challenges in the field of PD 
research is to connect the associated genes into molecular pathways to further 
our understanding of disease pathology. 
 
1.4.2. Familial PD genes 
Thus far, 18 chromosomal loci have been linked to PD, all termed PARK loci. 
Within each locus are multiple genes, and in some cases, the causative gene 
within an identified locus has not been determined. There are, however, genes 
which are unequivocally linked to heritable, monogenic Parkinson’s disease 
(Table 1.1). Mutations in SNCA, which encodes alpha synuclein and lies within 
the PARK1 locus, and mutations in the kinase LRRK2 gene, which lies in the 
PARK8 locus, result in an autosomal-dominant (AD) form of PD (Zimprich et 
al., 2004; Paisán-Ruíz et al., 2004; Bardien et al., 2011; Funayama et al., 
2005). Mutations in the retromer component VPS35 (PARK17) have also been 
linked to AD forms of PD (Williams et al., 2017; Vilariño-Güell et al., 2011; 
Zimprich et al., 2011). There are also mutations in Parkin, PINK1, DJ-1, 
PLA2G6, FBXO7, SYNJ1 and ATP13A2 which all result in an autosomal 
recessive (AR) form of PD (Blauwendraat et al., 2020). In addition to these 
identified chromosomal loci, other genetic risk factors have been identified. 
For example, alternative splice variants of Rab29 (also known as Rab7L1) in 
the PARK16 locus have been linked to an increased risk of PD (MacLeod et 
al., 2013).  PD has been linked to the lysosomal storage disease, Gaucher’s 
disease (GD) (Riboldi and Di Fonzo, 2019). People with Gaucher’s disease 
are more likely to develop PD compared to the general population. In both 
conditions, mutations in the GBA gene have been linked to pathology. GBA 




Fonzo, 2019). The links between these two diseases highlight the role of the 
endolysosomal system in PD pathology.  
 
Table 1.1 Genes associated with PD pathology 
Gene Protein Inheritance 
SNCA (PARK1/PARK4) a-synuclein  AD 
LRRK2 (PARK8) Leucine rich repeat kinase 2 
(LRRK2) 
AD 
VPS35 (PARK17) Vacuolar protein sorting-associate 
protein 35 
AD 
Parkin (PARK2) Parkin AR 
PINK1 (PARK6) PTEN induced kinase-1 AR 
DJ-1 DJ-1 AR 
SYNJ1 Synaptojanin-1 (SYNJ1) AR 
FBXO7 F-Box only protein 7 (FBXO7) AR 
ATP13A2 Probable cation-transporting 
ATPase 13A2 
AR 
PLA2G6 85/88 kDa calcium-independent 
phospholipase A2 
AR 
DNAJC6 DnaJ Heat shock protein family 
(HSP40) member C6 
AR 
 
1.4.3. Parkinson’s disease and Melanoma 
Patients who are diagnosed with PD are less likely to get all types of cancer, 
except for melanoma, which they are more than twice as likely to get compared 
to the general population (Huang et al., 2015). Although this data was 
published in 2015, no subsequent work has shone light on how these diseases 
are linked, or why melanoma does not follow the same trend as other types of 
cancer. It is also not known whether there are specific PD related mutations 
which confer vulnerability to melanoma, or whether these cases fall into the 
sporadic pool of patients. One obvious factor which links both diseases is the 
affected cell type. Melanoma is cancer of the pigment producing melanocyte 
cells (Section 1.3.1) and the initial site affected by PD is the pigmented SNpc 





1.4.4. Endolysosomal system in Parkinson’s disease 
Many of the genes outlined in Table 1.1 have been linked to the 
endolysosomal system. Additionally, high-throughput sequencing and GWAS 
studies have identified numerous risk factors for sporadic PD- many of which 
are functional in the endolysosomal system. Neurons, and in particular 
dopaminergic neurons, put a high burden on the endolysosomal system. 
Synaptic vesicles (SVs) are produced in the soma of the cell and transported 
down axons to the pre-synapse for release. However, newly synthesised SVs 
are not sufficient to maintain active firing synapses. Therefore, clathrin 
mediated endocytosis of neurotransmitters from the synaptic junction reforms 
SVs for re-release into the synapse (Saheki and De Camilli, 2012). Additionally, 
the rapid firing of synapses in neurons may result in a back log of damaged 
and exhausted organelles which need to be disposed of. For this, 
autophagosomal selection and retrograde transport to the lysosomal 
compartment is required (Yang et al., 2013; Maday et al., 2014). To facilitate 
this, extended microtubule networks span the axonal distance for transport of 
vesicles and cargos back and forth from the soma to the pre-synapse (Maday 
et al., 2014). This higher strain on the endolysosomal system along with their 
higher dependence on cell/protein homeostasis, makes neurons more 
susceptible and sensitive to defects in endosomal and lysosomal function. In 
addition, neurons are post-mitotic and long-lived cells adding another layer of 
vulnerability. 
 
DNAJC6 also known as auxilin is a PD related gene linked to AR forms of PD.  
It is a member of the heat shock protein family (Hsp40) (Gorenberg and 
Chandra, 2017). It acts in the pre-synaptic terminus and is involved in the 
uncoating of clathrin vesicles following endocytosis. Auxillin recruits the 
ATPase Hsc70 to the pre-synaptic terminus where it executes its function in 
catalysing the dissolution of the clathrin coat for recycling of its contents 
(Gorenberg and Chandra, 2017). In addition, evidence shows that loss of 
function of auxilin attenuates the effect of a-synuclein overexpression (Song 




of CCVs and empty clathrin cages (Yim et al., 2010). LRRK2 has been found 
to phosphorylate auxilin, leading to accumulation of oxidised dopamine and a-
synuclein. These studies highlight the cross talk between PD related genes 
(Nguyen and Krainc, 2018).  
 
SYNJ1 is a phosphatase domain containing protein with two phosphatases- a 
5-phosphatase and a Sac1 domain (McPherson et al., 1996). The 5-
phosphatase works in conjunction with Hsc70 and auxilin in the dissolution of 
the clathrin coat from endocytosed vesicles from the synaptic junction 
(Cremona et al., 1999). The Sac1 domain has also been linked to clathrin 
uncoating, however, this function is less robustly established (Cao et al., 2017). 
Mutations occur within the Sac1 domain, which are found to cause AR PD 
(Krebs et al., 2013). Studies have found evidence for Sac1 mutations causing 
endocytic trafficking defects at the synapse including accumulation of CCVs 
(Cao et al., 2017; Quadri et al., 2013). There is also evidence that defects in 
SYNJ1 cause defective autophagy in the synaptic terminal (Vanhauwaert et 
al., 2017). SYNJ1 can interact with Endophilin A. Endophilin A functions in 
clathrin independent endocytosis in the synaptic terminal, and promotes 
membrane bending for vesicle formation (Watanabe et al., 2018; Westphal 
and Chandra, 2013). Endophilin A recruits SYNJ1 to the pre-synaptic terminus 
for its function in vesicle recycling. LRRK2 can phosphorylate Endophilin A 
which impairs its function and results in defects in the endocytic pathway and 
regulation of autophagy (Soukup et al., 2016; Matta et al., 2012).   
 
a-synuclein is a protein found in the pre-synaptic terminals of neurons as well 
as many non-neuronal cell types (Kramer and Schulz-Schaeffer, 2007). It is 
highly expressed in the brain and is found to be enriched in the Lewy body 
inclusions which are found in the surviving neurons of patient brains post-
mortem (Dickson et al., 2009; Fearnley and Lees, 1991). There is a consensus 
that a-synuclein accumulation is particularly critical to the pathology of PD. As 
well as pathogenic point mutations in a-synuclein, which are linked to 
increased aggregation, genomic duplicates and triplicates of the gene have 




al., 2004). a-synuclein functions in the transmission of neurotransmitters and 
the organisation of SVs. Over-expression of a-synuclein has been found to 
inhibit the release of synaptic vesicles, whereas aggregated a-synuclein 
impairs synaptic endocytosis (Vargas et al., 2014; Greten-Harrison et al., 
2010). Furthermore, there is evidence that a-synuclein aggregates impact SV 
recycling by impairing the removal of the clathrin coat and impairing Hsc70 
activity leading to an accumulation of CCVs (Banks et al., 2020). 
 
1.4.5. Mitochondria Quality control and Mitophagy in PD 
Like the endolysosomal system, many of the genes which have been related 
to PD have been linked to mitophagy. Mitophagy is the selective form of 
autophagy which deals with the degradation of worn or damaged mitochondria. 
This is of particular importance in cell homeostasis, as mitochondria produce 
a variety of molecules (for example, ROS) which could be damaging if 
released into the cell. Therefore, mitochondria and their contents must be 
effectively disposed of to prevent toxicity to cells. It is thought that in 
neurodegenerative diseases, defects in mitophagy result in the inefficient 
clearance of damaged mitochondria, which leads to accumulation of toxic 
components in the cell which in turn would lead to neuronal death (Vidyadhara 
et al., 2019). In particular, there has been much research conducted into the 
PINK1/Parkin pathway of mitophagy, as these two genes have been robustly 
linked to AR forms of PD (Bodnar et al., 1998; Vidyadhara et al., 2019). Studies 
in drosophila found the first mechanistic link between two PD related genes 
which converged on the mitophagy pathway (Park et al., 2006; Clark et al., 
2006). PINK1 acts as a sensor for damaged mitochondria. Under normal 
conditions, PINK1 enters into the TOMM/TIMM complex on mitochondria and 
is cleaved by PARL protease (Yamano and Youle, 2013; Jin et al., 2010). 
PINK1 is extracted and degraded by the proteasome degradation system. In 
response to mitochondrial depolarisation or damage, PINK1 can no longer 
enter into the TIMM complex to be cleaved and accumulates on the outer 
mitochondrial membrane (Narendra et al., 2010; Matsuda et al., 2010). PINK1 




membrane. PINK1 can phosphorylate Parkin, leading to its activation (Kane et 
al., 2014; Koyano et al., 2014). Parkin then adds ubiquitin to a number of outer 
mitochondrial membrane proteins. PINK1 can also phosphorylate ubiquitin on 
the outer mitochondrial membrane proteins. This generates a feedback loop 
as Parkin binds phospho-ubiquitin. The ubiquitylated substrates recruit the 
autophagy machinery to the damaged mitochondria and they are selectively 
engulfed for degradation. These mitophagosomes are then targeted to the 
lysosome where they fuse to form autolysosomes, and the damaged 
mitochondria are degraded. Mutations in PINK1 and Parkin are linked to 
defects in this pathway leading to ineffective disposal of damaged 
mitochondria. 
 
1.4.6. Rab7 and mitochondrial dynamics 
Rab7 has many well characterised roles in the later stages of the 
endolysosomal pathway, as well as a role in the melanogenesis pathway 
(Section 1.2.8 and Section 1.3.12). More recent years have found a growing 
body of evidence that Rab7 has a key role in mitophagy. Wong at al., showed 
that Rab7 GTP binding is required for the formation of lysosome-mitochondrial 
contact sites. They also showed that Rab7 GTP-hydrolysis mediated by 
TBC1D15, a mitochondrial Rab7 GAP protein, led to the untethering of these 
contact sites. Finally, this study suggested that these contact sites are 
important for mitochondrial fission events, and therefore mitochondrial 
dynamics (Wong et al., 2018). Richard Youle’s lab implicated Rab7 in 
mitophagy, promoting autophagosome formation and morphology via 
interactions with Fis1 and TBC1D15 (Yamano et al., 2014). They later showed 
Rab7 to be important for Parkin mediated mitophagy (Section 1.4.5). Using 
immunoelectron microscopy they were able to show that Rab7 can directly 
interact with the OMM in response to mitophagy induction. Loss of Rab7 by 
siRNA knockdown resulted in a failure to clear mitochondria and defects in 
autophagic flux. They also show Rab7 is recruited to damaged mitochondria 
by the GEF Mon1/CCZ1, downstream of Rab5 and the Rab5 GEF RABGEF1 




increasing interest to the field of PD research as it has been linked to two 
related familial PD genes, LRRK2 and VPS35 (Jimenez-Orgaz et al., 2018; 
Gómez-Suaga et al., 2014). This work links Rab7 to yet another familial PD 
gene. 
 
1.4.7. LRRK2  
Leucine-rich repeat kinase 2 (LRRK2) is the most commonly mutated gene in 
familial PD (Zimprich et al., 2004; Paisán-Ruíz et al., 2004; Bardien et al., 2011; 
Funayama et al., 2005). At 286 kDa in size, it is a large protein and is unusual 
in that it contains 2 adjacent catalytic domains- a serine/threonine kinase 
domain; and a Ras of Complex (ROC)- C-terminal of ROC (COR)-GTPase 
domain, as well as a number of protein interaction domains. There are a 
number of pathogenic mutations confirmed within LRRK2, the majority of 
which lie in the catalytic domains and result in hyperactive kinase activity 
(Khan et al., 2005; Hur et al., 2019; Cookson, 2010; West et al., 2005). 
Although the molecular mechanisms of how these mutations manifest into PD 
remain unclear, the hyperactive kinase activity has made LRRK2 appear an 
attractive pharmacological target for the treatment and prevention of PD (Yao 
et al., 2013). In addition, variants in the LRRK2 gene were determined to be 
risk factors for idiopathic PD (Satake et al., 2009; Rudenko and Cookson, 2014; 
Simón-Sánchez et al., 2009; Nalls et al., 2014).  
 
Figure 1.12 LRRK2 protein domains and pathogenic 
mutations 
LRRK2 is a 286 kDa protein containing two catalytic domains: a 
serine/threonine kinase domain and a ROC-COR GTPase 
domain. LRRK2 also contains a number of protein interaction 
domains including an Armadillo repeat domain (ARM), an 
Ankyrin repeat domain and a WD40 repeat domain. The 
identified familial PD mutations in LRRK2 largely map to the 





1.4.8. Pathogenic mutations in LRRK2 
Multiple heritable pathogenic mutations have been identified within LRRK2 
(Table 1.2, Figure 1.12). The most common is the [G2019S] mutation which 
lies within the kinase domain and results in a hyperactive kinase 2-fold more 
active than the wild type (WT) (Jaleel et al., 2007; Khan et al., 2005; West et 
al., 2005). There are also a number of mutations in the ROC-COR GTPase 
domain, such as [R1441C/G/H] and [Y1699C], which also result in a 
hyperactive kinase which is over 3-fold more active than the WT (Khan et al., 
2005; Hur et al., 2019; Cookson, 2010; West et al., 2005). This is, however, 
only the case in vivo and is dependent on the increased ability of these mutant 
proteins to bind GTP and be hyperactivated by an upstream regulator (Steger 
et al., 2016, 2017; Purlyte et al., 2018; Sheng et al., 2012).  
 
Table 1.2 Pathogenic mutations identified in the LRRK2 gene 
Mutation  Domain Population Ref 
G2019S Kinase North American/ European 
families   
(Di Fonzo et al., 
2005) 
R1441C ROC-COR Western Nebraska family D (Zimprich et al., 2004) 
R1441G ROC-COR Basque family  (Paisán-Ruíz et al., 
2004) 
R1441H ROC-COR European/ Taiwanese 
families  
(Mata et al., 2005) 
Y1669C ROC-COR German-Canadian family A (Zimprich et al., 2004) 
I2020T Kinase Funayama Japanese family (Funayama et al., 
2005) 
N1437H ROC-COR Norwegian family F04 (Aasly et al., 2010) 
 
1.4.9. LRRK2 and Rab proteins 
Although LRRK2 is thought to be an attractive therapeutic target, the clinically 
significant substrate(s) of LRRK2 remain unknown. Many potential substrates 
have been identified via various methodologies, however, there is no 
consensus in the field which, if any, are the most important in the context of 
PD. One significant breakthrough came with an unbiased and comprehensive 
proteomic study which yielded the discovery that LRRK2 can phosphorylate a 
distinct subset of Rab proteins. Phosphorylation occurs at a conserved serine 
or threonine residue in their switch II domain (Steger et al., 2016, 2017). This 




membrane trafficking defects and PD is largely thought of as a disease of 
membrane traffic (Hasegawa et al., 2017; Bandres-Ciga et al., 2019; Hunn et 
al., 2015; Clague and Rochin, 2016). Other phosphoproteomic work showed 
that PINK1 is also able to phosphorylate a separate subset of Rab proteins 
(Lai et al., 2015a). Additionally, a number of Rab proteins have also been 
linked to PD, solidifying that membrane traffic, and the role Rab proteins play 
in its regulation, are somehow key in understanding pathogenesis (Shi et al., 
2017; Gao et al., 2018; Gitler et al., 2008; Lai et al., 2015b; Cooper et al., 2006; 
Mata et al., 2015; Wilson et al., 2014).  
 
16 Rab proteins have been proposed as LRRK2 substrates (Rab1A/B, 
Rab3A/B/C/D, Rab5A/B/C, Rab8A/B, Rab10, Rab12, Rab29, Rab35 and 
Rab43) (Steger et al., 2017; Jeong et al., 2018) (Table 1.3). In addition to 
potentially being significant in understanding PD pathology, the 
phosphorylation of Rab proteins also provides a useful readout for LRRK2 
activity. Phos-tag gels produce a mobility shift between the non-
phosphorylated and phosphorylated forms of proteins (Ito et al., 2016). This 
allows for changes in the phosphorylation state of Rabs to be analysed by 
western blotting. A phospho-specific antibody against the LRRK2 
phosphorylation site of Rab10 has been developed as another tool to measure 
LRRK2 activation and kinase activity (Lis et al., 2018; Mir et al., 2018). Rab29 
is unusual in that is has a serine residue at the conserved LRRK2 
phosphorylation site with an adjacent threonine residue (Thr71 and Ser72) 
(Steger et al., 2017). Although it can do both, data suggests that LRRK2 
phosphorylates the neighbouring threonine rather than the serine residue, in 
line with a preference for threonine (Liu et al., 2018). LRRK2 pathogenic 
mutations which result in hyperactive kinase activity are found to increase the 
phosphorylation of substrate Rab proteins (Liu et al., 2018; Ito et al., 2016; 
Steger et al., 2017, 2016; West et al., 2005).  
 
Initial data suggested that LRRK2 phosphorylation of Rab proteins affects their 
ability to bind effector proteins. In particular, phosphorylation in the switch II 




chaperone proteins, which remove inactive Rab proteins from their acceptor 
membrane (Figure 1.2B). This was predicted to put a hold on the Rab cycle 
leaving an increased pool of inactive Rab proteins docked at the membrane 
(Steger et al., 2016, 2017). The general view in the field now is that the effects 
of LRRK2 phosphorylation are more complex than this initial model and are 
likely Rab protein specific.  
 
As well as being substrates of LRRK2, specific Rab proteins have been found 
to recruit LRRK2 to membranes. The Rab32 subfamily consist of three Rab 
proteins with high homology. Rab32 and Rab38 are highly similar and act 
redundantly in many cell types. LRRK2 substrate, Rab29, is also a member of 
this family. All three family members have been shown to interact with LRRK2, 
which is proposed to be via LRRK2’s ARM domain (Waschbüsch et al., 2014; 
McGrath et al., 2021). However, some work has proposed that Rab29 interacts 
with LRRK2’s ANK domain (Purlyte et al., 2018). Rab29 has been shown to 
recruit LRRK2 to the Golgi membrane, whereas Rab32 has been shown to 
recruit LRRK2 to various endo-lysosomal membranes (Beilina et al., 2020; 
Purlyte et al., 2018; Liu et al., 2018; Waschbüsch et al., 2014). 
 





Localisation   Reference  
Rab1A T75 ER and Golgi (Jeong et al., 2018) 
Rab1B  ER and Golgi (Jeong et al., 2018) 
Rab3A T86 Secretory vesicles (Steger et al., 2017) 
Rab3B T86 Secretory vesicles (Steger et al., 2017) 
Rab3C T94 Secretory vesicles (Steger et al., 2017; 
Jeong et al., 2018) 
Rab3D T86 Secretory vesicles (Steger et al., 2017) 
Rab5A S84 Early Endosome (Jeong et al., 2018; 
Steger et al., 2016) 
Rab5B S84 Early Endosome (Steger et al., 2016) 




Rab8A T72 Lysosomes, Primary 
cilia, Golgi 
(Steger et al., 2017; 
Jeong et al., 2018) 
Rab8B T72 Lysosomes, Primary 
cilia, Golgi 
(Steger et al., 2017; 
Jeong et al., 2018) 
Rab10 T73 Lysosomes, 
mitochondria 
(Steger et al., 2017; 
Jeong et al., 2018) 
Rab12 S106 Recycling endosome (Steger et al., 2017) 
Rab29 S72 and T71 Golgi  (Steger et al., 2017) 
Rab35 T72 Plasma membrane, 
recycling endosome 
(Steger et al., 2017; 
Jeong et al., 2018) 
Rab43 T82 Golgi apparatus (Steger et al., 2017) 
 
1.4.10. LRRK2 and the endolysosomal system  
LRRK2 activity and its mutations have been found to cause disruption to the 
endolysosomal system across various models. Fibroblasts from [G2019S] 
LRRK2 carriers show an enlarged lysosome phenotype with increased 
clustering to the perinuclear area (Henry et al., 2015; Hockey et al., 2015; Ho 
et al., 2020; MacLeod et al., 2013). This phenotype is also observed in mouse 
neurons in aged subjects with the [R1441G] mutation, accompanied by a 
reduction in lysosomal degradative capacity (Ho et al., 2020). [G2019S] 
expressing neurons have also been linked to mis-trafficking of the CIMPR 
(MacLeod et al., 2013). LRRK2 may also impact retrograde traffic through 
Rab32 and Rab38. As mentioned above, Rab32/38 are LRRK2 interactors. 
They can also interact with the retromer complex via SNX protein SNX6. 
Defects in Rab32 have been linked to ineffective retrograde traffic measured 
by CIMPR distribution (Waschbüsch et al., 2019, 2014). It is not clear if these 
defects are related to the interaction between LRRK2 and Rab32. Additionally, 
LRRK2 activity changes have also been linked to lysosome dysfunction via 
glucocerebrosidase (GCase) activity (Nguyen and Krainc, 2018; Ysselstein et 
al., 2019).  Collectively these studies implicate LRRK2 as a key regulator of 






LRRK2 is highly expressed in the kidneys and this region shows the most 
severe phenotypes. Alterations in lysosomal morphology, size, distribution and 
activity have been linked to LRRK2 depletion and mutation in mouse kidneys 
(Hinkle et al., 2012; Tong et al., 2012, 2010a; Baptista et al., 2013; Kuwahara 
et al., 2016). LRRK2 knockout mice also exhibit defects in autophagy in their 
kidneys, however, there is some dispute over where in the autophagic 
pathway the defects lies (Hinkle et al., 2012; Tong et al., 2010a). Some studies 
suggest that LRRK2 affects autophagic initiation and maturation, whereas 
others suggest that there is a defect in autophagic flux. It could be that there 
are issues with autophagic initiation which are exacerbated by defects in 
lysosomal function. In LRRK2 and LRRK1 double knockout mice brains, there 
are defects in autophagy accompanied with age dependent dopaminergic 
neuronal degeneration. In this study, kidney defects were initiated with LRRK2 
single knockout. However, knockout of LRRK1 was also required for the 
neuronal defects (Giaime et al., 2017). This may indicate that the low levels of 
LRRK2 in the brain can be compensated for by LRRK1 but this is not sufficient 
for the high endogenous levels in the kidney.  
 
LRRK2 has been shown to phosphorylate Rab5 (Steger et al., 2016). 
Expression of hyperactive LRRK2 mutants was shown to delay the recruitment 
of Rab5 to the early endosome and cause subsequent delays in the Rab5 to 
Rab7 endocytic switch (see Section 1.1.6) (Gómez-Suaga et al., 2014). 
LRRK2 has also been linked to vesicle sorting from lysosomes. Lysosome 
permeabilization by lysomotrophic reagent L-leucyl-L-leucine methyl ester 
(LLOME) recruited LRRK2 to lysosomes in a system independent of 
lysophagy. LRRK2 was localised to tubules emerging from disrupted 
lysosomes which were also positive for JIP4. The model proposed suggests 
that LRRK2 phosphorylates Rab35 and Rab10 which are then retained at the 
lysosomal membrane. This phosphorylation event is required for recruitment 
of JIP4 which is responsible for the formation of tubular structures which are 





1.4.11. LRRK2 and mitophagy  
In addition to a role in the endolysosomal system, there has been much 
evidence supporting a role for LRRK2 in the parallel pathway of mitophagy. 
LRRK2 kinase activity was able to disrupt the PINK1/Parkin induction of 
mitophagy by blocking interaction of Parkin with dynamin-like protein 1 (DLP1) 
(see Section 1.4.5). This defect could be rescued by expression of a kinase 
dead form of LRRK2 or by chemical inhibition of LRRK2 kinase activity 
(Bonello et al., 2019). LRRK2 substrate Rab10 was shown to accumulate on 
the mitochondrial membrane and recruit optineurin (OPTN) for the induction 
of mitophagy. Hyperactivating mutations in LRRK2 were found to result in 
decreased interaction of Rab10 with OPTN and therefore a reduction in the 
initiation of mitophagy (Wauters et al., 2020).  
 
As well as the PINK1/Parkin pathway, [G2019S] LRRK2 has been shown to 
affect basal mitophagy in neuroepithelial cells as marked by a decrease in 
mitochondrial clearance and an increase in the number of fragmented 
mitochondria (Walter et al., 2019). The mitochondrial membrane potential and 
intracellular ATP levels were reduced in LRRK2 [G2019S] derived patient 
samples (Mortiboys et al., 2010).  [G2019S] LRRK2 mutant neurons show an 
increase in the autophagy markers p62 and LC3 indicating a more general 
defect in autophagic pathways (Schwab et al., 2017).  Finally, LRRK2 has 
been found to interact with Mitochondrial Rho (Miro), a small mitochondrial 
GTPase involved in mitochondrial transport and homeostasis. LRRK2 
[G2019S] mutation was found to stabilise Miro and impact damaged 
mitochondrial clearance. This study found that [G2019S] mutation negatively 
impacted mitophagy initiation which was rescued with depletion of LRRK2 
(Wang, 2017; Hsieh et al., 2016). 
 
1.4.12. LRRK2 and the TGN 
Rab29 (also sometimes referred to as Rab7L1) is one of 5 genes within the 
PARK16 locus and has been identified as a genetic risk factor for the 




reported to primarily localise to the Golgi apparatus as well as tubules 
emerging from the Golgi (Spanò et al., 2011; MacLeod et al., 2013). Rab29 
was originally identified as a phosphorylation target of LRRK2 (Steger et al., 
2016, 2017). There is clear evidence that LRRK2 and Rab29 operate in 
common pathways, although it is currently poorly understood how they are 
functionally related. Studies have shown that LRRK2 and Rab29 act together 
to control axonal elongation in C. elegans neurons with Rab29 acting 
upstream of LRRK2 (Kuwahara et al., 2016).  LRRK2 hyperactive pathogenic 
mutations are known to induce reduced neurite process length in rat neurons, 
which can be rescued by the overexpression of Rab7L1. Knockdown of 
Rab7L1 was also able to phenocopy LRRK2 hyperactivation (MacLeod et al., 
2013). The same study showed that overexpression of retromer component 
and PD related gene VPS35 was able to rescue the neurite process length 
phenotype induced by LRRK2 mutation. Genetic studies have found common 
variants in the LRRK2 and Rab29 loci which function non-additively to affect 
the risk of Parkinson’s disease (Kuwahara et al., 2016; MacLeod et al., 2013).   
 
Additionally it has been shown that Rab29 can recruit LRRK2 to the TGN 
(Purlyte et al., 2018; Beilina et al., 2020; MacLeod et al., 2013; Liu et al., 2018). 
Further evidence for Rab29 being upstream of LRRK2 was found when 
overexpression of Rab29 enhanced the phosphorylation of Rab10 and Rab29 
by LRRK2 as well as LRRK2 autophosphorylation (Purlyte et al., 2018; Liu et 
al., 2018). Data shows that the ROC-COR domain mutants (such as 
[R1441C/G/H]) are more readily activated by Rab29 compared to WT LRRK2 
and [G2019S] mutant LRRK2. Studies speculate this is due to the fact that 
these LRRK2 mutants more readily bind GTP, and that GTP binding is 
required for Rab29 activation of LRRK2 (Liu et al., 2018; Purlyte et al., 2018). 
It has been shown in several studies that hyperactive LRRK2 results in 
disruption of the TGN, a phenotype which can be rescued by treatment with 
LRRK2 inhibition. A recent study has shown that Rab29 and LRRK2 can 
functionally interact with the Golgi Associated Retrograde Protein (GARP) 
complex (Beilina et al., 2020). LRRK2 and Rab29 can associate via the VPS52 




Rab29 can recruit the GARP complex when overexpressed. Loss of GARP 
complex components disrupts Rab29 mediated recruitment of LRRK2 to the 
TGN. Both LRRK2 and GARP component VPS52 can interact with the SNARE 
proteins at the TGN (Beilina et al., 2020). This suggests a role for the LRRK2-
GARP complex interactions in stabilising the SNARE proteins at the TGN and 
therefore a role in membrane fusion and trafficking.   
 
1.4.13. VPS35  
Vacuolar protein sorting-associated protein 35 (VPS35) makes up one of the 
three core retromer components alongside VPS26 and VPS29. It is part of the 
vacuolar protein sorting gene family originally identified in yeast. It binds in a 
heterotrimeric complex with the other core components, which provides a 
scaffold for the large multimeric protein retromer complex. VPS35 is therefore 
essential for the recycling of proteins from the endosomal network to the TGN 
by retrograde transport. VPS35 is the largest component of the retromer and 
serves as a platform for VPS26 and VPS29 to bind to (Swarbrick et al., 2011; 
Seaman, 2004, 2012; Seaman et al., 2009, 1997, 1998). 
 
1.4.14. VPS35 in Parkinson’s Disease 
Pathogenic mutations have been identified in VPS35 which result in an 
autosomal dominant inheritance pattern. The most common mutation is the 
VPS35 [D620N] mutation resulting in a late-onset levodopa-responsive form 
of PD (Zimprich et al., 2011; Vilariño-Güell et al., 2011; Williams et al., 2017). 
Other more rare mutations in VPS35 have been linked to PD but the 
pathogenicity of these mutations is not confirmed (Williams et al., 2017). 
Because neurons have a long axis between the soma of the cell and the 
synaptic terminals, there is a greater challenge to both anterograde and 
retrograde transport through the endolysosomal system (Vidyadhara et al., 
2019). VPS35 and the other retromer complex components are therefore 





It has been proposed that pathogenic mutations in VPS35 inhibit its ability to 
associate with the other retromer components therefore impairing retrograde 
transport (Williams et al., 2017). However, other studies have shown that 
[D620N] VPS35 is able to form the retromer complex with the same efficiency 
as wild type (Ishizu et al., 2016). The [D620N] mutation has also been reported 
to disrupt the interaction of retromer with FAM21, a component of the WASH 
complex important to retrograde transport (McGough et al., 2014). Mutations 
in VPS35, as would be expected, led to lysosome dysfunction manifesting in 
enlarged lysosomes. In addition, studies found that loss of function of VPS35 
or depletion led to a-synuclein aggregates, dopaminergic neuron loss and 
autophagy (Follett et al., 2016; Tang et al., 2015b). Studies showed an 
increase in the turnover of LAMP2 in VPS35 [D620N] mutant cells which the 
authors speculated is due to a defect in retrograde transport. Misfolded a-
synuclein is turned over by the lysosome, a process where LAMP2 is thought 
to be important (Tang et al., 2015a). a-synuclein has also been found to 
disrupt the retromer complex by interacting with the VPS26 and VPS29 core 
subunits. This results in a reduced binding capacity for VPS35 as well as the 
SNX-BAR adaptors (Patel and Witt, 2018). Therefore, a vicious cycle ensues 
where, dysfunction in VPS35 is thought to lead to accumulation of a-synuclein 
through reduced turnover and accumulated a-synuclein further impairs 
retromer function via disruption at the core complex.  
 
1.4.15. Retromer and mitochondrial dynamics 
The canonical role for the retromer is endosome to TGN retrograde transport 
through the endolysosomal system. One landmark paper identified a role for 
the retromer complex in the formation of mitochondrial derived vesicles (MDVs) 
(Braschi et al., 2010). MDVs are a mitochondrial quality control pathway which 
is independent of mitophagy (Sugiura et al., 2014).  
 
Steinberg’s group showed a role for the retromer in mitophagy. The retromer 
is a well-established effector of Rab7, with active Rab7 being essential for 




2008; Seaman et al., 2009). Work from Steinberg’s group showed that 
knockout of VPS35 increased the level of “active”, GTP-bound Rab7 in cells. 
They propose this is via TBC1D5- a Rab7 GAP which can interact with core 
retromer component VPS29. This study proposes a model where Rab7 
recruits the retromer to the endosomal system, and once there, the retromer 
is able to “switch off” active Rab7 via its interaction with TBC1D5 which allows 
Rab7 to localise to mitochondria (Jimenez-Orgaz et al., 2018). 
 
Another study has shown that VPS35 mutations cause mitochondrial 
dysfunction through a relationship with DLP1. DLP1 is a key regulator of 
mitochondrial fission (Li et al., 2018). The paper showed that overexpression 
of VPS35 induced mitochondrial fragmentation and dysfunction which was 
further enhanced by VPS35 pathogenic mutation. They show that VPS35 
interacts with DLP1 and is responsible for DLP1 turnover via its role in MDV 
formation (Sugiura et al., 2014).  
 
1.4.16. LRRK2 as part of a Parkinson’s network 
Both LRRK2 and VPS35 have been linked to both major pathways implicated 
in PD and there is significant evidence that they operate in common and 
overlapping pathways (Figure 1.13). The pathogenic mutations in LRRK2 and 
VPS35, as discussed in Sections 1.4.10, 1.4.11 and 1.4.14, have been shown 
to cause a variety of different phenotypes, depicted in Figure 1.14. There is 
some disagreement in the literature regarding the effect of the [D620N] 
mutation on VPS35 activity. Loss of binding interactions of VPS35 would 
suggest a loss of function mutation. VPS35 [D620N] mutation has been found 
to hyperactivate LRRK2 kinase activity, suggesting VPS35 is upstream of 
LRRK2 (Mir et al., 2018). Heterozygous mutation of VPS35 resulted in an 
increase in Rab10 phosphorylation by LRRK2 which would suggest this is a 
gain of function.  
 
LRRK2 and VPS35 have both been shown to regulate Rab7 activity. It is 




inactivation of Rab7. LRRK2 has been reported to negatively regulate Rab7, 
with hyperactive LRRK2 [G2019S] decreasing GTP-Rab7 in patient derived 
fibroblasts relative to WT (Gómez-Suaga et al., 2014). Interestingly, Rab7 is 
not a direct substrate of LRRK2, but is in fact a substrate of its homologue, 
LRRK1 (Malik et al., 2020). It has not been determined whether the effect of 
VPS35 on Rab7 is mediated by its activation of LRRK2 kinase activity, or 
whether these two PD related proteins negatively regulate Rab7 by two distinct 
mechanisms. It has been suggested that LRRK2, VPS35 and Rab29 are three 
PD related genes which operate in the same pathway, with VPS35 and Rab29 
being upstream regulators of LRRK2 activity (Figure 1.14) (MacLeod et al., 
2013; Liu et al., 2018; Purlyte et al., 2018). However, it still remains unclear if 










Figure 1.13 LRRK2, VPS35 and Rab29 work in an 
interconnected PD network 
Parkinson’s disease related proteins LRRK2, VPS35 and Rab29 
have been shown to operate in a variety of cell biology pathways. 
LRRK2 can phosphorylate a subset of Rab proteins including Rab5, 
Rab10 and Rab8. These phosphorylation events have been linked 
to deficient endolysosomal trafficking and protein homeostasis. 
Additionally, LRRK2 can be recruited to the TGN by Rab29. LRRK2 
is able to interact with DLP1 and Miro at mitochondria. 
Phosphorylation of Rab10 was shown to increase OPTN 
recruitment to mitochondria for mitophagy. The retromer has been 
shown to function in the MDV quality control pathway, as well as in 
its canonical role in retrograde trafficking. It acts as a Rab7 effector 
at MVBs and is able to recruit the WASH complex. Created with 








Figure 1.14 Mutations in LRRK2 and VPS35 cause a wide 
array of trafficking and homeostasis defects 
ROC-COR LRRK2 mutations are hyperactivated by Rab29 
overexpression and are more efficiently recruited to the TGN. Most 
LRRK2 mutations cause a hyperactive kinase leading to excessive 
phosphorylation of target Rab proteins. They also lead to defects 
in efficient endolysosomal trafficking of proteins, lysosome function 
and general protein homeostasis. LRRK2 mutations are also 
associated with reduced quality control of mitochondria and 
mitophagy clearance. The PD associated [D620N] mutation in 
VPS35 has been shown to hyperactivate LRRK2 kinase activity 
suggesting it lies upstream of LRRK2 in a common pathway. 
[D620N] has also been shown to alter retrograde traffic in the 
endolysosomal system, recruitment of the WASH complex as well 
as altering mitochondrial dynamics and homeostasis.  Created with 




1.5. Aims of study  
LRRK2 functions in a wide variety of pathways and these functions overlap 
with other PD related proteins. Understanding the physiological function of 
LRRK2 in these processes is as important as understanding its 
pathophysiology, especially as LRRK2 represents an attractive therapeutic 
target. I thus aimed to gain a better understanding of the physiological role of 
LRRK2 in cells, and how this would relate to other PD linked proteins. I also 
aimed to investigate if LRRK2 plays a role in the relationship between PD and 
melanoma, as data from the cancer cell line encyclopaedia shows that LRRK2 
is highly expressed across melanoma cell lines. In addition to this, early work 
showed LRRK2 is inversely related to the expression of pigmentation markers 
in melanoma cells.   
 
In Chapter 3, I generate tools which provide a platform to study the physiology 
of both LRRK2 and VPS35 in the context of their pathogenic mutations. In 
particular, I have generated the tools required to study the effect of both 
LRRK2 and VPS35 on the activity of Rab7.  
 
In Chapter 4, I will show the effect of LRRK2 depletion and inhibition on a 
number of organelle markers in the context of melanoma cells and 
melanocytes. Prior to this thesis there were multiple studies indicating a role 
for LRRK2 in membrane traffic in the endolysosomal system, however, the 
mechanisms underpinning these pathways remain poorly understood.  
 
Finally, in Chapter 5, I will report on a role for LRRK2 in melanogenesis and 
melanoma progression phenotypes. PD has been linked to an increase in the 
incidence of melanoma compared to the general populations, but the reason 
for this is not known. Although LRRK2 mutations only account for a small 
proportion of PD patients, LRRK2 is highly expressed across melanoma cell 







2. Chapter 2: Materials and Methods 
2.1.  Cell Culture 
2.1.1. Materials and Reagents 
RPMI 1640 W/GLUTAMAX-I (#61870-036), Dulbecco’s Modified Eagle’s 
Medium, high glucose, GlutaMAXTM Supplement, pyruvate (DMEM, #31966-
021), DMEM F12 GlutaMAXTM (#10565018), AIM VTM Medium (#31035025), 
Trypsin 0.5% EDTA, 10X (#15400054), Penicillin-Streptomycin (#15140122), 
MEM Non-Essential Amino Acids Solution (MEM NEAA, #11140-035), Sodium 
Pyruvate (#11360070), Fetal bovine serum (#10270106) were all purchased 
from Invitrogen (UK). GeneJuice (#70967), Phorbol 12-myristate 13-acetate 
(TPA, #P8139), N-Phenylthiourea (PTU, #P7629) Doxycycline (Dox, D9891), 
and G418 (#4727878001) were purchased from Sigma. Flp-In kit (#K601002), 
Blasticidin (#R21001) and Zeocin (#R25005) were purchased from Thermo 
Fisher scientific. LRRK2 lentivirus was purchased from Ku Leuven (Error! R
eference source not found.). Polybrene (#TR-1003) was purchased from 
Merk-Millipore. All plasticware was purchased from Corning Inc. (NY, USA).  
For work in Sheffield Minimum Essential Medium (MEM), with Earle’s Salts, 
with L-Glutamine(#E15-825) and Foetal Bovine Serum (FBS) Gold (#A15-151) 
were purchased from PAA. Penicillin / Streptomycin Solution (100X 
concentrate) (#17-602E), MEM Vitamins Solution (100X) (#11120-037), MEM 
Non-Essential Amino Acids (100X) (#11140-035) and Na Pyruvate (#13-115E) 
were all purchased from Lonza (USA). Uridine (#U-3003) was purchased from 
Sigma.   
 
2.1.2. Cell lines 
Melan-a melanocyte cell line was obtained from E. Sviderskaya (London, UK). 
Parental human telomerase reverse transcriptase immortalised retinal-
pigment epithelial Flp-In (hTERT-RPE1 Flp-In (RPE1 Flp-In)) cells were 
provided by Dr Jon Pine (ICR, London). The WM266.4 cell line was obtained 




Invitrogen. MNT1 cells were obtained from Graca Raposo (Institut Curie, 
Paris).  
 
Fibroblast lines derived from patient skin punches were cultured at the 
Sheffield Institute of Translational Neuroscience (SiTraN) under the 
supervision of Dr Heather Mortiboys. iNPCs were derived from reprogramming 
patient fibroblasts carried out by Dr Heather Mortiboys. Dopaminergic neurons 
were derived from these iNPCs as per protocol in Section 2.1.10 under the 
supervision of Dr Heather Mortiboys. 
 
2.1.3. Cell line culture 
Melan-a cells were maintained in RPMI 1640 W/GLUTAMAX-I gassed at 10% 
CO2, supplemented with 10% non-heat-inactivated fetal bovine serum, 200 nM 
TPA. TPA was added to cells fresh with each passage. Media was also 
supplemented with 200 µM PTU for the first 3 days of culture. Cells were split 
1:3 every 2-3 days up to a maximum passage number of 30 and were 
maintained in a humidified 10% CO2 atmosphere at 37°C. WM266.4 cells and 
HEK293 Flp-In cells were maintained in DMEM + GlutaMAXTM supplemented 
with 10% heat-inactivated fetal bovine serum, 1% MEM NEAA in a humidified 
5% CO2 atmosphere at 37°C. Cells were split 1:6 every 2-3 days. RPE1 Flp-
In cells were maintained in DMEM F12 (1:1) supplemented with 10% heat-
inactivated fetal bovine serum, 1% MEM NEAA in a humidified 5% CO2 
atmosphere at 37°C. MNT1 cells were maintained in DMEM + GlutaMAXTM 
supplemented with 20% FBS, 10% AIM-V, 1% NEAA and 1% sodium pyruvate 
in a humidified 5% CO2 atmosphere at 37°C. 
 
2.1.4. Flp-InTM T-RExTM System  
The Flp-In T-Rex system is a system marketed by Themo Fisher Scientific for 
the rapid generation of cell lines using a Flp recombination target (FRT) site. 
This system utilises cells that have two plasmids (pCDNA6/TR and 
pFRT/lacZeo, Figure 2.1) stably integrated into their genome. The 




of interest into the genome of the cell at a transcriptionally active locus. The 
pCDNA6/TR plasmid contains the TetR gene which results in the expression 
of the Tet repressor protein. In this system, the gene of interest (GOI) 
integrated into the cell’s genome is only expressed with the addition of 
doxycycline or tetracycline. They can displace the Tet repressor protein from 
the promotor region of the gene and allows for transcription and expression 
(Figure 2.2). The pCDNA6/TR and pFRT/lacZeo plasmids each have their 
own antibiotic selection marker- Blasticidin and Zeocin respectively (Figure 
2.1). These antibiotics are used to maintain the cells prior to transfection to 
ensure cells have retained the plasmids stably integrated into their genome. It 
is also important cells only have one FRT site within their genome- as this 
ensures that each GOI is only integrated into one site and that cell lines are 
comparable. 
 
The GOI is cloned into a pCDNA5/FRT/TO plasmid with a resistance gene for 
selection of clones. The plasmid is co-transfected with a pOG44 plasmid which 
encodes the recombinase enzyme required for the integration (Figure 2.3). In 
the original system, the pCDNA5/FRT/TO plasmid has hygromycin as the 
selection marker for stably transfected cells. One benefit of this system is the 
generation of isogenic models for different mutations of the same protein. 
Integration at the FRT site means that WT and mutant forms of a protein 
should be expressed at the same levels- something which cannot be 







Figure 2.1 Plasmids stably integrated into the genome of 
Flp-In cells 
pFRT/lacZeo and pCDNA6/TR plasmids are stably integrated 
into Flp-In cells. This ensures that the integrated gene of interest 
is added at a transcriptionally active locus. It also ensures that 
the expression of the gene of interest is controlled by the Tet 
repressor and therefore can be induced with doxycycline. 
 
 
In the case of my project, we wanted to generate hTERT-RPE1 (RPE1) Flp-In 
cells with GOI VPS35 WT or VPS35 [D620N]. In this case the GOI was cloned 
into a pCDNA5 FRT/TO Neo plasmid, as RPE1 cells are already resistant to 
hygromycin (Bodnar et al., 1998). RPE1 cells were co-transfected with one of 
two VPS35 plasmids (VPS35 WT or [D620N]) alongside pOG44 plasmid and 
positive clones were selected with G418 selection media. Clones were 
screened for VPS35 expression +/- doxycycline followed by western blotting. 






Figure 2.2 Repression of gene of interest expression in Flp-
In cells 
RPE1 Flp-In cells contain a Tet repressor (TetR) gene. The gene 
of interest is cloned into a locus under the control of the Tet 
repressor protein. Addition of doxycycline displaces the Tet 
repressor protein and activates expression of the gene of 







Figure 2.3 Integration of GOI into FRT site by a 
recombinase enzyme 
Transfection of a pCDNA5 FRT/TO plasmid encoding the gene 
of interest alongside a plasmid encoding the recombinase results 
in the integration of the gene of interest at the FRT site. This 
ensures the integration occurs at a transcriptionally active locus 
and that cell lines are comparable as they should have even 







Figure 2.4 Workflow of generation of RPE1-VPS35 Flp-In 
cell lines 
pCDNA5 FRT TO vector containing the gene of interest (GOI) 
was co-transfected with pOG44 Flp vector containing the 
recombinase enzyme. Cells were split from a 6 well plate into a 
10 cm dish and put under antibiotic selection. Colonies were 
picked from the 10 cm dish into multi-well plates and screened 
by adding doxycycline to induce expression. Clones were 
screened by western blotting and immunofluorescence.  
 
 
2.1.5. Generating VPS35 Flp-In Cell lines 
On day 1, RPE1 Flp-In parental cells were co-transfected with pCDNA5 
FRT/TO Neo plasmids generated with HA-VPS35 (WT or [D620N] mutant) 
(100 ng) and pOG44-Flp plasmid (900 ng) using Genejuice transfection 
reagent (see below). An additional well was transfected with GFP plasmid to 
check transfection efficiency. Transfection efficiency was approximately 30%. 
On day 2, cells were split 1:4 from a 6-well plate into a 10 cm dish in selection 
media (DMEM F12 + Blasticidin + G418) in order to get single colonies. Once 
single colonies were visible, they were picked into 24-well plates and from 






2.1.6. Screening VPS35 Flp-In clones 
Selected colonies were seeded into 6-well plates and treated +/- doxycycline 
(1 µg/ml) for 24 hours. Cells were lysed and screened by western blot, probing 
for HA and VPS35 (see below for methods). Cells were also screened by IF 
staining for HA expression to check if cells were single clones. This work was 
carried out in collaboration with Katy McCarron. 
 
2.1.7. Single cell dilution of mixed clones 
Mixed clones were trypsinised and counted using a haemocytometer. Cells 
were diluted 1:100. 150 cells were then split across 3 x 96 well plates to obtain 
single clones. Clones were expanded from 96 well plates and then screened 
as above. This work was carried out in collaboration with Katy McCarron. 
 
2.1.8. Generating LRRK2 Lentivirus cell lines 
Single RPE1 Flp-In clones, VPS35 WT 3B4 and VPS35 [D620N] 1F3, 
generated in section 2.1.7 were transduced with LRRK2 lentivirus purchased 
from Ku Leuven (see Table 2.1). From the viral titre, a multiplicity of infection 
(MOI) of 0.8 was calculated for each virus. Cells were transduced with virus in 
full media with polybrene. Media was exchanged after 48 hours. Cells were 
expanded to 15 cm dishes. Cells were then trypsinised, washed in PBS then 
resuspended in FACS buffer (PBS + 1% FBS). GFP-positive cells were sorted 
using FACS (carried out by Ailbhe Brazel). Polybrene only control was used 
to set the gating. Positive cells were expanded and screened by live cell 










Table 2.1 LRRK2 lentiviruses 
Production 
number   










PD-12-233 LV-CMV-eGFP (control) 2.13E+13 
 
2.1.9. Fibroblast cell culture  
Patient derived fibroblasts were maintained in MEM supplemented with 10% 
Foetal bovine serum gold, 1% MEM vitamins solution, 1% MEM Non-Essential 
Amino Acids, 1% Penicillin/Streptomycin, 1% sodium pyruvate and Uridine 
(200 µM). Cells were maintained in a humidified 5% CO2 atmosphere at 37°C. 
Cells were split 1:3 once a week and fed every other day with a full media 
change. 
 
2.1.10. Dopaminergic neuron differentiation 
iNPCs were plated into a 6-well plate in DMEM/F-12 medium with Glutamax 
supplemented with 1% NEAA, 2% B27 supplement. Cells were cultured for 2 
days with full media plus DAPT (2.5 µM). After 2 days, DAPT media was 
removed, and replaced with full media supplemented with SAG and FGF8 (1 
µM) factors. Cells were maintained in these factors for 10 days, changing the 
media every day. On day 12, neurons were re-plated into plates for assaying. 
Following this, factors were replaced with BDNF (30 ng/ml), GDNF (30 ng/ml), 
TGF-b3 (2 mM) and dCAMP (2 mM) for 15 days. On the final day cells were 










2.2. Cell Biology 
2.2.1. Materials and reagents  
Lipofectamine RNAiMAX (#13778075), Lipofectamine LTX with PLUS 
(#15338100), Opti-MEM™ Reduced Serum Medium, GlutaMAX™ 
Supplement (#51985034), and RPMI 1640 no phenol red (11835030), 
LysoTrackerTM Red DND-99 (#L7528), were all purchased from Invitrogen 
(UK). MLi-2 (#5756) and Torin1 (#4247) were purchased from TOCRIS 
(Abingdon, UK). GSK2578215A (#S7664), GNE-0877 (#S7367), Rapamycin 
(#S1039) were purchased from Selleckchem (TX, USA). HG-10-102-01 
(#438195) and GeneJuice Transfection Reagent (#70967) were purchased 
from Merck Millipore (Dorset, UK). Cycloheximide (CHX) (#C7698), were 
obtained from Sigma- Aldrich (Merck). Magic Red Cathepsin B Kit (#ICT937) 
was purchased from Bio-Rad (Deeside, UK). Cathepsin D activity assay kit 
(#ab65302) was purchased from abcam (Cambridge, UK). siRNA 
oligonucleotides were purchased from Dharmacon (Cambridge, UK). IBIDI 
products purchased from Thistle Scientific (Glasgow, UK). Hoechst 33342 
(#62249) was purchased from Thermo Fisher Scientific.  
 
2.2.2. siRNA knockdown  
Melan-a cells were seeded into 6 well plates at a density of 2x105 per well on 
day 1. WM266.4 and RPE1 Flp-In cells were seeded into 6 well plates at a 
density of 1.5x105 on day 1. On day 2 cells were transfected with siRNA (40 
nM) using Lipofectamine RNAiMAX in Opti-MEM medium at a 1:1 ratio 
according to manufacturer’s protocol. The reaction was added to cells for 6 
hours before it was exchanged for normal media. Reactions were left for 72 










Table 2.2 siRNA oligonucleotide sequences  
All siRNAs were purchased from Dharmacon (CO, USA) 























































































































































For HEK293 Flp-In and RPE1 Flp-In cells, Genejuice transfection reagent was 
used as per the manufacturers protocol. In short, cells were seeded on Day 1 
to be at 70% confluency on day 2 for transfection. On day 2, Genejuice 
transfection reagent was diluted in Opti-MEM serum free medium and 
incubated at room temperature for 5 min. DNA was added to the mixture and 
incubated at room temperature for 15 min. Genejuice was used at a ratio of 3 
µL per 1 µg of DNA. Media was exchanged on cells for fresh full media and 
the reagent/DNA mixture was added dropwise over cells. Cells were imaged 
or harvested after either 24 or 48 hours.  
 
2.2.4. Drug treatments 
Melan-a cells were treated with PTU (200 µM) for the first 3 days of culture to 
inhibit melanogenesis. Melan-a cells were incubated for 72 hours with 1 µM 
Rapamycin to increase pigmentation. To inhibit LRRK2 activity, cells were 
treated with 200 nM MLi-2 for 1-72 hours or 500 nM GNE-0877, HG-10-102-
01 or GSK2578215A for 1-72 hours. For RPE1 Flp-In cells VPS35 expression 
was induced with doxycycline at 0.1 µg/ml for the time point indicated in figures. 
All drug treatments were carried out in full regular culture media. The duration 
of each treatment is indicated on the respective figures.  
 
2.2.5. LysoTracker Assay 
Cells were seeded at the desired density into IBIDI glass bottomed plates and 
treated with the relevant siRNA or inhibitor. Following the desired incubation 




along with 1 µg/ml Hoechst nuclear dye and incubated for 1 hour at 37°C. 
LysoTracker media was removed, and cells washed 2 x 1 min in RT PBS. 
Media without phenol red was then added and cells immediately imaged live.  
 
2.2.6. Magic Red-Cathepsin B Lysosome activity assay 
To measure the activity of lysosomal Cathepsin B, Magic Red-Cathepsin B 
(Magic Red) reagent was used. Magic Red is a fluorescent probe which 
consists of a cresyl violet fluorophore with two target sequences for Cathepsin 
B attached. With both target sequences attached, the fluorophore is held in a 
non-fluorescent state. Entry of the Magic Red reagent into active lysosomes 
results in the cleavage of one or both of the target sequences by active 
Cathepsin B resulting in the cresyl violet emitting fluorescence. A schematic 
of how Magic Red-Cathepsin B reagent works is depicted in Figure 2.5. 
Cells were seeded at the desired density into IBIDI glass bottomed plates for 
live imaging and the appropriate treatments carried out. Magic Red reagent 
was incubated with cells in full media at 20 µL per 500 µL of cells at 106 cells/ml 
along with 1 µg/ml Hoechst nuclear dye. Reagents were incubated with cells 
for 1 hour at 37°C. Media was removed and cells washed 3 x 1 minutes in 
room temperature PBS. Media without phenol red was then added and cells 
immediately imaged live.  
 
2.2.7. Cathepsin D activity assay  
To measure the proteolytic activity of Cathepsin D, a commercially available 
activity assay from Abcam (ab65302) was used according to the 
manufacturers protocol. Briefly, Melan-a cells were lysed in the kit lysis buffer 
for 10 mins on a wheel in the cold room. Lysates were clarified by spinning for 
20 mins at 23,000 g at 4°C. The supernatant was collected. Reactions were 
set up in triplicate in a 96 well plate with kit reaction buffer and Cathepsin D 
substrate. Plates were incubated at 37°C for 2 hours before measuring the 





Figure 2.5 Schematic to show principle of Magic Red-
Cathepsin B assay 
Magic Red fluorescent probe is a readout for cathepsin B activity. 
The cresyl violet fluorophore is attached to two target sequences 
for Cathepsin B cleavage.  Prior to cleavage of either target 
sequence there is no fluorescence. Cleavage of one or both of 
the target sequences by Cathepsin B results in fluorescence.  
 
 
2.2.8. Incucyte cell proliferation assays  
WM266.4 cells were seeded for siRNA knockdown on day 1, and the reaction 
was carried out as stated in section 2.2.2. After 48 hours cells were replated 
into the final assay vessel (usually a 24 well plate) at a low density. After a 
further 24 hours (72 hours post KD) the plate was placed in an Incucyte live 




intervals for 3 days. After the final acquisition, image analysis was carried out 
using the Incucyte software. Images were segmented to identify cells and 
calculate the percentage confluence in each frame. This was then plotted over 
time to measure the speed of cell proliferation.  
 
2.2.9. Cell tracking experiments  
For experiments requiring siRNA knockdown, WM266.4 cells were treated as 
detailed in Section 2.2.2. 48 hours post knockdown, cells were replated into 
a fresh 6 well plate with 40,000 cells per well. 24 hours later (72-hour post 
knockdown), time-lapse imaging was set up. For experiments with inhibitor 
treatments, 20,000 WM266.4 cells were seeded per well into a 6 well plate. 
Cells were treated with MLi-2 for 24 hours on day 2. Time-lapse imaging 
experiments were set up on day 3. Time-lapse imaging experiments were 
acquired with a NIKON Ti-Eclipse Microscope with a CFI Plan Fluor DLL x10 
objective. Brightfield images were acquired every 15 minutes for 24 hours. 
Cells were maintained at 37°C and 5% CO2 for the duration of the experiment. 
 
2.3. Molecular Biology and Protein Preparation  
2.3.1. Materials and Reagents 
The RNeasy Mini kit (#74106), QIAshredder (#79656), QIAprep MiniPrep Kit 
(#27106), PCR clean up kit (#28104) and HiSpeed Maxiprep kit (#12633) were 
purchased from Qiagen. All primers for qPCR were ordered from Eurofins 
Scientific. All restriction digest enzymes, T4 DNA ligase reagents, 1Kb DNA 
ladder (#N3232) and 100bp DNA ladder (#N3231) as well as BL21 competent 
cells (#C2530H) were purchased from New England Biolabs. TAE buffer was 
purchased from National Diagnostics. S.O.C. medium (#1554-034), DH5α 
subcloning efficiency cells (#18265-017), SYBR Safe DNA gel stain (#S33102) 
and electrophoresis grade agarose were obtained from Invitrogen. PCR 
nucleotide mix (#C1441) and RNasin plus RNAse inhibitor (#N2611) as well 
as standard PCR reagents were purchased from Promega. Reverse 
Transcriptase (#10121360) and Reverse transcriptase buffer (#10512703) 




SYBR Green Supermix was purchased from Bio-Rad. Nuclease free water 
(#W4502), Bacterial protease inhibitors (#P8465) and all other chemicals were 
obtained from Sigma-Aldrich. 
 
Table 2.3 Table of plasmids 
Plasmid name GOI Obtained from 
pCDNA5 FRT TO VPS35 
WT 
VPS35 MRC PPU 
pCDNA5 FRT TO VPS35 
[D620N] 
VPS35 [D620N]  MRC PPU 
pGEX-4T-3-mR7BD RILP domain  Addgene  
pCDNA5 FRT TO Neo Backbone  
pGEX-6P-1 Backbone Addgene 
 
 
2.3.2. DNA PCR for cloning and subcloning process 
For this project I was required to make constructs for the generation of VPS35 
Flp-In cell lines. We obtained pCDNA5/FRT/TO HA-VPS35 (WT and [D620N]) 
constructs from Dundee which encode a hygromycin resistance gene. These 
constructs were not suitable for use in the RPE1 Flp-In cells which are already 
hygromycin resistant. I therefore needed to subclone the HA-VPS35 WT and 
HA-VPS35 [D620N] into a pCDNA5/FRT/TO Neo backbone which has a 
neomycin resistance gene instead. A schematic of the workflow used is shown 
in Figure 2.6. The VPS35 inserts were amplified by PCR for insertion into the 
neomycin resistance vector. I designed primers to retain the N-terminal HA tag 
on VPS35 and introduce an N-terminal KpnI restriction site for cloning into the 
destination vector (Table 2.5). The reverse primer retained the NotI restriction 
site at the C-terminus for cloning into the destination vector. The reaction 
mixture used for the amplification is shown in Table 2.4. The amplification 
product was run on a 1% agarose gel by electrophoresis and a band of the 
expected size was extracted. The linear product was digested with KpnI and 
NotI restriction enzymes. The digested PCR product was then purified with a 




a gel to extract the digested backbone. The two digested products were ligated 
together using a T4 DNA ligase reaction mixture  
Table 2.6). All plasmids were then sent for sequencing. This work was carried 
out in collaboration with Katy McCarron. 
 
Table 2.4 PCR reaction mixture for DNA amplification 
per reaction µl 
H2O adjusted 
10x Pfu-buffer 5 
dNTPs (25mM) 0.5 
Primer Forward (10µM) 1 
Primer Reverse (10µM) 1 
DNA template (100ng) adjusted 
HS Ultra-II Pfu fusion 1 
Total 45µl 
 
Table 2.5 DNA PCR Primers 
Gene Primer Used for Sequence 
No 







Table 2.6 T4 DNA ligase reaction mixture 
Reagent Per Reaction 20 µl 
T4 DNA ligase buffer (10X) 2 µl 
Vector (5 kb) 50 ng 
Insert (2.5 kb) 150 ng 
Nuclease free water Varied 





Figure 2.6 Schematic for the cloning process for VPS35 Neo 
plasmids 
The HA-VPS35 WT and [D620N] cDNA was amplified by PCR 
from the pCDN5/FRT/TO plasmids purchased from Dundee 
MRC PPU. Primers were designed to include the appropriate 
restriction sites. PCR products and destination vectors were 
digested with the relevant restriction enzymes. The digest 
products were ligated together to give the pCDNA5/FRT/TO Neo 
HA-VPS35 (WT/[D620N]) plasmids required to generate RPE1 
Flp-In cells. 
 
2.3.3. mRNA extraction and cDNA synthesis 
mRNA was extracted from cells using QIAshredder columns to homogenise 
cells, followed by an RNeasy mini kit according to the manufacturers protocol. 
Concentration of extracted RNA was measured using a NanoDrop 
Spectrophotometer ND100 at 260 nm. The quality of extracted mRNA was 




of mRNA was reverse transcribed to cDNA. An 11 μl solution was prepared 
which contained a total of 1 μg of mRNA and 1 μl of Oligo DT primer in sigma 
water. The solution was incubated at 70 °C for 5 minutes. During incubation 
reverse transcription buffer was prepared as per Table 2.6 below. 8 μl of 
reverse transcription buffer was added to each reaction and this mixture 
incubated at 37°C for 5 minutes followed by the addition of 1 μl of MuLV 
reverse transcriptase. The final mixture was incubated for 1 hour at 42°C 
before a final incubation at 70°C for 10 minutes. The cDNA synthesis products 
were diluted 1:4 in sigma water ready for qPCR analysis. 
 
Table 2.7 Reverse transcription reaction buffer 
Per reaction 
5x Reverse transcription 
buffer 
4 μl 
PCR nucleotide mix 2 μl 
RNasin  0.5 μl 
Nuclease free ddH2O 1.5 μl 
 
2.3.4. Quantitative real-time polymerase chain reaction (qRT-
PCR) 
Primers used for qRT-PCR are listed in Table 2.8. Prior to qRT-PCR analysis 
of samples, primers were tested in an end-point PCR reaction to ensure that 
they only produce one amplicon of the correct number of base pairs. For each 
primer pair a reaction master mix was assembled as listed in Table 2.9 and 6 
μl of this reaction added to all relevant wells of a qPCR plate. 4 μl of cDNA 
was spiked into the relevant wells before qRT-PCR was performed using the 
CFX Connect Real-Time PCR Detection system (Bio-Rad). The incubation 
cycle used is as follows: 95°C for 3 minutes for denaturation of the cDNA, 40 
cycles of a two-step amplification protocol: 95°C for 10 seconds and 60°C for 
30 seconds before a final incubation at 72°C for 10 minutes. The Ct values 




housekeeping gene Actin (ΔCt). These values were expressed as 2-ΔCt and 
the relative values to the control sample are shown as ΔΔCt. 
 
Table 2.8: qRT-PCR Primers 










LRRK2 Human 2092 F- CCCTGCCATACGAGATTACC 
2093 R- GCACATTTTTACGCTCCG 
TFEB Human 2407 F- CAGTGCTCCCAATAGCCCCA 
2406 R- CTGCTGGACAGGGGTAGCGT 
Lrrk2 Mouse 2414 F- GGAAATACGGGGAGCGG 
2415 R- GGGTCATGAAGTGGGGGT 
Tfeb Mouse 2412 F- CCTTCAGAGCGAGGGAG 
2413 R- TCAGACAGATACTCCCGAACC 
Tyrosinase Mouse 2766 F- CAGGCTCCCATCTTCAGCAGAT 
2766 R- ATCCCTGTGAGTGGACTGGCAA 
TYRP1 Mouse 2768 F- AGCCACAGGATGTCACTCAGTG 
2769 R- GCAGGGTCATATTTTCCCGTGG 
 
Table 2.9 qRT-PCR Reaction mixture 
Per reaction AND per primer pair  




Forward Primer (20 μM) 0.15 μl 





2.3.5. Bacterial Transformation  
DH5α and BL21 Escherichia coli cells were used for plasmid DNA preparation 
and protein preparation respectively. 50 μl of competent cells were thawed on 
ice before adding 100 ng of plasmid DNA. Cells were incubated on ice for 20 
minutes then heat shocked for 60 seconds in a 42°C water bath. Cells were 
then placed on ice for 2 minutes. 350 μl SOC media was added to cells 
followed by shaking at 245 rpm for 1 hour at 37°C. Reactions were plated on 
LB agar plates with an antibiotic selection marker and incubated at 37°C 
overnight. 
 
For screening DH5α colonies, multiple clones were picked into 5 ml of LB broth 
+ antibiotic and grown shaking at 245 rpm at 37°C overnight. Plasmid DNA 
was isolated using a Qiagen MiniPrep kit. Preps were first tested by double 
restriction digest and colonies that gave the appropriate dropout bands were 
sent for sequencing at the DNA sequencing service (MRC-PPU, Dundee).  
For verified constructs, a glycerol stock was made by inoculating the original 
culture into 250 ml antibiotic supplemented LB broth for overnight culture. 5 ml 
of the overnight culture was pelleted at 4000 rpm. The pellet was resuspended 
into 40% glycerol/LB broth and stocks kept at -80°C.     
 
2.3.6. Restriction Digests  
Restriction digests were used routinely to initially screen isolated plasmid DNA. 
For digest reactions 1 μg of plasmid DNA was used per reaction and 
incubation conditions and buffers were adjusted depending on the restriction 
enzymes to be used. For each digest, single digest and uncut plasmid controls 
were run to check the activity of both enzymes.  
 
2.3.7. Agarose gel electrophoresis 
DNA was resolved in 1% agarose gels using electrophoresis. Electrophoresis 
grade agarose was mixed with TAE buffer and heated using a microwave to 




SYBR Safe DNA gel stain (1x). Gels were cast into a running cassette and 
allowed to set. Samples were diluted in 6X loading buffer without SDS before 
loading. Gels were run in a horizontal midi electrophoresis tank (Fisher 
Scientific) in TAE buffer at 120V for 45 minutes. DNA was visualized using an 
ultraviolet (UV) light.  
 
2.4. Biochemistry 
2.4.1. Materials and Reagents  
2-mercaptoethanol (#M6250), Bovine IgG (immunoglobulin G), Ponceau stain 
(#P7170), Goat Serum Donor Herd (#G6767) and mammalian protease 
inhibitor (#P8340) were obtained from Sigma-Aldrich (Poole, UK). Marvel 
skimmed milk powder was ordered from Premier Brands, UK. BCA protein 
assay kit (#23225) was ordered from Pierce Biotechnology (Rockford, IL, 
USA). Nu-PAGE Bis-Tris 4-12% gels (#NP0321BOX, #NP0303BOX) as well 
as NuPAGE MOPS and MES running buffers, SimplyBlue SafeStain 
(#LC6060), DAPI (4’6-Diamidino-2-Phenylindole Dihydrochloride) (#D1306) 
were purchased from Invitrogen (Paisley, UK). Amersham Protran 0.45 μm 
nitrocellulose membrane (#10600002), Glutathione Sepharose 4B 
(#17075601) and GSTrap 1ml columns (#17528101) were purchased from GE 
healthcare. Reduced glutathione (#G4251), PD-10 Columns (GE17-0851-01), 
Lysozyme (#1052810001), IPTG (#I6758), DNase (#DN25), Protease inhibitor 
cocktail powder (#P8465), cOmplete, Mini, EDTA-free protease inhibitor 
cocktail (#11836170001) and Mowiol (#475904) were purchased from Merck 
Millipore (Darmstadt, Germany). Pre-stained broad range molecular weight 
marker (#P7708S) as well as unstained broad range marker (#P7704) were 
ordered from New England Biolabs (NEB) (Hitchin,UK). Bovine serum albumin 
(BSA, #40-00-410) was purchased from First Link (UK).  
 
2.4.2. Cell lysis 
Plates for lysis were placed on ice and washed twice in ice cold PBS before 
the addition of RIPA buffer (10mM Tris-HCL pH 7.5, 150mM NaCl, 1% Triton-




supplemented with mammalian protease inhibitor cocktail (1:250). For Melan-
a cells, cells were scraped into lysis buffer and transferred into eppendorfs on 
ice for 15 minutes. Cells were then sonicated 3 x 10 seconds with a sonicator 
probe on a low setting. For all other cell lines, RIPA buffer was added, and the 
plate rocked on ice for 15 minutes. Lysates were then centrifuged at 21,000 g 
for 30 minutes at 4°C.   
 
For hot lysis, cells were washed 2x in warm PBS before addition of pre heated 
hot lysis buffer (2% SDS, 1 mM EDTA, 50 mM NaF). Cells were scraped into 
hot lysis buffer and boiled at 110°C for 10 mins, vortexing at 2-minute intervals. 
Lysates were then clarified at 21,000g for 20 mins at RT.  
 
2.4.3. Membrane fractionation  
Plates for fractionation were placed on ice and washed twice in ice cold PBS. 
Cells were scraped into PBS and pelleted at 200 g for 4 mins. Pellets were 
washed in HIM buffer (200 mM Mannitol, 70 mM sucrose, 1 mM EGTA, 10 mM 
HEPES, pH 7.5) and pelleted again at 200 g for 4 mins. Pellets were 
resuspended in HIM buffer supplemented with mammalian protease inhibitor 
cocktail (1:250). For Melan-a cells, cells were passed through a 23G needle 7 
times before passing through a cell cracker with an 8.01 mm ball 
approximately 10 times until cells had been homogenised. The nuclear fraction 
was removed by spinning homogenate at 600 g for 10 mins. Post nuclear 
supernatant (PNS) was collected, and nuclear fraction discarded. A sample of 
PNS was retained for western blotting. The remainder was spun in an 
ultracentrifuge at 100,000 g for 30 mins. The supernatant was removed and 
labelled cytoplasmic fraction. The membrane pellet was resuspended in 20% 
of the total homogenisation volume, in HIM buffer supplemented with MPIs.  
 
2.4.4. Melanosome fractionation 
Melan-a cells (2x 15cm dish per condition) were placed on ice and washed 
twice in ice cold PBS. Cells were scraped into PBS and pelleted at 200 g for 4 




1 mM EGTA, 10 mM HEPES, pH 7.5) and pelleted again at 200 g for 4 mins. 
Pellets were resuspended in HIM buffer supplemented with mammalian 
protease inhibitor cocktail (1:250). Cells were passed through a 23G needle 
7x before passing through a cell cracker with an 8.01 mm ball approximately 
10x until cells had been homogenised. The nuclear fraction was removed by 
spinning homogenate at 600 g for 10 mins. Post nuclear supernatant (PNS) 
was collected, and nuclear fraction discarded. A sample of PNS was retained 
for western blotting. The PNS was loaded onto a sucrose cushion (2 M) and 
spun for 30 mins at 11,000 g. The melanosome rich fraction was collected and 
spun for a further 60 mins at 100,000 g. The resulting pellet was resuspended 
in 50 µl of HIM buffer. Once resuspended 50 µl of 2x RIPA buffer was added. 
Samples were analysed by BCA and made up in sample buffer to run by WB.  
 
2.4.5. Protein assay and sample preparation 
A BCA protein assay kit was used to determine the protein concentration of 
collected lysates. Bovine IgG in duplicate was used to create a standard curve. 
3 repeats of 3 μl of sample was used for each assay. BCA assay kit reagents 
were made up in a ratio of 50:1 Reagent A: Reagent B respectively. After 
addition of the kit reagents, plates were incubated at 37°C for 30 minutes 
before reading at OD562 using a Thermo Labsystems Multiskan Spectrum plate 
reader.  For pierce 660 protein assay, provided protein standards were set up 
in duplicate to generate a standard curve. 3 repeats of 3 μl of sample was used 
for each assay. 150 μl of pierce reagent was added per well and incubated at 
RT for 5 mins before scanning using a Thermo Labsystems Multiskan 
Spectrum plate reader.  Once protein concentrations were determined, 
samples were diluted to the same concentrations in lysis buffer. Samples were 
diluted in 5x sample buffer ((312.5mM Tris-HCl, pH6.8, 15% w/v SDS, 50% 
w/v glycerol, 16% w/w 2-Mercaptoethanol, 0.05% w/v Bromophenol Blue) (to 





2.4.6. Sodium Dodecyl Sulphate Polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western Blotting 
Equal amounts of protein per condition were resolved on a 4-12% Bis-Tris 
precast NuPAGE gel in MOPS or MES running buffer. In general, gels were 
run at 150V for 90 minutes. For western blots, resolved proteins were 
transferred onto a nitrocellulose membrane is transfer buffer (3.03g Tris, 14.4g 
Glycine, 200ml methanol, topped up to 1L with distilled H20) at a constant 
current 1A, 25V for 2 hours on ice or 1 hour at RT. Transfer and loading 
efficiency was preliminarily checked using Poncaeu. Poncaeu staining was 
removed by incubation in blocking buffer for 5 minutes. Membranes were then 
transferred into fresh blocking buffer for 1 hour. Unless otherwise stated, 
membranes were blocked in 5% Marvel milk powder/ TBS-T (0.1% w/v Tween 
20). For some antibodies blocking and antibody incubation was in 5% bovine 
serum albumin (BSA)/ TBS-T. Primary antibodies were then incubated with 
membranes as per conditions stated in Table 2.10. Membranes were then 
washed 3 x 5 minutes in TBS-T before incubation with the appropriate 
secondary antibodies, incubation conditions stated in Table 2.11. Membranes 
were washed a further 3x 5 minutes in TBS-T with a final 5-minute wash in 
TBS. Membranes were scanned using a LI-COR Odyssey imaging system.  
 
2.4.7. Western blot quantification  
 All quantification for western blots was carried out in Image Studio Lite 
software. The analysis tab was used to draw around the relevant bands and 
subtract the background. The final signal values were exported to excel. 
 
Table 2.10 Primary Antibodies used for western blot 
Target Species Source/Catalogue No. Incubation 
Conditions 
LRRK2 Mouse Neuromab N241A/34 1:50, o/n, 4°C 
TYRP1 Mouse Abcam, ab178676 1:1000, 1 hr, RT 
PMEL 
(Pep13) 
Rabbit Dawn Harper and M. Marks 
Philadelphia 




LAMP1 Mouse DSHB Iowa, 1D4B 1:100, o/n, 4°C 
Rab32 Rabbit Sigma, SAB4200086 1:1000, 1 hr, RT 
Cathepsin D Rabbit Cal Biochem, 219361 1:2000, 1 hr, RT 
MITF Mouse Santa Cruz, SC-56725 1:1000, o/n, 4°C 
Actin Mouse Proteintech, 66009-1-Ig 1:10000, 1 hr, 
RT 
Actin Rabbit Proteintech, 20536-1-AP 1:10000, 1 hr, 
RT 
E Cadherin Mouse Cell signalling, 3195 1:1000, o/n, 4°C 
MART-1 Mouse Abcam ab3168 1:200 o/n, 4°C 
b-catenin Mouse BD Biosciences, 610154 1:1000, 1 hr, RT 
N-Cadherin Mouse BD Biosciences, 610921 1:1000, 1 hr, RT 
Rac1 Mouse Upstate 05-389 1:1000, 1 hr, RT 
TFEB Goat  Novus Biologicals NB100-
1030) 
1:400, 1 hr, RT 
RAB27A Sheep R&D systems AF7245 1:400 o/n, 4°C 
RAB10 Rabbit Cell signalling Technologies 
8127 
1:1000, 1 hr, RT 
pThr73-
RAB10 
Rabbit Abcam ab230267 1:1000, 1 hr, RT, 
BSA 
RAB7a Rabbit Abcam ab137029 1:1000, 1 hr, RT 
pS935-
LRRK2 
Rabbit MRX PPU Dundee, Dundee 
UK 
1:1000, 1 hr, RT 
VPS35  Goat Abcam ab10099 1:1000, 1 hr, RT 
VPS26 Rabbit Abcam ab23892 1:400, o/n 4°C 
TBC1D5 Mouse Santa Cruz sc-376296 1:1000, 1hr, RT 









Table 2.11: Secondary antibodies used for western blot. 




Donkey anti-mouse IR Dye 
800CW 
LI-COR (926-32212) 1:10,000, 1 hr, RT 
Donkey anti-mouse IR Dye 
680CW 
LI-COR (926-32222) 1:10,000, 1 hr, RT 
Donkey anti-rabbit IR Dye 
800CW  
LI-COR (926-32213) 1:10,000, 1 hr, RT 
Donkey anti-rabbit IR Dye 
680CW 
LI-COR (926-32223) 1:10,000, 1 hr, RT 




1:10,000, 1 hr, RT 
Donkey anti-sheep IR Dye 
680CW 
LI-COR (92632224) 1:10,000, 1 hr, RT 
Goat anti-rat IR Dye 800CW LI-COR (926-32219) 1:10,000, 1 hr, RT 
 
2.4.8. GST and GST-R7BD Production  
For the production of GST fused to the Rab7 binding domain of RILP (GST-
RILP) The cDNA for this domain was subcloned into the pGEX-6P-1 backbone 
vector. The cDNA for the domain was double digested out from pGEX-4T-3-
mR7BD plasmid from Addgene alongside a double digest of pGEX-6P-1 
destination vector. Digests were run on a 1% agarose gel, and the drop out 
band and digested backbone were extracted. Vector and insert were ligated 
together using a T4 DNA ligation reaction, see  
Table 2.6, to produce pGEX-6P-1-RILP plasmid.  
 
For production of GST control protein and GST-RILP (GST-mR7BD), plasmids 
pGEX-6P-1 and pGEX-6P-1-RILP were transformed into BL21 bacteria as in 
section 2.3.5. Colonies were selected on ampicillin LB-Agar plates and picked 
into a 5-10 ml starter culture grown for 16 hours. The starter culture was 




grown to an OD600 of 0.6-0.8. A 1 ml pre-induction sample was taken. Protein 
production was induced with IPTG (0.5 mM). For GST, bacteria were shaken 
for 4 hours at 37°C. For GST-RILP, the culture was shaken at 20°C for 20 
hours for an overnight induction. A 1 ml post-induction sample was taken. 
Bacteria were pelleted at 4500 rpm for 15 minutes at 4°C. Pellets were washed 
with PBS and then re-pelleted as before. Bacteria were flash frozen in liquid 
nitrogen and stored at -80°C until lysis. Pellets were lysed in PBS + 0.5 mg/ml 
lysozyme + DNase (10 µg/ml) + Bacterial protease inhibitors (1:500) on ice for 
30 minutes. Lysates were sonicated on ice with a sonicator probe set to high 
for 10 x 20 seconds. Lysates were pelleted in an ultracentrifuge at 100,000 g 
at 4°C for 25 minutes. The supernatant was filtered before it was run through 
an ÄKTA purification system.  
 
2.4.9. Running pre- and post-induction pellets 
1 ml pre- and post-induction samples were pelleted in a table-top centrifuge 
and the supernatant was removed. The pellet was resuspended in hot lysis 
buffer and boiled at 110°C for 10 mins, vortexing every 2 mins. 10x sample 
buffer was added to samples which were boiled for a further 5 mins at 95°C. 
Samples were spun at max speed for 5 mins to pellet any debris. 10 µl of 
samples were loaded onto a gel and run as normal. Resolved proteins were 
stained with SimplyBlue SafeStain.   
 
2.4.10. Purification of GST using Sepharose beads  
1 ml of glutathione-sepharose beads were washed 3x 5 mins in PBS. Washed 
beads were incubated with the supernatant containing the GST control protein 
for 4 hours on a wheel at 4°C. The beads were pelleted, and the supernatant 
was removed. Beads were washed 3x in PBS as before. Bound proteins were 
eluted using 50 mM Tris-HCL, 10 mM reduced glutathione. Eluted protein was 
dialysed in 2.5 litres of dialysis buffer (HEPES-KOH (pH 7.6) (20 mM), KCl 
(100 mM), DTT (0.2 mM) for 2 hours and a fresh 2.5 litres overnight. The 




assay. Aliquots of recombinant protein were flash frozen in liquid nitrogen and 
stored at -80°C until ready to carry out the assay. 
 
2.4.11.  Purification of GST-RILP using a GSTrap column 
The supernatant from lysed GST-RILP pellets was loaded onto an ÄKTA 
purification system and GST-RILP protein was captured on a 1 ml GSTrap 
column. The column was washed with 3 ml PBS (3 column volumes) to remove 
sticky proteins. Bound proteins were eluted from the column with 50 mM Tris-
HCL, 10 mM reduced glutathione. 500 µl fractions were collected and a UV 
trace was used to determine which fractions contained GST-RILP. Relevant 
fractions were pooled for buffer exchange. PD10 columns were equilibrated 
with GST storage buffer (10% glycerol, 50 mM Tris (pH 7.4), 150 mM NaCl, 5 
mM MgCl2, and 1 mM DTT). The pooled fractions were spun through the 
column to remove reduced glutathione and exchange GST-RILP into storage 
buffer. Aliquots of the purified protein were flash frozen in liquid nitrogen and 
stored at -80°C until ready to use for assay. Collected fractions were also run 
by SDS-PAGE and the gel stained with Simply blue Safe stain to determine 
purity of collected fractions. This work was carried out in collaboration with 
Katy McCarron. 
 
2.4.12. GST-RILP-Rab7 pulldown assay 
The night before the assay, 20 µl of sepharose beads per condition were 
washed 3x in PBS. GST or GST-RILP recombinant protein (250 μg/ml) was 
added to the washed beads and incubated on a wheel in the cold room 
overnight. The morning of the assay, beads were washed 3x in assay wash 
buffer (Tris-HCl (pH7.8, 20 mM), NaCl (50 mM), MgCl2 (3 mM)). On the day of 
the assay cells were lysed in a high magnesium buffer (Tris-HCl (pH 7.8, 20 
mM), NaCl (50 mM), 0.5% Triton x-100, 1 mM MgCl2, Roche protease inhibitor 
without EDTA) for 15 mins on a wheel in the cold room. Lysates were clarified 
at 21,000 g for 20 mins. Protein concentrations were determined using a BCA 
assay kit. Samples were made up to the same concentration and a 50 μg input 




RILP beads for 2 hours at 4°C on a wheel.  Beads were pelleted and the 
unbound fraction discarded. Beads were washed 3 times in assay wash buffer 
(Tris-HCl (pH7.8, 20 mM), NaCl (50 mM), MgCl2 (3 mM)). Washed beads were 
dried, and bound proteins were eluted in 2x sample buffer. Beads were boiled 
at 95°C for 5 mins and eluted proteins were resolved by SDS-PAGE.  
 
2.4.13. Immunofluorescence  
The type of fixation used was selected based on the primary antibody 
datasheet guidelines and in some cases both methods were tried in the 
optimisation. The fixation method used in each experiment is stated in the 
figure legends. Details of antibody dilutions and incubation is listed in Table 
2.12. Cells were seeded onto glass coverslips on day 1 of the experiment. 
siRNA and drug treatments were carried out as indicated for each experiment.  
For methanol fixed coverslips, cells were washed with room temperature PBS 
before fixing with 1 ml ice cold methanol for 5 minutes at -20°C. For PFA fixed 
coverslips, cells were washed twice with room temperature PBS before fixing 
with 1 ml 4% PFA in PBS for 15 minutes. The reaction was quenched with 50 
mM NH4Cl for 10 minutes. Coverslips were then permeabilised with 0.2% 
Triton x-100 for 4 minutes. For staining, unless otherwise stated, coverslips 
were blocked in 10% Goat serum in PBS for 30 minutes. Coverslips were then 
incubated with the primary antibody diluted in 5% goat serum unless otherwise 
indicated in Table 2.12. Coverslips were washed 3x 4 minutes in PBS followed 
by incubation with the relevant secondary antibody for 30 mins ( 
Table 2.13). Coverslips were washed 3x 4 minutes before being dipped in 
Millipore H2O and mounted onto glass slides using Mowiol with or without 










Table 2.12 Primary antibodies used for immunofluorescence 
Target Species Source/Catalogue Number Fixation/Dilution 
TYRP1 
(TA99) 
Mouse Abcam, ab3312 PFA 1:200 BSA + 
saponine, 1 hr 
PMEL 
(Pep13) 
Rabbit Dawn Harper and M.Marks, 
Philadelphia, USA 
PFA 1:200, 1 hr  
PMEL 
(HMB45) 
Mouse Abcam, ab787 PFA 1:200 BSA + 
saponine, 1 hr 
LAMP1 Mouse DSHB Iowa, ID4B PFA 1:100, 1 hr 
EEA1 Mouse BD Transduction 
Laboratories, 610456 
PFA 1:2000, 1 hr 
TOMM20 Rabbit Sigma, HPA011562 PFA, 1:1000, 1hr 
CIMPR Rabbit Gifted by Paul Luzio PFA, 1:500, 1 hr 





PFA, 1:40, 1 hr 
HA Mouse Covance MMS-101P PFA, 1:1000, 1 hr 
HA Rat Roche 11867423001 PFA, 1:500, 1 hr 
p230 Mouse BD 611281 PFA, 1:500, 1 hr 
HRS Goat Everest Biotech. EB07211 MeOH, 1:200, 1hr 
LAMP2 Mouse DSHB Iowa, H4B4 PFA, 1:50, 1 hr 
FAM21 Rabbit Abcam ab137029 PFA/MeOH, 
1:1000, 1 hr 












Table 2.13 Secondary antibodies used for 
immunofluorescence 






Invitrogen, A21202 1:500 
Donkey anti-mouse 
AF594 
Invitrogen, A21203 1:500 
Donkey anti-rabbit 
AF488 
Invitrogen, A21206 1:500 
Donkey anti-rabbit 
AF594 
Invitrogen, A21207 1:500 
Donkey anti-sheep 
AF594 
Invitrogen, A11016 1:500 
Donkey          anti-rat  
AF647 
Invitrogen A21247 1:500 
 
2.5. Live and fixed cell imaging and quantification 
2.5.1.  Live Imaging 
Confocal live imaging experiments were carried out using a Marianas spinning 
disk confocal microscope (3i, Intelligent Imaging Innovations, Germany) with 
a Plan-Apo 63x/ 1.4NA Oil objective M27. All live cell imaging was carried out 
at 37°C, 5% CO2 in a humidified chamber for live cell imaging.  
 
2.5.2. Fixed Cell imaging  
Widefield brightfield and fluorescence images were acquired with a NIKON Ti-
Eclipse Microscope with a CFI Plan Fluor DLL 10X objective, a CFI Plan Apo 
40x objective or a CFI Plan Apochromat VC 60X objective lens. Confocal 
images were acquired with a Marianas spinning disk confocal microscope (3i, 
Intelligent Imaging Innovations, Germany) with a Plan-Apo 40x/1.3NA oil 




were also acquired using a Zeiss LSM800 or Zeiss LSM900 with Airyscan 
confocal laser scanning microscope (CLSM) using a 63x 1.4 NA Zeiss Plan 
Apochromat objective or a 40x LD C-Apochromat objective. 
 
2.5.3. Electron microscopy 
Samples for EM were plated on day 1 and treated with MLi-2 as indicated for 
each experiment. Cells were fixed and processed for EM by Alison Beckett at 
the Biomedical Electron Microscopy unit at the University of Liverpool. 
Samples were mounted onto grids and images were acquired using a FEI 
120kV Tecnai G2 Spirit BioTWIN TEM microscope.  
 
2.5.4. ER-Mitochondria contact site quantification  
Images were acquired at 4200x, imaging the whole cell. The total perimeter of 
mitochondria per image was measured first using the ROI tool in FIJI. 
Mitochondria were categorised based on the number of contact sites per 
mitochondria. The length of each contact site was measured using the free 
hand line tool. Contact sites were defined as the ER and mitochondrial outer 
membrane being within 30 nm of each other.  
 
2.5.5. LysoTracker quantification  
For LysoTracker images, the background labelling was too high to be able to 
resolve individual punctae. Therefore, the total intensity per cell was measured 
to quantify acidic organelles. Images were thresholded and the total intensity 
of each cell was measured using the ROI selection tool.  
 
2.5.6. LAMP1 quantification  
For the analysis of LAMP1 positive vesicles, the analyse particles tool in FIJI 
was used. Cells were selected using the ROI tool. LAMP1 positive vesicles 






2.5.7. TGN morphology quantification  
To analyse the morphology of the TGN, images from cells stained with p230 
were used. For the mixed RPE1 Flp-In clones, cells were co-stained with HA 
to ensure that only positive cells were quantified. The ROI selection tool in FIJI 
was used to draw around the space occupied by the TGN and the area of each 
ROI was taken.  
 
2.5.8. Phalloidin cell morphology quantification 
To identify cell morphology changes with LRRK2 inhibition, cells were drawn 
around using the ROI selection tool in FIJI. The shape descriptors tool was 
selected in the “set measurements” window in FIJI. The roundness and aspect 
ratio measurements were then taken for each cell.  
 
2.5.9. Cell tracking analysis 
Time lapse images of WM266.4 cells (section 2.2.9) were uploaded into 
MATLAB CellTracker graphic user interface (GUI). The manual tracking 
feature was used to generate tracks for individual cells. These manual tracks 
were used to generate coordinates which were then input into Chemotaxis 
software (ibidi). Chemotaxis software was used to generate data for individual 
cells including the accumulated distance.  
 
2.5.10. OPERA imaging 
For fluorescent images taken in Sheffield, an OPERA Phoenix High Content 
Screening Imaging System was used. The objective used is indicated in 
individual figure legends. For imaging with the OPERA, cells were seeded into 
glass bottom, black-walled 96 well plates.  
 
2.5.11.  Opera imaging quantification 
Quantification measurements from OPERA images were taken using 




total cell area across images to be analysed was selected using a minimum 
signal parameter. The number of nuclei per image was also counted for per 
cell calculations. LAMP1, Rab7, and Magic Red positive puncta were counted 
using the find spots tool. Parameters were kept the same across each 
condition to ensure there wasn’t any bias in the analysis. A schematic of the 
work-flow is depicted in Figure 2.7. 
 
2.5.12. IN Cell Analyser 2200 imaging  
For brightfield images of neurons taken over their differentiation, an IN Cell 
Analyser 2200 imaging system (GE healthcare) was used. Images were taken 
in the last 15 days of the differentiation protocol. Images were acquired with a 
10X objective in brightfield only. Random fields of view from wells were 












3. Chapter 3: Generation and Optimisation of 
Project tools 
3.1. Introduction  
It is now well accepted that Parkinson’s disease (PD) and melanoma are linked; 
in contrast to the relationship between PD and all other types of cancer, there 
is a higher incidence of melanoma in PD patients relative to the general 
population (Huang et al., 2015). However, there has been no progress in 
determining the molecular mechanisms which link these two seemingly 
unrelated diseases. One of the issues faced when addressing such a question 
is that 85-90 % of PD patients are idiopathic, meaning there is no specific 
target to pursue. It has not been determined whether one of the identified 
familial genes in PD is relevant to the link between dopaminergic neuron loss 
and melanoma. It is, however, interesting that the substantia nigra, the primary 
region of the brain affected by PD, is pigmented, which provides a loose link 
between the cell types affected by the two diseases. 
 
For my project, my aim was to look at specific aspects of LRRK2 function 
within melanosomes and melanoma. One reason for pursuing this avenue is 
that LRRK2 is the most commonly mutated gene in familial PD, and so has 
the widest reach of familial pathogenic targets. Another compelling reason for 
selecting LRRK2 as the primary focus is the high level of LRRK2 expression 
across melanoma cell lines, as can be observed by referring to the Cancer 
Cell line Encyclopaedia (Figure 3.1) (Broad institute, MIT and Harvard) 
https://portals.broadinstitute.org/ccle (Barretina et al., 2012) . 
 
The work carried out in this chapter generating Flp-In cells and establishing 







Figure 3.1 LRRK2 mRNA abundance across cell lines 
Plot showing mRNA expression of LRRK2 across cancer cell 
lines taken from the Cancer Cell Line Encyclopaedia. Data are 
gene expression profiles of 917 human cancer cell lines. The 
number of lines used for each cancer type is shown in brackets. 
mRNA abundance for each line obtained using Affymetrix U133 
plus 2.0 arrays. RMA normalisation was used. Data is shown as 
log2 gene expression signal.  (Barretina et al., 2012) 
https://portals.broadinstitute.org/ccle 
 
3.2. Characterisation of cell lines expressing 
endogenous LRRK2  
3.2.1. LRRK2 is highly expressed across melanoma cells  
I determined the endogenous levels of LRRK2 expression across both 
melanoma and non-melanoma cell lines by probing lysates available in the 
laboratory by western blotting. The melanoma cell lines tested were A375P, 
501-mel, WM266.4 and MNT1 cell lines, a mixture of pigmented and non-
pigmented lines. The non-melanoma cell lines included RPE1, SK-N-BE-2, 
SH-SY5Y and HeLa lines (Figure 3.2A). I also looked at pigmentation markers 
across these cell lines such as melanogenic transcription factor MITF, and late 
melanosome markers TYRP1 and MART-1 (Figure 1.10). Western blotting 




relative to the non-melanoma cell lines. LRRK2 signal was quantified using 
Image studio software (LI-COR) to measure the total intensity of the LRRK2 
band (Figure 3.2B). This is consistent with the data from the Cancer Cell Line 
Encyclopaedia (CCLE) which indicates that there is an enrichment of LRRK2 
across melanoma cell lines.  
 
This pattern observed in Figure 3.2 also suggests an inverse relationship 
between LRRK2 and pigmentation markers; in cell lines where levels of 
LRRK2 are high, the levels of pigmentation proteins are low. For example, the 
highest levels of LRRK2 were seen in the WM266.4 cell line. This is a highly 
metastatic, non-pigmented and advanced melanoma cell line, which has 
largely lost expression of MITF, TYRP1 and MART-1 in accordance with the 
loss of pigmentation in this cell line. Comparatively, the levels of LRRK2 are 
approximately 6-fold lower (Figure 3.2B) in the MNT1 cell line- a melanoma 
cell line which has retained its pigmentation along with high levels of 
expression of pigmentation-related proteins. It is also noteworthy that the non-
melanoma cell line which showed the highest levels of expression of LRRK2 
was the hTERT-immortalised retinal pigmented epithelial (RPE1) cell line 







Figure 3.2 Protein expression of LRRK2 and melanosome 
markers across a panel of melanoma and non-melanoma 
cell lines.  
A 20 μg of protein per cell line was resolved by SDS-PAGE and 
analysed by western blotting. Lysates were probed for LRRK2, 
as well as melanogenesis markers MITF, TYRP1 and MART-1. 
B LRRK2 protein signal across cell lines was quantified using LI-









3.2.2. Western blotting as a readout for LRRK2 activity 
The majority of pathogenic mutations identified in LRRK2 result in hyperactive 
kinase activity (West et al., 2005). This makes LRRK2 inhibitors attractive as 
potential therapeutic agents. As a result, there are a number of commercially 
available LRRK2 inhibitors suitable for use in the laboratory. These include 
GNE-0877 (GNE), GSK2578215A (GSK), HG-10-102-01 (HG-10) and MLi-2 
(Estrada et al., 2014; Choi et al., 2012; Fell et al., 2015; Reith et al., 2012). 
Furthermore, the discovery that LRRK2 phosphorylates a subset of Rab 
proteins, including Rab10, has led to the development of a phospho-specific 
Rab10 antibody. This recognises Rab10 phosphorylated at the LRRK2 target 
site-threonine 73 (Thr73) (Lis et al., 2018). Lysates from WM266.4 cells 
treated with one of these distinct LRRK2 inhibitors were run via western blot 
and the level of LRRK2 inhibition was measured by the reduction in 
phosphorylation of Rab10 at Thr73 (Figure 3.3A). For all inhibitors, reduction 
in Rab10 phosphorylation shows effective inhibition of LRRK2 kinase activity, 
with MLi-2 being the most effective inhibitor. LRRK2 contains an 
autophosphorylation site at serine 1292. However, the efficiency of the 
antibody for this site varies greatly between cell lines and has not been used 
in this project. LRRK2 possesses a number of upstream kinase sites, including 
serine 935, which become rapidly dephosphorylated upon LRRK2 inhibition. 
There has been much speculation about which kinases phosphorylate LRRK2 
at these sites, and many candidates have been proposed including casein 
kinase 1a (CK1a), the IκB family and protein kinase A (PKA) (Berwick et al., 
2019). Lysates from WM266.4 cells treated with 40 nM siRNA targeting 
LRRK2, or MLi-2 LRRK2 inhibitor, were run by western blot (Figure 3.3B). 
The reduction in total and pSer935-LRRK2 as well as pThr73-Rab10 in the 
siRNA treated cells demonstrates effective depletion of LRRK2. Reduction of 
both pSer935-LRRK2 and pThr73-Rab10 (but not total LRRK2) in MLi-2 
treated cells shows effective inhibition of LRRK2 activity. These results show 
that both the antibody against pSer935-LRRK2 and pThr73-Rab10 are viable 
readouts for LRRK2 activity in WM266.4 cells, and that both siRNA depletion 






Figure 3.3 LRRK2 kinase activity can be depleted by 
chemical inhibition and siRNA depletion 
A Lysates from WM266.4 cells treated with LRRK2 inhibitors for 
24 hours (500 nM except for MLi-2 which was 200 nM) were 
analysed by western blotting probing for the indicated antibodies. 
n=1. B Lysates from WM266.4 cells treated with either 40 nM 
siRNA (Smartpool (SP) or single oligonucleotide (O7)) for 72 
hours, or MLi-2 inhibitor (200 nM) for the indicated time points 












3.2.3. Optimisation of Reagents in WM266.4 cells 
HG-10-102-01 (HG-10) and MLi-2 were selected as the most effective LRRK2 
inhibitors guided by the western blot data presented in Figure 3.3A. Depletion 
of LRRK2 with 40 nM siRNA for 72 hours was tested using both a pool of 4 
oligonucleotides and an individual oligonucleotide. Lysates from siRNA 
knockdowns were analysed by western blot. Probing with LRRK2 antibody 
revealed effective depletion of LRRK2 by both the pool and single 
oligonucleotides (Figure 3.4A). To inhibit LRRK2 kinase activity, cells were 
treated with two concentrations of HG-10 for 48 hours. The level of inhibition 
was measured with the pS935-LRRK2 antibody. Results showed HG-10 
treatment for 48 hours at 500 nM strongly inhibited LRRK2 activity. 
Replenishing media after 24 hours was deemed unnecessary.  
 
WM266.4 cells were treated with MLi-2 across two concentrations and multiple 
time points. Lysates were analysed by western blot and the efficiency of 
inhibition was determined using the pS935-LRRK2 antibody (Figure 3.4B). 
200 nM was deemed the optimal concentration for LRRK2 inhibition. A time 
course of MLi-2 inhibitor was carried out in WM266.4 cells and lysates probed 
with pThr73-Rab10 antibody. (Figure 3.4C). The level of pThr73- Rab10 was 
depleted 1-hour post-treatment and did not decrease further with the longer 
time points. Therefore, acute inhibition of LRRK2 is sufficient to reduce the 







Figure 3.4 Optimisation of LRRK2 reagents in WM266.4 cells 
A Lysates from WM266.4 cells treated with HG-10-102-01 (HG-
10) for 48 hours, or 40 nM siRNA for 72 hours, were analysed by 
western blotting probing for the indicated antibodies. Lanes 
marked with a * had their media exchanged with fresh inhibitor 
after 24 hours. n=1. B Lysates from WM266.4 cells treated with 
MLi-2 at the indicated concentrations and time points were 
analysed by western blotting probing for the indicated antibodies. 
n=1. C WM266.4 cells treated with a time course of MLi-2 (200 
nM) were lysed and analysed by western blotting probing for the 
indicted antibodies. n=1. All quantification was carried out in 







3.2.4. Melan-a cells as a pigmented model for studying LRRK2 
WM266.4 cells were selected as a non-pigmented melanoma model due to 
their high level of expression of LRRK2. For a pigmented model, MNT1 cells 
were initially considered due to their relatively high level of expression of 
LRRK2 relative to other pigmented melanoma cell lines (Figure 3.2). However, 
due to their high pigmentation, the length of time you can culture MNT1 cells 
before they reach maximal pigmentation is very limited. As we were interested 
in studying pigmentation, the Melan-a cell line was selected as the main 
pigmented model for this study. Melan-a cells are a non-tumorigenic, 
immortalised, mouse melanocyte cell line which are pigmented at a much 
lower level relative to the MNT1 cell line (Bennett et al., 1987). As with the 
WM266.4 cell line, the efficiency of depleting LRRK2 levels and activity by 
siRNA and inhibition was tested. We also tested the ability of the pThr73-
Rab10 antibody to detect changes in LRRK2 activity in a mouse cell line. 72-
hour depletion with both a pool of siRNA oligonucleotides as well as single 
oligonucleotides targeting LRRK2 resulted in depletion of LRRK2 protein 
levels (Figure 3.5A).  A time course of the MLi-2 inhibitor was carried out in 
Melan-a cells and protein lysates were analysed by western blot (Figure 3.5B). 
As seen by a reduction in pThr73-Rab10, inhibition of LRRK2 was seen as 






Figure 3.5 Optimisation of reagents in Melan-a cells  
A Lysates from Melan-a cells treated with 40 nM siRNA targeting 
LRRK2 for 72 hours were analysed by western blotting, probing 
for the indicated antibodies. n=1. B Lysates from Melan-a cells 
treated with a time course of MLi-2 (200 nM) were analysed by 
western blotting, probing for the indicated antibodies. n=1. For A 
and B, bands were quantified using image studio lite software. 
Samples were normalised to actin and the control sample. 
 
 
3.3. Generating Project tools  
3.3.1. GST-RILP Protein production 
One of the aims of this project was to determine if there is a link between the 
effect of hyperactive LRRK2 on Rab7 activity and the effect of VPS35 knockout 
on Rab7 activity (Jimenez-Orgaz et al., 2018; Gómez-Suaga et al., 2014)  
(see Section 1.4.16). The PD-related mutation [D620N] in VPS35 has been 
found to hyperactivate LRRK2 kinase activity, resulting in 
hyperphosphorylated Rab proteins. This is in contrast to loss of VPS35 which 




wanted to determine if VPS35’s action on Rab7 activity is via LRRK2 or an 
independent pathway. 
 
To answer this question, it was important to have a reliable assay to measure 
the activity levels of Rab7. To do this, we set up an already characterised 
assay within the laboratory. The assay exploits the Rab7 binding domain of 
RILP (mR7BD), which is only able to bind to “active” or GTP-bound Rab7 (Sun 
et al., 2009) (Section 2.4.12). This domain was produced by protein 
preparation with a GST tag attached. The GST tag was used to bind the 
recombinant protein to glutathione beads which were used to pull down active 
Rab7 from cell lysates. cDNA for mR7BD was digested out from the pGEX-
4T3-mR7BD construct from Addgene. The excised insert was then ligated into 
pGEX-6P-1 vector backbone to generate GST-mR7BD. This was preferable 
as the pGEX-4T3 backbone has a thrombin cleavage site between the GST 
tag and the gene of interest (GOI), whereas pGEX-6P-1 has a precision 
cleavage site between GST and the GOI. The precision cleavage site is a 
longer linker and is more stable than the thrombin site, meaning less of the 
produced protein is cleaved from the tag (Figure 3.6A). The pGEX-6P-1-
mR7BD construct was transformed into BL21 competent E. coli and positive 
colonies were picked into a starter culture overnight. The following day the 
starter culture was used to inoculate a 2-litre culture. GST-RILP expression 
was induced with IPTG, followed by shaking for 20 hours at 20°C. Pre- and 
post-induction sample pellets were run on a gel to check efficiency of induction 
(Figure 3.6B). Gels showed successful induction of GST-RILP production 
indicated by the band appearing in post induction samples indicated with a *.  
 
Bacterial pellets were lysed with sonication on ice and lysates were clarified 
by ultracentrifugation at 100,000 g for 20 minutes. The supernatant was 
filtered and GST-RILP protein was immobilised by running samples through a 
GSTrap column using an AKTA chromatography system. Once bound to the 
column, GST-RILP was eluted using reduced glutathione. The UV trace over 
the course of the elution was used to determine which fractions to collect 




fractions collected (Figure 3.7B). Fractions A3-A9 were selected to be pooled. 
The gel showed that the purification was clean, however, the presence of a 
lower band indicated the purification of some GST alone.  
 
3.3.2. Validation of GST-RILP Rab7 Binding assay  
To check that the GST-RILP produced was suitable for pulling down GTP-
bound Rab7, HEK293 Flp-in cells were transfected with constructs expressing 
either: GFP, GFP-Rab7 WT or a GFP-dominant negative form of Rab7 (GFP-
Rab7 DN). Transfections were also carried out for LRRK2 constructs; however, 
the transfection efficiency was very low for these samples, and they should be 
disregarded. 24 hours after transfection cells were lysed in Rab7 assay lysis 
buffer and an input sample was taken. Lysates were incubated with GST-RILP 
beads and bound proteins were eluted. Samples were analysed by 
immunoblot for Rab7 (Figure 3.8). The levels of total Rab7 in WT and DN 
transfected inputs are comparable. Transfection with GFP-Rab7 gave a strong 
band in the GST-RILP pulldown lane, much stronger than the endogenous 
active Rab7. This band was not present in the GFP-Rab7 DN transfected lane. 
GST control protein was also produced and no Rab7 was pulled down with 
beads conjugated to GST alone (Appendix 1). This data shows that the GST-
RILP Rab7 binding assay is specific and an accurate readout for Rab7 activity. 
We also validated the assay by knocking down TBC1D5. TBC1D5 is a Rab7 
GAP. Therefore, depletion of TBC1D5 should increase the levels of GTP-
bound Rab7. RPE1 Flp-In parental cells were treated with siRNA targeting 
TBC1D5 and the assay carried out as above. Input and pulldown samples 
were run by western blot (Figure 3.9). Depletion of TBC1D5 resulted in a clear 
increase in GTP-bound Rab7, with no increase in the total Rab7 in the input 
samples. This result is what we would expect and shows that the GST-RILP 









Figure 3.6 Induction of GST-RILP Protein expression in BL21 
bacteria 
A BL21 bacteria were transformed with pGEX-4T3-mR7BD 
plasmid and selected on Amp plates. Positive colonies were 
picked into a starter culture which was used to inoculate a 1 litre 
maxi culture. B BL21 bacteria were transformed with pGEX-6P-
1-mR7BD plasmid and selected on Amp plates. Positive colonies 
were picked into a starter culture which was later used to 
inoculate two 1 litre maxi cultures. For both A and B cultures were 
grown to an OD600 of 0.6 and a pre-induction sample was taken. 
Protein expression was induced with IPTG (0.5 µM). Bacteria 
were shaken for 20 hours at 20 °C and a post- induction sample 
was taken. Pre- and post-induction samples were resolved by 
SDS-PAGE and gels stained for total protein. The band indicating 
induced GST-RILP expression is indicated with a * and GST 









Figure 3.7 Purification of GST-RILP Protein 
Lysates from induced BL21 bacterial pellets were passed through 
an AKTA purification system and GST-tagged proteins were 
collected using a GSTrap column. Bound proteins were eluted with 
reduced glutathione (10 mM) in 500 µl fractions. A A UV trace was 
used to determine which fractions contained GST-RILP. The blue 
line shows the UV trace. The fractions are indicated by red intervals. 
The increasing concentration of the reduced glutathione gradient is 
indicated by the green line. The pink dashed line shows the sample 
injection at the beginning of the run. B Collected fractions were 
resolved by SDS-PAGE and stained for total protein to determine 








Figure 3.8 Validation of GST-RILP Rab7 binding assay 
HEK293 Flp-In cells were transfected with the indicated 
constructs containing either GFP or a GFP-tagged Rab7 protein 
or a GFP-tagged LRRK2 protein (WT-Wild type, DN-dominant 
negative, HA-Hyperactive). 24 hours after transfection, cells 
were lysed, and samples were incubated with GST-RILP beads 
for 2 hours. Captured proteins were eluted and analysed by 






Figure 3.9 Validation of GST-RILP Rab7 binding assay with 
TBC1D5 depletion 
RPE1 Flp-In parental cells were treated with 40 nM siRNA 
targeting TBC1D5 for 72 hours.  Cells were lysed and samples 
were incubated with GST-RILP beads for 2 hours. Captured 
proteins were eluted and analysed by western blot probing for 
Rab7. n=1. 
 
3.3.3. Generating VPS35 Flp-In plasmids 
Another useful tool we wanted to establish for the project were RPE1 Flp-In T-
REx cell lines with control WT VPS35 and PD related mutant [D620N] VPS35. 
This cell line was selected for multiple reasons. It is a diploid cell line which is 
commonly used in my laboratory. We have an already established work-flow 
for generating knockouts in these cells which may be useful for further studies. 
These cells express a reasonable level of LRRK2 (Figure 3.2). RPE1 cells are 
also lightly pigmented which gave the possibility of cross talk between this 
branch of my project and the melanocyte work. We also wanted to use the Flp-
In system as this would allow us to have inducible control over the expression 
of exogenous VPS35 (Section 2.1.4). 
 
pCDNA5 FRT/TO HA VPS35 (WT and [D620N]) plasmids were obtained from 




In cells are already resistant  to hygromycin (Bodnar et al., 1998). Therefore, 
we generated plasmids which use neomycin (G418) as the antibiotic selection.  
The HA-VPS35 WT and HA-VPS35 [D620N] inserts were amplified by PCR 
with appropriate restriction sites for subcloning into the new backbone. The 
destination vector used was a pCDNA5/ FRT/TO Neo plasmid containing the 
G418 resistance gene. Double digests of the PCR products and the 
destination vector were then ligated together using a T4-DNA ligase reaction. 
All methodologies for subcloning are outlined in more detail in Section 2.3.  
 
3.3.4. Generating and screening RPE1 Flp-In VPS35 cell lines 
RPE1 Flp-In parental cells were transfected with a pCDNA5/FRT/TO Neo 
VPS35 plasmid (WT or [D620N] mutant) alongside a pOG44-Flp recombinase 
expression plasmid. Transfected cells were split 1:4 from a 6-well plate into a 
10 cm dish to select for single colonies. Cells were from this point maintained 
in selection media containing blasticidin and G418. Cells were grown for 
approximately 2 weeks before colonies were picked into 24 well plates. 
Colonies were expanded before cells were treated +/- doxycycline for 24 hours 
before lysing for screening by western blot (Figure 3.10). Lysates were probed 
with an antibody against HA to identify exogenous VPS35 expression. A 
number of positive clones were identified for both WT and [D620N] VPS35 cell 
lines. Full methods are shown in section 2.1.5 and section 2.1.6. 
 
3.3.5. Initial Characterisation of Flp-In Cells 
Induction of HA-VPS35 expression with doxycycline was optimised using a 
time course experiment. Two concentrations of doxycycline, across a number 
of time points were tested in two clones per line and resulting VPS35 levels 
were analysed by western blotting (Figure 3.11). It was determined that all 
clones produced similar levels of VPS35 across both WT and mutant clones. 
There appeared to be no difference in the levels of VPS35 induction between 
the 0.1 µg/ml and 1 µg/ml doxycycline treated cells. Therefore, 0.1 µg/ml was 
selected as the working concentration for future experiments. At 4 hours post-




seen in both the HA and VPS35 blots. Treatment with doxycycline for 20 and 
24 hours gave a much more pronounced induction of VPS35 expression 




Figure 3.10 Screening RPE1 Flp-In VPS35 cell lines 
Parental non-transfected cells (Par), A, WT or B [D620N] mutant 
HA-VPS35 RPE1 Flp-In colonies picked from transfected cells 
were treated +/- Doxycycline (1µg/ml) for 24 hours. Cells were 
lysed and protein resolved by SDS-PAGE before processing for 







Figure 3.11 Optimisation of HA-VPS35 expression in RPE1 
Flp-In cell lines 
A WT or B [D620N] mutant HA-VPS35 RPE1 Flp-In cells were 
treated with the indicated concentrations of doxycycline for the 
indicated time points. Cells were lysed and proteins resolved by 
SDS-PAGE before processing for western blot and 







Figure 3.12 Doxycycline induction time course in RPE1 Flp-
In VPS35 clones 
WT or [D620N] VPS35 RPE1 Flp-In cells were induced with 
doxycycline (0.1 µg/ml) for the indicated time points. Cells were 
lysed and proteins resolved by SDS-PAGE before processing for 
western blot and immunoblotting for the indicated antibodies. 
n=1. 
 
3.3.6. Characterisation of RPE1 Flp-In VPS35 lines by IF 
We next characterised the VPS35 RPE1 Flp-In cells using various markers 
and immunofluorescence (IF). First, cells were induced with doxycycline for 24 
hours and then fixed and stained for HA and early endosome marker EEA1 
(Figure 3.13). As expected, HA-VPS35 WT was found to localise to vesicle 
structures which partially overlapped with EEA1 staining. The staining for 
EEA1 in the [D620N]-positive cells showed no change in distribution or 
colocalisation compared with HA-VPS35 (Figure 3.13). This suggests that 
there is no change in the ability of VPS35 to localise to early endosomes with 
the pathogenic mutation.  This experiment also revealed that many cells in this 
culture were not positive for HA staining, meaning that cells were not from a 
single positive clone. Following this discovery, these cells were used for IF 




side by side. It was however, decided that for biochemistry experiments such 
as the GST-RILP pulldown assay, a 100% pure population from a single clone 
would be more optimal. 
 
Next, cells were fixed and stained for various cellular markers alongside the 
HA-tagged VPS35. Cells were stained for mitochondrial marker TOMM20, 
TGN marker p230 (Figure 3.14) or late endosome/lysosomal markers Rab7, 
LAMP1 or LAMP2 (Figure 3.15). Co-staining HA with the lysosomal proteins 
LAMP1 and LAMP2 revealed no change in these proteins’ distribution or 
colocalisation with HA-VPS35 (Figure 3.15). Staining for late endosomal 
marker Rab7 revealed that there was what appeared to be an increase in 
colocalisation between Rab7 and HA-VPS35. Other groups have shown that 
the [D620N] mutation in VPS35 results in mitochondrial dysfunction and 
fragmentation (Wang et al., 2016; Hanss et al., 2021). It has also been shown 
that VPS35 is able to regulate the activity of Rab7 (Jimenez-Orgaz et al., 
2018), which has been shown to regulate mitochondrial dynamics (Section 
1.4.6). In our cells the staining of TOMM20 showed there was no change in 
mitochondrial networks in the pathogenic mutant cells (Figure 3.14). This 
could, however, be due to the use of a different cell type.   
 
We wanted to look at the morphology of the TGN as hyperactivation of LRRK2 
has been shown to induce a disrupted network, and [D620N] VPS35 is 
reported to hyperactivate LRRK2 (Mir et al., 2018; Purlyte et al., 2018) 
(Section 1.4.16). Co-staining for Golgi marker p230 and the HA tag revealed 
the TGN appeared to be disrupted and more dispersed in the [D620N] positive 
cells compared with the WT positive cells (Figure 3.14). To confirm this, we 
quantified the area of the TGN in HA positive cells. This confirmed that there 
was an increase in p230 area and therefore an increase in TGN dispersal with 





Figure 3.13 Distribution of VPS35 and EEA1 in HA-VPS35 
RPE1 Flp-In cells 
WT and [D620N] HA-VPS35 RPE1 Flp-In cells were induced with 
0.1 µg/ml doxycycline for 24 hours. Cells were fixed in 4% PFA 
before processing for IF. Images were acquired with a Zeiss 
LSM800 scanning confocal x63 objective. Scale bar is 10 μm. 





Figure 3.14 Mitochondrial and Trans-Golgi markers in HA-
VPS35 RPE1 Flp-In cells 
WT and [D620N] HA-VPS35 RPE1 Flp-In cells were induced with 
0.1 µg/ml doxycycline for 24 hours. Cells were fixed in 4% PFA 
before processing for IF. Cells were stained for the TGN marker 
p230 or the mitochondrial marker TOMM20 alongside HA. 
Coverslips were mounted on Moviol supplemented with 4’,6-
diamidino-2-phenylindole (DAPI). Images were acquired with a 
Zeiss LSM800 scanning confocal x63 objective. Scale bar 10 μm. 












Figure 3.15 Late endosome and lysosomal marker 
distribution in HA-VPS35 RPE1 Flp-In cell lines 
WT and [D620N] HA-VPS35 RPE1 Flp-In cells were induced with 
0.1 µg/ml doxycycline for 24 hours. Cells were fixed in 4% PFA 
before processing for IF. Coverslips were mounted on Moviol 
supplemented with 4’,6-diamidino-2-phenylindole (DAPI). 
Images were acquired with a Zeiss LSM800 scanning confocal 






Figure 3.16 VPS35 [D620N] mutation induces disruption of 
the TGN 
A RPE1 Flp-In VPS35 WT or [D620N] cells were induced with 
0.1 µg/ml doxycycline for 24 hours. Cells were fixed in 4% PFA 
before processing for IF. Images were acquired using a Zeiss 
LSM900 confocal microscope. Scale bar 20 µm. 350 nm slice. B 
Average p230 area per cell. TGN area was quantified using p230 
signal in HA-positive cells using FIJI. Analysis: Paired t test (* 
p<0.05) n=3 biological replicates.  Error bars: SEM. Minimum 40 
cells quantified per condition per repeat. C p230 area values for 
individual cells. Analysis: Unpaired t test (**** p<0.0001).   
 
Steinberg’s group showed data suggesting that a pool of Rab7 localised with 
the mitochondria which is disrupted by VPS35 knockout (Jimenez-Orgaz et 
al., 2018).  We were interested to see if the [D620N] mutation would affect the 
localisation of Rab7 to mitochondria. Both WT and [D620N] mutant cells were 
induced with doxycycline and stained for HA, TOMM20 and Rab7 (Figure 
3.17). Unlike the previous study we were unable to identify a pool of Rab7 
colocalised with mitochondria. TOMM20 showed clear mitochondrial network 




in the staining with in the [D620N] expressing cells. This could be due to the 
use of a different cell type or the use of different fixation protocols. 
 
The same study also showed that knockout of VPS35 resulted in a change in 
the colocalisation of Rab7 and LAMP2, with a redistribution of Rab7 across 
the endolysosomal network. We tested to see if the [D620N] mutation altered 
Rab7 and LAMP2 colocalisation. HA-VPS35 WT and [D620N] RPE1 Flp-In 
cells were induced with doxycycline and stained for HA, Rab7 and LAMP2 
(Figure 3.18A). Initial studies indicated that there is an increase in 
colocalisation of Rab7 and LAMP2 in the VPS35 mutant cells compared to the 
WT cells. The Mander’s overlap coeffecient was slightly increased with the 
[D620N] mutation (Figure 3.18B). Further repeats would be needed to 
determine if there is a redistribution of Rab7 across the endolysosomal 
network with the [D620N] mutation, as observed by others with VPS35 




Figure 3.17 Rab7 and TOMM20 do not colocalise at 
mitochondria in HA-VPS35 RPE1-Flp-In cells 
WT and [D620N] HA-VPS35 RPE1 Flp-In cells were induced with 
0.1 µg/ml doxycycline for 24 hours. Cells were fixed in 4% PFA 
before processing for IF. Images were acquired using a Zeiss 






Figure 3.18 Colocalisation of Rab7 and LAMP2 may be 
altered with VPS35 [D620N] mutation 
A WT and [D620N] HA-VPS35 RPE1 Flp-In cells were induced 
with 0.1 µg/ml doxycycline for 24 hours. Cells were fixed in 4% 
PFA before processing for IF. Images were acquired using a 
Zeiss LSM900 confocal microscope x63 objective. Scale bar 20 
µm. 350 nm slice. B Mander’s overlap coefficient was calculated 
using FIJI Coloc2 plugin and corresponds to the fraction of Rab7 












3.3.7. Single cell diluting HA-VPS35 RPE1 Flp-In clones 
Following the discovery that WT C4 and [D620N] M9 were not from a single 
clone, cells were single cell diluted into 96 well plates to obtain true positive 
single clones. Once plated, cells were put into selection media for 10 days. 
Colonies that grew were expanded until they could be screened by western 
blot. Clones were also seeded onto coverslips and screened by fixing and 
staining for the HA tag (Figure 3.19 and Figure 3.20).   
From the images acquired it was determined that the clones which were from 
a single cell and had the most comparable expression of HA-VPS35 were WT 
3B4 and [D620N] 1F3. Cells were also screened by WB following 24-hour 
induction with doxycycline (Figure 3.21). Western blotting confirmed that 
clones such as [D620N] 1D1 were still not pure, reflected by their lower levels 
of HA and VPS35 following induction with doxycycline. In addition to blotting 
for VPS35 and HA, lysates were also probed for other key proteins-of-interest 
such as retromer component VPS26, LRRK2 and Rab7. There did not appear 
to be an effect on the levels of any of these related proteins with doxycycline 





Figure 3.19 Screening RPE1 Flp-In VPS35 WT single cell 
diluted clones by IF 
HA-VPS35 WT RPE1 Flp-In clones from single cell dilution of WT 
C4 were induced with doxycycline (0.1 µg/ml) for 24 hours. Cells 
were fixed in 4% PFA before processing for IF. Cells were 
stained with an antibody against the HA tag. Images were 
acquired using a NIKON Ti-Eclipse widefield microscope x20 







Figure 3.20 Screening RPE1 Flp-In VPS35 [D620N] single 
cell diluted clones by IF 
HA-VPS35 [D620N] RPE1 Flp-In clones from single cell dilution 
of [D620N] M9 were induced with doxycycline (0.1 µg/ml) for 24 
hours. Cells were fixed in 4% PFA before processing for IF. Cells 
were stained with an antibody against the HA tag. Images were 
acquired using a NIKON Ti-Eclipse widefield microscope x20 








Figure 3.21 Screening single cell diluted clones by western 
blot 
WT or [D620N] HA-VPS35 RPE1 Flp-In cells were induced with 
doxycycline (0.1 µg/ml) for 24 hours. Cells were lysed and 
proteins resolved by SDS-PAGE before processing for western 






















3.4. Generating LRRK2 WT and Mutant HA-VPS35 RPE1 
Flp-In Cells 
3.4.1. Lentiviral Transduction  
WT and [D620N] HA-VPS35 RPE1 Flp-In cells (clones 3B4 and IF3 
respectively) generated in section 3.3.7 were transduced with GFP-LRRK2 
lentiviruses detailed in Table 1.1. Each virus was used at a MOI of 0.8 to 
ensure only one integration per cell. After expansion cells were sorted by 
FACS to collect the GFP-positive population. FACS work was carried out by 
Dr Ailbhe Brazel. The positive pool was expanded, and aliquots frozen for use 
in experiments. Confirmation of GFP and GFP-LRRK2 expression was 
obtained by fluorescence microscopy (Figure 3.22).  
 
3.4.2. Characterisation of LRRK2 lentivirus lines 
Next, we confirmed the activity of LRRK2 in these pools by western blot 
(Figure 3.23A). The level of phosphorylated Rab10 was confirmed using the 
phospho-Thr73 antibody and the signal was quantified. The level of phospho-
Rab10 was then normalised to the level of total LRRK2 expression (Figure 
3.23B). The LRRK2 [G2019S/D1994A] construct was expressed at a lower 
level than both the WT and [G2019S] mutant constructs. Cells transduced with 
LRRK2 [G2019S] hyperactive mutant showed higher levels of Rab10 
phosphorylation relative to WT LRRK2 transduced cells when normalised to 
the level of LRRK2 expression. LRRK2 [G2019S/D1994A] harbouring the 
kinase-dead mutation did not increase the levels of Rab10 phosphorylation 
confirming that this increase is dependent on LRRK2 kinase activity. As part 
of ongoing work in the laboratory, these cells are being single cell diluted to 
have lines with comparable expression of WT, [G2019S] and 






Figure 3.22 Generation of RPE1 Flp-In VPS35 + LRRK2 
Lentivirus lines 
RPE1 Flp-In cells generated in section 3.3.7 were transduced 
with LRRK2 lentiviruses detailed in Table 1.1. Positive cells were 
sorted by FACS and the positive pool expanded. FACS work 
carried out by Dr Ailbhe Brazel. Images were acquired using a 





Figure 3.23 Phosphorylation of Rab10 in RPE1 Flp-In 
VPS35 + LRRK2 lentivirus lines  
A Lysates from RPE1 Flp-In VPS35 + LRRK2 lentivirus lines 
generated in section 3.4.1 were run by western blot and probed 
for total LRRK2 and phosphorylated Rab10 (WT-Wild type 
LRRK2, HA-Hyperactive [G2019S] LRRK2, KD-Kinase dead 
[D1994A] LRRK2) B Phospho-Rab10 signal was quantified using 
image studio lite software and normalised to the level of LRRK2 











3.5. Discussion  
In this chapter I outline several optimisation steps carried out for this project 
as well as tools which were generated for use in this project and overlapping 
projects. As LRRK2 is a hot topic in PD research there are a number of well-
established commercially available reagents which were found to be suitable 
for use in both the human and mouse cell lines selected for the project. 
Although there are no published papers on LRRK2 in melanoma, the finding 
that LRRK2 is highly expressed in melanoma cell lines could suggest a 
potential role for LRRK2 in linking PD and the increase incidence of melanoma. 
Melanoma progression is often characterised by the so-called “Phenotypic 
switch” (Li et al., 2015). In this phenomenon the core tumour producing cells 
express a distinct set of genes which drive proliferation and other cellular 
functions that are required for tumour formation and maintenance. A different 
pattern of genes is often expressed in the invasive metastatic cells from the 
same original cancer. For example, both MITF and Rab7 are examples of early 
drivers of tumour formation and growth by driving proliferation and cell survival. 
However, they become down-regulated to promote metastasis in later stages 
of cancer progression (Goodall et al., 2008; Hoek and Goding, 2010; Alonso-
Curbelo et al., 2014) (Sections 1.3.16 and 1.3.17). The pattern of LRRK2 
expression across melanoma cells is inverse to that seen with Rab7 and MITF 
and could represent a novel marker of phenotypic switching in melanoma cells. 
It may be the case that melanoma cells upregulate LRRK2 expression as a 
beneficial gene to promote late-stage melanoma progression. In PD the 
pathogenic LRRK2 mutations identified are gain-of-function. If a higher level 
of LRRK2 expression (and therefore presumably higher levels of LRRK2 
activity) is a driver for melanoma, then PD related mutations in LRRK2 could 
also be a positive driver for melanoma progression. The effect of LRRK2 on 
key characteristics associated with melanoma will be explored in more detail 
in Chapter 5.  
 
In this chapter we also set up the GST-RILP Rab7 binding assay for measuring 
the levels of active, GTP-bound Rab7, which we validated using various Rab7 




phosphorylate a subset of Rab proteins, Rab7 is not a direct substrate (Table 
1.3). More recent studies have reported that Leucine Rich Repeat Kinase 1 
(LRRK1) is able to directly phosphorylate Rab7 (Malik et al., 2020). Despite 
not being a direct substrate, data has shown that LRRK2 is able to mediate 
the activity levels of Rab7, with hyperactivating mutations in LRRK2 causing a 
reduction in Rab7 activity (Gómez-Suaga et al., 2014). This could be 
significant as Rab7 is one of the best characterised late endosomal/lysosomal 
Rab proteins and alterations in its activity could be relevant to the trafficking 
defects observed in LRRK2 mutant cells and in PD related models in general.  
 
We also made RPE1 Flp-In cell lines with inducible VPS35 WT or VPS35 
[D620N] mutant. We made both mixed clones to be used for IF and single 
“pure” clones to be used for biochemical assays. The [D620N] mutation in 
VPS35 causes familial PD, but the exact mechanisms that underpin this are 
poorly understood. We found that the localisation of [D620N] VPS35 alongside 
many markers was unchanged compared to the WT, consistent with previous 
studies (Ishizu et al., 2016). VPS35 has been found to function in a common 
pathway with LRRK2 and Rab29, both PD related genes (MacLeod et al., 2013; 
Mir et al., 2018) (Section 1.4.16). [D620N] VPS35 results in hyperactivation 
of LRRK2, suggesting that VPS35 lies upstream of LRRK2. VPS35 has also 
been linked to Rab7 with KO of VPS35 inducing increased active Rab7. It is 
not currently known the effect of the [D620N] mutation on the levels of active 
Rab7. We were particularly interested in identifying if the effects of LRRK2 and 
VPS35 on Rab7 activity are part of the same pathway or distinct pathways. 
The cell lines and assay established provide us with the tools to answer this 
question. This is part of ongoing work being carried out within the laboratory. 
I will revisit the relationship between LRRK2 and Rab7 later (Section 4.3.7). 
Additionally, we also made pools of LRRK2 lentivirus transfected cells in both 
the VPS35 WT and [D620N] Flp-In cells. This will allow us to look at the effects 
of the hyperactive and kinase dead LRRK2 mutants and help to overcome the 






When characterising the localisation of various compartmental markers in the 
RPE1 Flp-In cells, the WT and [D620N] mutation mostly appeared unchanged. 
Previous work has suggested that KO of VPS35 results in a re-localisation of 
Rab7 to the late endosomal/lysosomal compartment as marked by 
colocalisation with LAMP2 (Jimenez-Orgaz et al., 2018). We looked with triple 
staining of the RPE1 Flp-In VPS35 lines to see if a similar phenotype was 
observed with the [D620N] mutations. Initial studies showed a slight increase 
in the colocalisation of Rab7 and LAMP2 with VPS35 pathogenic mutation, 
however, more repeats are needed to confirm this finding. Confirmation would 
indicate a change in the trafficking of Rab7 in the late endosomal/lysosomal 
system consistent with what is seen with VPS35 knockout.  
 
We also noticed that the TGN marker p230 appeared to be more dispersed in 
the cells expressing the VPS35 [D620N] mutation compared with the WT 
expressing cells. LRRK2 overexpression and hyperactivation has been found 
to induce disruption of the TGN, a phenotype which can be rescued following 
treatment with LRRK2 inhibitor (Purlyte, 2018). This will be discussed in further 
detail in Chapter 4 (Section 4.4.5). Recruitment of LRRK2 to the Golgi network 
and the downstream effects are suggested to be mediated by Rab29. The 
finding that the pathogenic mutations in both LRRK2 and VPS35 have the 
same effect on TGN integrity provides further evidence that these proteins 










4. Chapter 4: LRRK2 and LROs 
4.1. Introduction  
The proteins and pathways known to be associated with PD (as well as many 
other neurodegenerative diseases) can largely be assigned to one of two 
categories- mitophagy dysfunction or endolysosomal dysfunction (Liu et al., 
2019; Malik et al., 2019; Dauer and Przedborski, 2003; Perrett et al., 2015) 
(Sections 1.4.4 and 1.4.5). We know that there is significant crosstalk 
between these two quality control pathways which are predicted to be 
significant to PD pathogenesis (Plotegher and Duchen, 2017).  It is important 
to understand the physiological functions of LRRK2, as well as understanding 
the pathophysiology relating to PD. In this chapter I present data which shows 
that LRRK2 plays a significant role in membrane dynamics within a specialised 
cell type- specifically in the context of lysosomes and lysosome related 
organelles. 
 
Within research into neurodegenerative diseases, a wide variety of models are 
used to study the pathogenic mutations that have been identified in the field. 
These range from cell lines to in vivo models, such as drosophila and mouse 
models, all of which have their own benefits and draw backs. For example, 
many cell lines used are not physiologically relevant to PD. In drosophila, 
LRRK1 and LRRK2 homologues are represented by one protein Lrrk. Some 
data has also been gathered from human post-mortem brain samples, 
however, the information drawn from these samples is limited by the fact that 
most dopaminergic neurons have already been lost, making it impossible to 
study the pathogenesis of disease. 
 
Many laboratories have used reprogramming techniques to provide cellular 
models from patients which harbour known pathogenic mutations. A common 
model is induced pluripotent stem cells (iPSCs) derived from patient skin 
fibroblasts. These dedifferentiated cells can be pushed to differentiate into 
various cell types (Unternaehrer and Daley, 2011). One major draw-back of 




reprogramming for iPSCs removes the aged, epigenetic phenotype of these 
cells which is likely to be significant when studying an ageing disease (Meyer 
et al., 2014; Ebrahimi et al., 2019). Induced neural progenitor cells (iNPCs) are 
an alternative model to differentiate dopaminergic neurons. In this model 
fibroblasts derived from patients and controls are reprogrammed so that they 
retain their aged phenotype (Meyer et al., 2014; Kim et al., 2011a). From these 
cells, treatment with several factors can then be used for differentiation into 
astrocytes or dopaminergic neurons.  
 
4.2. LRRK2 and MiT transcription factors 
4.2.1. LRRK2 is inversely related to MITF and TFEB in Melan-a 
cells 
Following the finding that LRRK2 expression is inversely related to the levels 
of pigmentation markers (Figure 3.2), I performed an siRNA knockdown of 
LRRK2 or pigmentation related transcription factor MITF in Melan-a. cells. A 
fellow member of the MiT transcription factor family, TFEB, was knocked down 
as a control. The levels of proteins were measured by western blot (Figure 
4.1A). All proteins were efficiently depleted by siRNA. Loss of LRRK2 resulted 
in an increase in the level of MITF protein levels. As expected, depletion of 
MITF resulted in a decrease in the levels of both MITF and Rab27A- one of its 
transcriptional targets (Chiaverini et al., 2008)  (Appendix 2). Interestingly, 
loss of MITF also resulted in an increase in the levels of LRRK2. Furthermore, 
depletion of LRRK2 induced an increase in the levels of TFEB and loss of 
TFEB resulted in an increase in the levels of LRRK2 protein- larger than that 
seen with loss of MITF. These results were quantified using Image Studio 
software (Figure 4.1B). This demonstrates an inverse relationship between 






Figure 4.1 Identification of an inverse relationship between 
LRRK2 and two related MiT transcription factors 
A Lysates from Melan-a cell treated with 40 nM siRNA for 72 
hours were analysed by western blot and probed with the 
indicated antibodies. Blot is representative of 5 biological 
repeats. B Bands from western blots were quantified using image 
studio lite software and normalised to NT1. n=5 biological 
replicates. Error Bars: SD. Analysis: one-way ANOVA with 
Turkey’s multiple comparison test. (* p<0.05, ** p<0.01, *** 
p<0.001. C Melan-a cells were treated with 40 nM siRNA 
targeting LRRK2 or TFEB for 72 hours. mRNA was extracted and 
reverse transcribed. Resulting cDNA was analysed by RT-qPCR 
using primers against LRRK2 or TFEB. 2^-ΔΔCt values 
normalised to NT1. n=3 biological replicates. Error bars: SD. 
Individual repeats displayed in different colours. Analysis: 




4.2.2. mRNA levels of LRRK2 and TFEB with knockdowns 
To determine if the changes in protein level seen by western blot were 
occurring at a transcriptional level, RT-qPCR was used to determine the 
mRNA levels of LRRK2 and TFEB following siRNA knockdown (Figure 4.1C). 
When quantified, depletion of TFEB resulted in a 2-fold increase in the levels 
of LRRK2 mRNA transcripts. Similarly, a loss of LRRK2 resulted in a 1.5-fold 
increase in the levels of TFEB mRNA. These results support the reciprocal 
relationship between LRRK2 and TFEB seen by western blot and suggest that 
the increase in protein level is at least in part a result of an increase in mRNA 
expression. 
 
4.3. LRRK2 and Lysosome related organelle number and 
function in Melan-a cells 
4.3.1. Depletion of LRRK2 increases LRO number in Melan-a 
cells 
I next investigated the effect of depletion of LRRK2 protein on lysosomes and 
lysosome related organelles (LROs). LRRK2 was depleted with siRNA for 72 
hours. Cells were labelled with LysoTracker Deep Red fluorescent dye and 
imaged live using confocal microscopy. LysoTracker compounds are cell 
permeable fluorophores which are highly specific for acidic organelles. 
Organelles expected to be labelled with LysoTracker red include some late 
endosomes, lysosomes, early melanosomes, and peroxisomes (Section 
1.2.7). Depletion of LRRK2 protein increased the number of LysoTracker 
positive vesicles by eye (Figure 4.2A). This was quantified by taking the total 
intensity per cell and averaging over the number of cells analysed. 
Quantification confirmed there was an increase in LysoTracker intensity with 
LRRK2 knockdown (Figure 4.2B).  
 
Next, I looked to confirm this result by imaging the number of lysosome-
associated membrane protein 1 (LAMP1) positive vesicles in fixed cells using 




confirmed that depletion of LRRK2 increased the number of LROs in Melan-a 
cells relative to NT1 treated cells (Figure 4.3A). Depletion of LRRK2 also 
increased the number of Rab7 positive vesicles in Melan-a cells further 




Figure 4.2 Depletion of LRRK2 in Melan-a cells increases 
LysoTracker labelling in Melan-a cells 
A Melan-a cells treated with 40 nM siRNA oligos against LRRK2 
and TFEB for 72 hours were incubated with LysoTracker Deep 
Red fluorescent dye (0.5 μM) for 1 hour. The nuclei were labelled 
with Hoechst. Live images were acquired using a 3i spinning disk 
confocal microscope x63 objective. Scale bar: 20 μm. 350 nm 
slice.  B Total intensity of LysoTracker signal was quantified per 
cell. Minimum of 25 cells analysed per condition. n=2 biological 







Figure 4.3 Depletion of LRRK2 increases the staining of 
LAMP1 in Melan-a cells. 
Melan-a cells treated with 40 nM siRNA oligos for 72 hours were 
fixed with 4% PFA before processing for IF. Coverslips were 
mounted on Moviol supplemented with 4’,6-diamidino-2-
phenylindole (DAPI). Images were acquired with a 3i spinning disk 
confocal microscope x63 objective. Scale bar: 20 μm. 350 nm slice 







Figure 4.4 Depletion of LRRK2 increases the number of 
Rab7 positive vesicles in Melan-a cells. 
Melan-a cells treated with 40 nM siRNA oligos for 72 hours were 
fixed with 4% PFA before processing for IF. Coverslips were 
mounted on Moviol supplemented with 4’,6-diamidino-2-
phenylindole (DAPI). Images were acquired using a Zeiss 
LSM800 confocal microscope x63 objective. Scale bar: 20 μm. 
350 nm slice. n=3 biological replicates. 
 
4.3.2. Inhibition of LRRK2 increases LRO number in Melan-a 
cells 
To further support the results seen with LRRK2 knockdown, I then looked at 
the number of acidic organelles in Melan-a cells with LRRK2 inhibition. Melan-
a cells were treated with inhibitors HG-10-102-01 (HG-10) and MLi-2 for 48 
hours then labelled with LysoTracker. Cells were imaged by live confocal 
microscopy.  Inhibition of LRRK2 increased the number of acidic organelles 
relative to DMSO treated cells (Figure 4.5A). LysoTracker images were 
quantified by taking the total intensity of LysoTracker signal per cell and 
averaging this value for the total number of cells quantified (Figure 4.5B). 






Figure 4.5 Inhibition of LRRK2 increases LysoTracker 
labelling in Melan-a cells  
A Melan-a cell treated with HG-10-102-01 (HG-10, 500 nM) or MLi-
2 (200 nM) for 48 hours were incubated with LysoTracker Deep red 
(0.5 μM) for 1 hour. Cells were imaged live using a 3i spinning disk 
confocal microscope Scale bar: 20 μm. 350 nm slice. B Total 
intensity of LysoTracker signal was quantified per cell. Minimum of 
25 cells quantified per condition per repeat. n=3 biological 
replicates. Error bar: SEM. 
 
Next, I looked to confirm this result by imaging the number of LAMP1 positive 
vesicles in fixed cells. Melan-a cells treated with HG-10 and MLi-2 inhibitors 
for 48 hours were fixed and stained for LAMP1 and coverslips imaged by 
confocal microscopy (Figure 4.6A). Inhibition of LRRK2 was shown to 
increase the number of LAMP1 vesicles relative to the control treated cells. 
The number of vesicles per cell was quantified using the analyse particles 
plugin in FIJI, and the average taken across three independent experiments 
(Figure 4.6B). Quantification showed an increase in the number of LAMP1 
positive vesicles per cell with LRRK2 inhibition, which is consistent with what 





Figure 4.6 Inhibition of LRRK2 increases the number of LAMP1 
positive vesicles 
A Melan-a cells treated with LRRK2 inhibitors HG-10 (500 nM), or 
MLi-2 (200 nM) for 48 hours were fixed with 4% PFA before 
processing for IF. Coverslips were mounted on Moviol 
supplemented with 4’,6-diamidino-2-phenylindole (DAPI). Images 
were acquired with a 3i spinning disk confocal microscope x63 
objective. Scale bar: 20 μm. 350 nm slice. B The number of LAMP1 
vesicles per cell was quantified using the analyse particles function 
in FIJI. Graph shows average number of vesicles per cell across 3 
biological repeats. Minimum 25 cells analysed per condition per 
repeat. Error bars: SEM. Analysis: Unpaired t test (* p<0.05). 
 
4.3.3. Inhibition of LRRK2 does not increase lysosome 
function 
To determine if the lysosomal activity of these cells had also increased, I 
utilised the Magic Red-Cathepsin B fluorescent probe (see schematic Figure 
2.5). This probe only becomes fluorescent within an active lysosomal 
compartment. The probe consists of a fluorophore conjugated to two cleavage 
peptides for Cathepsin B hydrolase. Prior to cleavage the probe is not 




the lysosome results in release of the fluorophore and a fluorescent signal 
(Van Noorden et al., 1997). Melan-a cells treated with LRRK2 inhibitors for 24 
hours were labelled with Magic Red-Cathepsin B and imaged live by confocal 
microscopy (Figure 4.7A). Melan-a cells treated with LRRK2 inhibitors did not 
show an increase in fluorescent signal. This indicated there was not a 
significant change in the activity of Cathepsin B. It must be noted that 
Cathepsin B has a broad pH optimum which does limit the conclusions we can 
draw from this assay, as the activity of more pH sensitive proteins may be 
affected by the changes seen in acidic organelles.     
 
I also used a plate reader assay to measure the activity of another lysosomal 
cathepsin protein- Cathepsin D. This works in a similar format to the Magic red 
probe in that cleavage of a target sequence by Cathepsin D results in a 
fluorescent signal read by a plate reader. Lysates from Melan-a cells treated 
with MLi-2 were incubated with Cathepsin D substrate and then the 
fluorescence per well quantified. Fluorescence was normalised to the amount 
of protein loaded onto the assay (Figure 4.7B). As with the Magic Red assay, 
there was no increase in the activity of Cathepsin D with LRRK2 inhibition. 
This data, together with that from the LysoTracker experiments, would indicate 
that with LRRK2 inhibition the number of LROs is increasing, but that there 
isn’t a concomitant increase in the degradative capacity of lysosomes.  
 
I also checked to see if inhibition of LRRK2 changed the Cathepsin D protein 
levels. Melan-a cells were treated with LRRK2 inhibitor and lysates probed 
with an antibody against cathepsin D. Cathepsin D exists as an immature “pro” 
form prior to delivery to the lysosome (Section 1.2.5). Neither the pro-, nor 
cleaved-cathepsin D bands showed any change with LRRK2 inhibition (Figure 
4.7C). Therefore, neither the pro-form levels, nor the active form of lysosomal 
hydrolases are increased with LRRK2 inhibition, consistent with no change in 






Figure 4.7 Inhibition of LRRK2 in Melan-a cells does not 
increase Cathepsin B or D proteolytic activity  
A Melan-a cells treated with LRRK2 inhibitor MLi-2 (200 nM) for 
24 hours were incubated with Magic Red-Cathepsin B 
fluorescent probe for 1 hour before live imaging with a 3i spinning 
disk confocal microscope x63 objective. Scale bar 20 μm. 350 
nm slice. n=3 biological replicates. B Lysates from Melan-a- cells 
treated with LRRK2 inhibitor MLi-2 (200 nM) for 24 hours were 
analysed with Cathepsin D activity assay kit. Signal was 
normalised to DMSO. n=3 biological replicates. Individual 
repeats displayed in different colours. Error bars: SD. C Lysates 
from Melan-a cells treated with MLi-2 (200 nM) for the indicated 
time points were probed with the indicated antibodies. Both pro 




4.3.4. LRRK2 inhibition results in a striking rapid change in 
late endosome and LRO markers in Melan-a cells 
I was next interested to determine the kinetics of this change in LRO number. 
Melan-a cells were treated with LRRK2 inhibitor for a range of time points and 
labelled with LysoTracker for 1 hour. For the 1-hour treatment, MLi-2 and 
LysoTracker were added simultaneously. Cells were imaged live using 
widefield microscopy. Imaging revealed that there was a large increase in the 
level of LysoTracker labelling after just 1 hour of treatment that recedes over 
time, indicating that LRRK2 is having a major acute effect on acidic organelles. 
(Figure 4.8A). To confirm this result, I repeated the experiment with just the 
1-hour time point but looked with confocal microscopy which confirmed there 
is an increase in acidic organelles after just 1 hour (Figure 4.8B).  
 
I next looked at fixed cells stained with a late endosome/lysosome marker to 
see if I could again observe an increase after 1 hour. Imaging of fixed cells 
treated with MLi-2 for various time points showed that there is an increase in 
staining of Rab7 in Melan-a cells after just 1 hour (Figure 4.9). Importantly, 
early endosomal markers EEA1 and HRS staining did not change with LRRK2 








Figure 4.8 LRRK2 inhibition results in a rapid increase and 
subsequent dissipation in LysoTracker labelling  
A Melan-a cells treated with MLi-2 (200 nM) for the indicated time 
points were labelled with LysoTracker Deep Red fluorescent dye 
(0.5 μM) for 1 hour before images were acquired live using a 
Nikon Ti-Eclipse microscope x40 objective. Scale Bar: 50 μm. B 
Melan-a cells treated with MLi-2 (200 nM) for 1 hour were 
labelled with LysoTracker Deep Red fluorescent dye. Images 
were acquired live using a 3i spinning disk confocal. Scale Bar: 









Figure 4.9 Acute inhibition of LRRK2 increases Rab7 
staining in Melan-a cells 
Melan-a cells were treated with MLi-2 LRRK2 inhibitor (200 nM) 
for the indicated time points before being fixed in 4% PFA and 
processed for IF. Coverslips were mounted with Moviol 
supplemented with 4’,6-diamidino-2-phenylindole (DAPI). 
Images were acquired using a Zeiss LSM800 confocal 








Figure 4.10 LRRK2 inhibition doesn't change EEA1 and HRS 
staining in Melan-a cells 
Melan-a cells were treated with MLi-2 LRRK2 inhibitor (200 nM) 
for the indicated time points before being fixed in 4% PFA and 
processed for IF. Cells were stained for the indicated antibodies. 
Coverslips were mounted with Moviol supplemented with 4’,6-
diamidino-2-phenylindole (DAPI). Images were acquired using a 
Zeiss LSM800 confocal microscope x63 objective. Scale bar 20 




In addition to the confocal images taken of fixed cells, quantification was 
carried out for Melan-a cells stained with LAMP1 antibody by IF using an 
OPERA high content screening system. Cells were treated with MLi-2 for 
multiple time points before fixing and staining for LAMP1 and nuclear stain 
Hoechst. Random fields of view were then imaged for each well. Quantification 
was carried out using Harmony software to select cell area, cell nuclei and 
“spots” (LAMP1 positive vesicles). Calculations were then run in the harmony 
software to determine values such as average number of lysosomes per cell, 
average number of lysosomes per cell area, average intensity of lysosomes 
and average size of lysosomes (Figure 2.7). Quantification showed that there 
was a striking increase in the number of lysosomes per cell area at the 1-hour 




consistent with what had been seen by IF (Figure 4.11A). There was not an 




Figure 4.11 Acute inhibition of LRRK2 increases the number 
of LAMP1 positive vesicles in Melan-a cells 
Melan-a cells were treated with LRRK2 inhibitor MLi-2 (200 nM) 
for the indicated time points. Cells were fixed in 4% PFA before 
processing for IF. Cells were stained with a LAMP1 antibody and 
nuclei labelled with Hoechst. An OPERA phoenix high content 
screening system was used to image cells at random throughout 
conditions. A Harmony software was used to quantify the 
average number of lysosomes per cell. B Harmony software was 
used to calculate the average intensity of spots measured. C 
Harmony software was used to measure the average area of 
LAMP1 positive spots. Samples were normalised to the DMSO 
sample. n=3 biological replicates. Minimum 500 cells quantified 
per condition per repeat. Error bars: SEM.  
 
4.3.5. The effect of LRRK2 on lysosomes is independent of 
TFEB  
My initial interest in LRRK2 and lysosomes came from the early finding that 
LRRK2 knockdown results in an increase in the levels of TFEB at both a 
protein and mRNA transcript level. However, the later finding that there is an 
effect on LROs as early as 1 hour after treatment suggests that this process 
is too quick for translation to be involved. Therefore, I sought to determine if 
the changes seen in LysoTracker and LRO marker labelling were independent 




treated them with LRRK2 inhibitor MLi-2. I then fixed and stained them with an 
antibody against Rab7. Cells were imaged by confocal microscopy (Figure 
4.12). Treatment with LRRK2 inhibitor in TFEB depleted cells resulted in an 
increase in Rab7 staining. 
 
 
Figure 4.12 The effect of LRRK2 on lysosomes in Melan-a 
cells is independent of TFEB 
Melan-a cells were treated with 40 nM siRNA against TFEB for 
48 hours before the addition of MLi-2 (200 nM) for an additional 
24 hours. Cells were fixed in 4% PFA before processing for IF. 
Images were acquired with a 3i spinning disk confocal 





4.3.6. Total levels of lysosomal proteins do not change with 
LRRK2 inhibition or depletion 
To determine if the changes seen by IF were due to an increase in protein 
levels of these markers, or a change in dynamics, Melan-a cells were treated 
with LRRK2 inhibitors HG-10 or MLi-2 or siRNA targeting LRRK2. Lysates 
were probed for total levels of late endosome/lysosome associated proteins 
LAMP1 and Rab7 (Figure 4.13). There were no changes in the total levels of 




Figure 4.13 Total levels of lysosomal proteins do not change 
with LRRK2 inhibition or siRNA depletion 
A Melan-a cells were treated with 40 nM siRNA targeting LRRK2 
for 72 hours B Melan-a cells were treated with HG-10 (500 nM) 
and MLi-2 (200 nM) LRRK2 inhibitors for 24 hours. Lysates were 
analysed by western blot. Membranes were probed with the 
indicated antibodies. n=3 biological replicates. Representative 
blots shown.  
 
 
4.3.7. Inhibition of LRRK2 increases GTP-bound active Rab7 
To determine if the Rab7 phenotype observed in Melan-a cells could be due 
to a change in the nucleotide binding status of Rab7 I used the GST-RILP 
binding assay described in Chapter 3 (Section 3.3.2). Melan-a cells were 
treated with MLi-2 inhibitor for 1 hour or 24 hours. Cells were lysed, and lysates 




beads were analysed by western blot (Figure 4.14A).  Active Rab7 signal was 
quantified and normalised to the total Rab7 in the input sample (Figure 4.14B). 
Both at the 1-hour and 24-hour time points an increase was seen in the amount 




Figure 4.14 LRRK2 inhibition increases GTP-bound Rab7 
A Melan-a cells were treated with MLi-2 (200 nM) for the 
indicated time points. Cells were lysed in Rab7 assay lysis buffer 
and lysates loaded onto GST-RILP beads. Bound proteins were 
eluted and analysed by western blot. 10 μg input loaded. B 
Levels of GTP-bound active Rab7 were quantified using image 
studio software. Levels were normalised to total Rab7 levels from 
input. Values were then normalised to DMSO. n=3 biological 
replicates. Error bars: SD.  
 
4.4. LRRK2 in iNPC derived dopaminergic neurons 
4.4.1. Differentiation of iNPCs into dopaminergic neurons 
In order to look at LRRK2 in a more physiologically relevant setting, under the 
supervision of Heather Mortiboys at The Sheffield Institute for Translational 
Neuroscience (SITraN), I carried out work in dopaminergic neurons derived 
from iNPCs. Skin samples were taken from 2 healthy age-matched controls 
and 2 individuals carrying the [G2019S] LRRK2 mutation. One of the 
individuals with the [G2019S] LRRK2 mutation is symptomatic for PD, and 
derived samples will be referred to as manifesting mutant (MM). The other 




samples will hereafter be referred to as the non-manifesting mutant (NMM). 
Skin samples were used to extract fibroblasts for cell culture. Cells were 
reprogrammed from fibroblasts to iNPCs by Heather Mortiboys. From iNPCs, 
dopaminergic neurons were differentiated over a 27-day protocol. The full 
methods for dopaminergic neuron differentiation are given in section 2.1.10. 
Representative images of Control 1 cells undergoing the final stretch of 
differentiation are shown in Figure 4.15. 
 
 
Figure 4.15 Differentiation of dopaminergic neurons from 
control 1 iNPCs 
iNPCs were differentiated into dopaminergic neurons across a 
27-day protocol outlined in section 2.1.10. On day 12 cells were 
re-plated into the final assay vessel and grown in BDNF (30 
ng/ml), GDNF (30 ng/ml), TGF-b3 (2 mM) and dCAMP (2 mM) 
for 15 days. Images were acquired on the indicated days of the 
protocol to show morphology changes and monitor differentiation 
progress. Cells were imaged with an IN Cell Analyser 2200 




4.4.2. LRRK [G2019S] mutation increases LAMP1 staining in 
dopaminergic neurons 
Dopaminergic neurons differentiated from iNPCs from control and mutant 




then visualised using an OPERA Phoenix high content screening imaging 
system. Random fields of view from each well were captured to remove bias. 
Representative images of each neuron line are shown in Figure 4.16A. Both 
the non-manifesting and manifesting [G2019S] mutant lines showed an 
increase in LAMP1 staining compared to control lines. Harmony high content 
imaging and analysis software was used to quantify the number of cells 
(number of nuclei), cell area analysed and the number of spots (number of 
LAMP1 positive vesicles). From this the number of LAMP1 positive spots per 
cell/cell area was quantified. Quantification analysis confirmed what was 
evident by eye, that there was an increase in the number of LAMP1 positive 
vesicles in the mutant lines relative to the control lines. This quantification 
workflow is shown in more detail in Figure 2.7. Quantification also showed 
that there was an increase in the area of lysosomes, but only in the case of 
the manifesting mutant (Figure 4.16B).  
 
4.4.3. LRRK2 [G2019S] does not increase lysosomal activity 
Following the increase in LAMP1 staining, I was next interested in the 
lysosomal activity in the mutant neurons compared to the control neurons.  
In order to look at this I utilised the same Magic Red-Cathepsin B assay used 
in the melanocytes (see Section 4.3.3). Neurons were differentiated from 
iNPCs, and on the final day of the differentiation protocol were labelled with 
Magic Red-Cathepsin B probe. Neurons were imaged live using an OPERA 
Phoenix high content screening imaging system. Random fields of view were 
captured for each neuron line to prevent bias. Representative images are 
shown in Figure 4.17A. The number of active lysosomes was quantified using 
Harmony high content imaging and analysis software as above. Cells were 
counted by nuclei staining and cell area and active lysosomes (number of 
spots) quantified. In contrast to the LAMP1 staining, there was not an increase 
in the number of active lysosomes in LRRK2 mutant neurons relative to the 
control neurons (Figure 4.17B). In fact, there was a decrease in lysosomal 




measurements taken for active lysosome (signal) intensity and active 




Figure 4.16 LRRK2 [G2019S] mutation increases LAMP1 
staining in iNPC derived dopaminergic neurons 
A Dopaminergic neurons were differentiated from iNPCs and 
fixed in 4% PFA before processing for IF. Cells were stained with 
a primary antibody against LAMP1 and imaged using an OPERA 
high content screening imaging system. x40 objective used. 
Maximum projection shown. B The number, intensity and area of 
LAMP1 positive vesicles was quantified using Harmony high 
content imaging and analysis software. Minimum of 526 cells 






Figure 4.17 LRRK2 [G2019S] mutation doesn't increase 
lysosome activity 
A Dopaminergic neurons were differentiated from control and 
[G2019S] mutant iNPCs lines. Cells were labelled with Magic-
Red Cathepsin B reagent at the end of the differentiation protocol 
and imaged live with an OPERA high content screening imaging 
system x40 objective. Scale bar 20 µm. Maximum projection 
shown.  B The number, intensity and area of active lysosomes 
was quantified using Harmony high content imaging and analysis 









4.4.4. LRRK2 [G2019S] manifesting mutant dopaminergic 
neurons have reduced Rab7 staining 
I next wanted to see if the increase in LAMP1 staining was due to a general 
issue within the endolysosomal system. Dopaminergic neurons differentiated 
from iNPCs were fixed on the final day of differentiation and stained with an 
antibody for Rab7. Images were acquired with an OPERA Phoenix high 
content screening imaging system. Random fields of view from each well were 
captured to remove bias. Representative images of each neuron line are 
shown in Figure 4.18A. For manifesting mutant cells there was a dramatic 
reduction in the Rab7 signal when compared to the control neuron lines. 
Quantification was carried out as above to determine the number of Rab7 
positive vesicles per cell (Figure 4.18B). This confirmed there is a significant 
decrease in the number of Rab7 positive vesicles in the manifesting mutant 
[G2019S] neuron line compared with the control lines. The non-manifesting 
mutant showed no difference in staining compared with the control lines.   
 
4.4.5. LRRK2 [G2019S] mutants have a disrupted TGN  
It has previously been shown that hyperactive mutation of LRRK2 affects the 
morphology of the TGN in a number of cell models (Purlyte et al., 2018; Liu et 
al., 2018) (Section 1.4.12). To further investigate the finding that there is not 
an increase in the activity of lysosomes despite there being an increase in the 
number of total lysosomes, I next looked at the distribution of the mannose-6-
phosphate receptor (CIMPR). Neurons were differentiated from iNPCs and 
fixed and stained with an antibody for CIMPR on the final day of differentiation. 
Images were acquired with an OPERA Phoenix high content screening system. 
Representative images are shown in Figure 4.19. The CIMPR would be 
expected to reside in the Golgi apparatus and TGN at steady state, with only 
a small portion trafficking back from the endosomal network (Cooper and 
Stevens, 1996). This was the case in both control and mutant lines. However, 
as previously reported, the morphology of the Golgi and the TGN was affected 
by the [G2019S] mutation in both the non-manifesting and manifesting mutant 




In both [G2019S] LRRK2 mutant lines, the Golgi and TGN was more dispersed 




Figure 4.18 Manifesting [G2019S] LRRK2 mutant neurons 
have reduced Rab7 staining 
A Control and [G2019S] mutant neurons differentiated from 
iNPCs were fixed on the final day of differentiation in 4% PFA 
before processing for IF. Cells were stained with an antibody 
against Rab7. Cells were imaged with an OPERA high content 
screening imaging system x40 objective. Scale bar 50 µm. 
Maximum projection shown.  B The number of Rab7 positive 
vesicles per cell was quantified using Harmony high content 







Figure 4.19 LRRK2 [G2019S] mutation disrupts the TGN  
Control and [G2019S] mutant neurons differentiated from iNPCs 
were fixed on the final day of differentiation in 4% PFA before 
processing for IF. Cells were stained with an antibody against 
CIMPR. Cells were imaged with an OPERA high content 
screening imaging system x40 objective. Scale bar 20 µm. 











In this chapter I identified a relationship between LRRK2 and two related 
transcription factors which drive related organelle biogenesis pathways, MITF 
and TFEB (Figure 1.6). The inverse relationship between MITF and LRRK2 is 
consistent with the pattern of LRRK2 expression seen in Melanoma cells 
shown in Figure 3.2, where high levels of LRRK2 correlate with low levels of 
pigmentation markers and vice versa. Although LRRK2 has been linked to 
many trafficking defects, in particular within the endolysosomal system, 
LRRK2 has not previously been linked to the lysosome biogenesis 
transcription factor TFEB. Western blotting showed a striking increase in 
LRRK2 levels with TFEB KD and an increase in TFEB protein with LRRK2 
depletion. However, the qPCR data showed a much smaller fold change in 
mRNA levels compared to total protein levels. This suggests that the inverse 
relationship between LRRK2 and TFEB is only in part due to changes in 
transcription, and instead post translational changes are relevant. The data in 
this chapter indicates LRRK2 inhibition leads to dysfunction in the late stages 
of the endolysosomal pathway. No changes were observed in early 
endosomal markers. The inverse relationship with TFEB made us question 
whether this was due to an increase in lysosome biogenesis. Changes seen 
in staining for acidic organelles as well as LAMP1 and Rab7 occur as early as 
1 hour post inhibition of LRRK2 suggesting this is not the case. It does not 
seem conceivable that changes observed could be due to the generation of 
new organelles in such a short time frame. This is also supported by the finding 
that total amounts of late endosome/lysosome proteins are unchanged with 
LRRK2 inhibition or depletion.  
 
It has recently been shown that LRRK2, and Rab29 interact with Vps52 
(Beilina et al., 2020). Vps52 is a component of the GARP complex- a tethering 
factor responsible for the retrograde transport from the endosomal system to 
the TGN (Bonifacino and Hierro, 2011). Knockdown of LRRK2 was shown to 
reduce the normal trafficking of CIMPR and CtxB to the TGN and was 
proposed to do this through its interaction with GARP. This would suggest that 




and therefore lysosome function and homeostasis (Beilina et al., 2020). In our 
model, LRRK2 inhibition did not alter lysosomal enzyme activity. The lack of 
an increase in lysosomal hydrolase activity would suggest that the degradative 
capacity of cells is unchanged. This supports the assumption that we do not 
generate more lysosomes, as you would expect a concomitant increase in 
lysosomal protein and activity. Therefore, this phenotype is more likely to be 
due to changes in fission/fusion events, or recruitment of markers to 
membranes. The occurrence of such events could be based on an initial 
response at shorter time points, that is independent of TFEB, or one in which 
TFEB plays a role in the sustained effect on the endolysosomal system 
following longer inhibition or knockdown periods. 
 
Rab7 staining by immunofluorescence was dramatically increased after 1-hour 
inhibition of LRRK2 and was sustained at longer time points, as well as with 
LRRK2 depletion. Although LRRK2 can phosphorylate a subset of Rab 
proteins (Steger et al., 2016), Rab7 is not a direct substrate of LRRK2 (Table 
1.3). LRRK1, a paralogue of LRRK2, is able to phosphorylate Rab7 (Malik et 
al., 2020). Despite not being a substrate, Rab7 activity has been linked to 
LRRK2 kinase activity. Hyperactivating mutations in LRRK2 negatively 
regulate Rab7, resulting in an increase in Rab7-GDP (Gómez-Suaga et al., 
2014). The mechanism through which LRRK2 exerts its regulatory function on 
Rab7 is not currently known. You would expect the hyperactivating mutations 
in LRRK2, and inhibition of LRRK2 activity to have opposing phenotypes. In 
this case you would expect that inhibition of LRRK2 would induce a higher 
proportion of Rab7-GTP, or “active Rab7”. In Melan-a cells LRRK2 inhibition 
increased GTP-bound active Rab7 with both acute and longer inhibition time 
points. Rab proteins are inserted into membranes via their lipid-based 
geranylgeranyl PTM, after which they can exchange GDP for GTP, with the 
help of their GEF (Zerial and McBride, 2001; Zerial and Stenmark, 1993). You 
would expect that GTP bound Rab7 would be localised to membranes as 
opposed to the cytoplasm. Under baseline conditions, only a small percentage 
of total Rab protein is in the active GTP bound form. One explanation for the 




of GTP and prevents the progression of the Rab cycle. This would prevent the 
extraction of Rab7 from the membrane and give the appearance of an increase 
in Rab7 positive punctae. The change in staining pattern could also be related 
to Rab7’s function in late endosome- lysosome fusion events and lysosomal 
positioning. Rab7 interacts with the HOPS complex which tethers late 
endosomes and lysosomes together prior to fusion (Khatter et al., 2015; Lin et 
al., 2014). Therefore, there could be an increase in tethering of Rab7 positive 
vesicles in response to LRRK2 inhibition. In imaging experiments changes 
were observed in Rab7, LAMP1 and LysoTracker, with varying responses. 
Since there is a large body of data already linking LRRK2 to the 
endolysosomal system, and PD being a disease of membrane traffic, it would 
be reasonable to assume that these vesicles are lysosomes. Due to the initial 
data linking LRRK2 and TFEB this was also my initial assumption.  
 
One caveat that should be noted is that many late endosomal markers are 
also present at melanosomes. LAMP1 has been identified as residing at 
melanosomes (Zhou et al., 1993). Rab7 has also been reported to be a 
melanosome associated protein (Jordens et al., 2006; Gomez et al., 2001). As 
melanosomes are lysosome related organelles, which originate from the same 
system, it is logical that they would share many markers. The rapid change in 
LysoTracker signal with acute LRRK2 inhibition indicates a rapid acidification 
process. Lysosomes are well characterised as having a low pH essential to 
their function. Early-stage melanosomes are also acidic. Via the action of a v-
ATPase isoform, they are acidified during the early stages of melanogenesis, 
then neutralised at the later stages prior to melanosome transfer (Ohbayashi 
and Fukuda, 2020)(Section 1.2.7). It therefore must be considered that the 
changes seen could all be the result of an effect on melanosomes as well as 
lysosomes. This would be consistent with the relationship observed between 
LRRK2 and MITF, and the inverse relationship seen between LRRK2 and 
pigmentation markers. No previous role for LRRK2 in melanogenesis has 
been identified. It would be beneficial to identify a marker which is a “true 
lysosomal marker”. However, it was difficult to find a lysosomal protein which 




to differentiate fully between the two compartments in this cell type. I will revisit 
this issue later in chapter 5, as well as looking at Rab7 and the acidification 
phenotypes in other cell lines. It is also possible that the changes observed 
are due to alterations in both pathways and that they share some regulatory 
machinery where LRRK2 plays a role.  
 
The work carried out in Sheffield utilising the differentiated dopaminergic 
neurons allowed me to look at LRRK2 biology in a more physiologically 
relevant setting, and to look at cells which are expressing a LRRK2 pathogenic 
mutation, rather than looking at LRRK2 depletion or inhibition. The finding that 
LAMP1 positive vesicles are increased in the non-manifesting and manifesting 
[G2019S] mutant is consistent with previous studies showing that LRRK2 
mutation results in trafficking defects in the lysosomal pathway (Ho et al., 2020; 
Henry et al., 2015; Hockey et al., 2015; MacLeod et al., 2013). Labelling of 
these cells with Magic Red-Cathepsin B did not indicate that there is an 
increase in the lysosomal activity within these cells. This is consistent with the 
phenotypes observed in the melanocytes with LRRK2 inhibition, despite the 
change in LRRK2 activity being in the opposite direction. This data contrasts 
with what was previously reported showing that the interaction between 
LRRK2 and GARP affects the trafficking of lysosomal hydrolases (Beilina et 
al., 2020). In our data, LRRK2 [G2019S] mutation in the dopaminergic neurons 
resulted in a more dispersed staining of CIMPR.  The staining was clearly 
consistent with TGN morphology, indicating that the CIMPR is localising 
normally, but that the morphology of the TGN itself is changed. This is 
consistent with previous studies which also show that hyperactive mutations 
in LRRK2 result in a more dispersed Golgi staining, which can be rescued by 
treating cells with MLi-2 (Liu et al., 2018; Purlyte et al., 2018). In these studies, 
they suggest that Rab29 and its ability to recruit LRRK2 to the TGN is 
significant to this disruption. This phenotype is also consistent with the data 
shown in chapter 3 where VPS35 [D620N] induced disruption of the TGN. This 
is consistent with the reports that VPS35 is upstream of LRRK2 and that the 





The staining for Rab7 in the dopaminergic neurons indicated that the 
manifesting mutant neurons had a lower number of Rab7 positive vesicles 
relative to the control cells and the non-manifesting mutant. This, unlike the 
LAMP1 and Magic Red data, is the opposite phenotype observed in the 
melanocytes with LRRK2 inhibition. The paper mentioned above suggests that 
hyperactive mutations in Rab7 increase the Rab7-GDP bound form (Gómez-
Suaga et al., 2014). Inactive Rab7 is more likely to be cytosolic and could 
account for the lack of Rab7 positive dots. However, it is unclear why the 
manifesting and non-manifesting [G2019S] mutants show different 
phenotypes for this marker. Unlike the melanocytes, the dopaminergic 
neurons do not have melanosomes which removes the ambiguity regarding 
whether we are looking at lysosomes or another related organelle. The data 
suggest that hyperactivating mutations in LRRK2 in this cell type result in wide 
scale defects in the endolysosomal system. 
 
The work in this chapter highlights that hyperactivating mutations in LRRK2 
and inhibition or depletion of LRRK2 do not always have opposite effects. It is 
possible that because LRRK2 is related to Rab proteins, changes in kinase 
activity in either direction cause dysfunction in a Rab cycle which can result in 






5. Chapter 5: LRRK2 and pigmentation  
5.1. Introduction  
Data in Chapter 4 showed clear trafficking defects in Melan-a cells following 
depletion of LRRK2 and inhibition of kinase activity. I next wanted to confirm 
exactly which compartment was affected in this cell type, i.e., is the effect 
specific to melanosomes or lysosomes or are both related compartments 
changed with LRRK2 disruption. The issue experienced previously was that 
many markers used to look at lysosomes would also be markers for 
melanosomes. In order to overcome this, I focused on looking at the 
pigmentation of cells by brightfield and EM as well as looking at specific 
melanosome markers. I also looked at two other cell lines, a pigmented and a 
non-pigmented melanoma cell line, to try and distinguish between effects on 
melanosomes and lysosomes. I also wanted to try and determine the 
mechanisms which underpin the rapid acidification phenotype observed with 
acute LRRK2 inhibition. Whilst working with the melanoma cells, I also looked 
at other key processes affected in melanoma including cell morphology, cell 
growth and cell migration, and the effect of loss of LRRK2.  
 
5.2. LRRK2 and pigmentation in Melan-a cells 
5.2.1. LRRK2 KD increases pigmentation in Melan-a cells 
Following the finding that depletion of LRRK2 increased the protein levels of 
MITF (Figure 4.1), I next looked at Melan-a cells by both brightfield and 
immunofluorescence microscopy to investigate the effect of LRRK2 depletion 
or inhibition on pigmentation. For immunofluorescence, antibodies against 
PMEL and TYRP1 were used as early and late melanosome markers 
respectively (Raposo and Marks, 2007).  
 
Rab27A is the Rab protein responsible for transporting mature melanosomes 
along the melanocyte projections for keratinocyte transfer (Jordens et al., 2006; 
Chiaverini et al., 2008; Wu et al., 2001; Lopes et al., 2007a; Futter et al., 2004). 




perinuclear area (Figure 5.1). Loss of MITF halted melanosome production 
resulting in a decrease in pigmentation. With MITF depletion, any pre-existing 
melanosomes were redistributed to the peri-nuclear space, reflecting loss of 
Rab27A which is itself under the transcriptional control of MITF (Appendix 2) 
(Chiaverini et al., 2008). Melan-a cells also appeared highly stressed with 
MITF depletion with frequent cell death observed (Figure 5.1 x10 images). In 
the case of both Rab27A and MITF depletion, the signal for TYRP1 appeared 
more intense around the perinuclear area due to the concentration of 
melanosomes to the perinuclear space. Depletion of LRRK2 using siRNA 
resulted in a moderate increase in the pigmentation of Melan-a cells (Figure 
5.2) visible from both the brightfield and TYRP1 stained images. This data 
would suggest that depletion of LRRK2 activity results in an increase in 
pigmentation in Melan-a cells. 
 
5.2.2. Inhibition of LRRK2 increases pigmentation 
I wanted to see if these results could be reproduced with LRRK2 inhibition. 
Rapamycin was used as a positive control. It has previously been shown that 
inhibition of the mTOR pathway using Rapamycin induces melanogenesis in 
melanocytes (Hah et al., 2012). Phenylthiourea (PTU) is an inhibitor of the 
enzyme tyrosinase, preventing the synthesis of melanin. Previously, treatment 
of melanocytes with PTU has been shown to result in an increase in early 
stage melanosomes (Chang, 2009) (Figure 5.3).  
 
Inhibition of LRRK2 kinase activity with MLi-2 for 72 hours resulted in an 
increase in pigmentation in Melan-a cells (Figure 5.4). These results suggest 
that LRRK2 acts as a negative regulator of pigmentation in this cell type. 
Although we did see increases in both the TYRP1 staining, as well as changes 
in the brightfield images with LRRK2 inhibition, these cells are very 
heterogenous when it comes to their pigmentation.  This means that there was 
great variation between cells imaged side by side. Staining with PMEL by IF 
comes with the issue that once cells begin to pigment and melanin is deposited 





Figure 5.1 Loss of MITF and Rab27A causes melanosome 
defects 
Melan-a cells treated with 40 nM siRNA for 72 hours were fixed 
in 4% PFA before processing for IF. Cells were stained for the 
late melanosome marker TYRP1. Coverslips were mounted on 
Moviol supplemented with 4’,6-diamidino-2-phenylindole (DAPI). 
Images were acquired with a Nikon Ti-Eclipse widefield 




Figure 5.2 Depletion of LRRK2 increases pigmentation in 
Melan-a cells 
Melan-a cells treated with 40 nM siRNA for 72 hours were fixed 
in 4% PFA before processing for IF. Cells were stained for the 
late melanosome marker TYRP1. Coverslips were mounted on 
Moviol supplemented with 4’,6-diamidino-2-phenylindole (DAPI). 
Images were acquired with a Nikon Ti-Eclipse widefield 








Figure 5.3 Rapamycin and PTU and pigmentation markers 
in Melan-a cells 
Melan-a cells treated with Rapamycin (1 μM) or PTU (200 μM), 
for 72 hours were fixed in 4% PFA before processing for IF. Cells 
were stained for early melanosome marker PMEL and late 
melanosome marker TYRP1. Coverslips were mounted on 
Moviol supplemented with 4’,6-diamidino-2-phenylindole (DAPI). 
Images were acquired with a Nikon Ti-Eclipse widefield 




Additionally, I found that the TYRP1 antibody staining did not always reflect 
pigmentation as seen by brightfield imaging. For example, in the cell 
projections in Figure 5.4. I therefore determined brightfield imaging to be the 
most reliable way of looking at pigmentation. I next took lower magnification 
images of cells treated with MLi-2 to get a more global look at pigmentation 
(Figure 5.5). Inhibition of LRRK2 resulted in an increase in pigmentation after 
24 hours, but not 1 hour treatment. 
                                                                                                                          
                                                                                                                          
                                                                                                                          
                                                                                                                          




                                                                                                                          
                                                                                                                           
                                                                                                                          
                                                                         
 
 
Figure 5.4 Inhibition of LRRK2 increases pigmentation in 
Melan-a cells 
Melan-a cells treated with MLi-2 (200 μM) for 72 hours were fixed 
in 4% PFA before processing for IF. Cells were stained for early 
melanosome marker PMEL and late melanosome marker 
TYRP1. Coverslips were mounted on Moviol. Images were 
acquired with a Nikon Ti-Eclipse widefield microscope x60 






Figure 5.5 LRRK2 inhibition increases pigmentation in 
Melan-a cells 
Melan-a cells were treated with LRRK2 inhibitor MLi-2 (200 nM) 
for the indicated time points. Cells were fixed in 4% PFA and 
coverslips were mounted on Moviol. Images were acquired using 
an LSM800 confocal microscope x20 objective. Scale bar: 50 
μm. 350 nm slice. n=3 biological replicates 
 
5.3.  LRRK2 and LRO in Melanoma cells 
5.3.1. Inhibition of LRRK2 increases acidification in MNT1 
cells 
One of the most striking phenotypes observed in Melan-a cells reported in 
chapter 4 was the rapid and sustained acidification following LRRK2 inhibition 
or depletion. I next wanted to see if the effect of LRRK2 inhibition on 
acidification was specific to Melan-a cells or could be replicated in another cell 
line. To do this, I used the MNT1 melanoma cell line. As discussed in chapter 
3, MNT1 cells are highly pigmented, human melanoma cells which have a 
good level of LRRK2 expression (Figure 3.2).  MNT1 cells treated with LRRK2 
inhibitors HG-10-102-01 and MLi-2 for 48 hours were labelled with the 
LysoTracker Deep Red fluorescent dye and imaged live using confocal 
microscopy (Figure 5.6). LysoTracker images showed an increase in the 
number of acidic organelles with LRRK2 inhibition in MNT1 cells relative to 





Figure 5.6 Inhibition of LRRK2 in MNT1 cells increases the 
number of acidic organelles 
MNT1 cells treated with LRRK2 inhibitors HG-10-102-01 (500 
nM) and MLi-2 (200 nM) for 48 hours were incubated with 0.5 μM 
LysoTracker Deep Red and nuclear dye Hoechst for 1 hour 
before live imaging with a 3i spinning disk confocal microscope 
x63 objective. Scale bar: 20 μm. 350 nm slice. n=3 biological 
replicates. 
 
In Melan-a cells, we saw an accumulation of acidic organelles 1 hour after 
treatment. I wanted to see if this rapid phenotype could be recapitulated in the 
MNT1 line. MNT1 cells were treated with MLi-2 for 1 hour and labelled with 
LysoTracker Deep Red (Figure 5.7). Cells were imaged live to visualise acidic 
organelles. There was a big increase in LysoTracker labelling after 1 hour of 
LRRK2 inhibition in MNT1 cells, consistent with what I had previously 





Figure 5.7 Acute inhibition in MNT1 cells increases acidic 
organelles 
MNT1 cells were treated with MLi-2 inhibitor (200 nM) for 1 hour 
and labelled with LysoTracker Deep Red and nuclear dye 
Hoechst for 1 hour before live imaging with a 3i spinning disk 
confocal microscope x63 objective. Scale bar: 20 μm. 350 nm 
slice. n=1.  
 
Unlike Melan-a cells, MNT1 cells are very homogenous in terms of their 
pigmentation. We therefore looked at the effect of LRRK2 inhibition on staining 
of TYRP1 in these cells. LRRK2 inhibition resulted in an increase in TYRP1 
staining much more consistent than that seen in the Melan-a cells (Figure 5.8). 
The data from MNT1 cells gives support to the idea that the data seen in 






Figure 5.8 LRRK2 inhibition increases TYRP1 staining in 
MNT1 cells 
MNT1 cells were treated with MLi-2 (200 nM) for 24 hours. Cells 
were fixed in 4% PFA before processing for IF. Coverslips were 
mounted on Moviol supplemented with 4’,6-diamidino-2-
phenylindole (DAPI). Cells were stained for late melanosome 
marker TYRP1. Images were acquired with an LSM900 confocal 
microscope. Scale bar 20 μm. 350 nm slice. n=1. 
 
5.3.2. 2 Inhibition of LRRK2 has no effect on LRO number in 
WM266.4 cells 
Next, I investigated if the same increase in LRO number could be observed in 
the non-pigmented human melanoma WM266.4 cells. WM266.4 cells were 
treated with MLi-2 for 48 hours before they were labelled with LysoTracker 
Deep Red fluorescent dye. Cells were imaged live using confocal microscopy 
(Figure 5.9). LRRK2 inhibitor treated cells did not show an increase in 
LysoTracker signal relative to control treated cells. 
 
WM266.4 cells treated with the same LRRK2 inhibitor were fixed after 48 hours 
treatment and stained with an antibody against LAMP1 (Figure 5.10). 




not result in an increase in the number of LAMP1 positive vesicles in WM266.4 
cells. Collectively the LysoTracker and LAMP1 data indicate that the 
phenotypes observed in the Melan-a and MNT1 cell lines are not conserved 
in the WM266.4 melanoma cell line. This could indicate that the changes 
observed in chapter 4 are specific to melanosomes rather than lysosomes, as 





Figure 5.9 Inhibition of LRRK2 in WM266.4 cells does not 
affect the number of acidic organelles 
WM266.4 cells treated with LRRK2 inhibitor MLi-2 (200 nM) for 
48 hours were incubated with 0.5 μM LysoTracker and nuclear 
dye Hoechst for 1 hour before live imaging with a 3i spinning disk 
confocal microscope x63 objective. Scale bar: 20 μm. 350 nm 





Figure 5.10 Inhibition of LRRK2 in WM266.4 cells has no 
effect on lysosome number.  
WM266.4 cells treated with LRRK2 inhibitors HG-10-102-01 (500 
nM) or MLi-2 (200 nM) were fixed in 4% PFA and processed for 
IF. Coverslips were mounted with Moviol supplemented with 4’,6-
diamidino-2-phenylindole (DAPI). Images were acquired with a 3i 
spinning disk confocal microscope x63 objective. Scale bar: 20 
μm. 350 nm slice. n=1. 
 
 
5.4. LRRK2 and cell invasion in Melanoma  
5.4.1. LRRK2 expression correlates with invasion markers in 
melanoma cells 
In melanoma, the loss of pigmentation is often simultaneous with an increase 
in invasive potential of cells. I was interested in the relationship between 
LRRK2 and invasion markers. The EMT switch is associated with solid 
tumours gaining malignancy (Kozar et al., 2019). A classical marker of EMT is 
the loss of E-cadherin and an increase in N-cadherin. Lysates from the 




pigmentation markers were also blotted for their expression of invasion 
markers Figure 5.11. In the melanoma cell lines tested, the levels of LRRK2 
were highest in cells which have high levels of N-Cadherin. For example, 
LRRK2 is highly expressed in the WM266.4 and A375-P cell lines which are 
highly metastatic cells, as well as having lost their pigmentation markers. We 
also blotted for the receptor tyrosine kinase, Axl, which is another protein 
differentially expressed at different stages of melanoma (Flem-Karlsen et al., 
2020; Simmons et al., 2020). High levels of Axl expression have been linked 
to slow cycling, highly invasive, drug resistant melanomas (Kozar et al., 2019). 
 
 
Figure 5.11 Expression of LRRK2 and cell invasion markers 
across cell lines 
20 μg of protein lysate per cell line was analysed by western blot 
probing for the indicated antibodies. n=1. 
 
 
5.4.2. Inhibition of LRRK2 induces cell morphology changes 
When looking at the effect of LRRK2 inhibition in both melanoma cells and the 
melanocytes, I noticed that loss of LRRK2 activity induced a change in 




treated with MLi-2 inhibitor and stained with F-actin probe phalloidin (Figure 
5.12A). This was used to draw around cells, and changes in morphology were 
determined using the shape descriptors tools in FIJI (Figure 5.12B).  For the 
WM266.4 cells I decided that the Aspect Ratio measurement was the most 
appropriate due to the irregular morphology of these cell under baseline 
conditions. The aspect ratio gives the major axis/minor axis. Inhibition of 
LRRK2 resulted in an increase in the aspect ratio of cells. This data shows 
that cells become more elongated with LRRK2 inhibition. 
 
 
Figure 5.12 LRRK2 inhibition in WM266.4 cells alters cell 
morphology 
A WM266.4 cells were treated with MLi-2 (200 nM) for 24 hours. 
Cells were fixed in 4% PFA before processing for IF. Cells were 
stained with Phalloidin-488 dye and coverslips mounted on 
Moviol supplemented with 4’,6-diamidino-2-phenylindole (DAPI). 
Images were acquired with an LSM900 confocal microscope x40 
objective. Scale bar: 50 μm. 350 nm slice. B Phalloidin stain was 
used to draw round cells and the shape descriptors tool in FIJI 
was used to analyse cell morphology. Aspect ratio 
measurements were used for WM266.4 cells. Each dot 
represents an individual cell. Different colours represent different 
experiments. n=2 biological replicates. Analysis: Unpaired t test 






5.4.3. LRRK2 inhibition changes cell morphology in Melan-a 
cells 
I next wanted to see if the same morphology change occurred with LRRK2 
inhibition in Melan-a cells. Melan-a cells were treated with MLi-2, fixed, then 
stained with Phalloidin (Figure 5.13A). Changes in morphology were analysed 
as above. Quantification showed that that there was an increase in the aspect 
ratio of cells with LRRK2 inhibition (Figure 5.13B-C). This is consistent with 
the data from the WM266.4 cells and indicates that indeed LRRK2 inhibition 
results in a more elongated cell morphology. 
 
 
Figure 5.13 Inhibition of LRRK2 alters cell morphology of 
Melan-a cells 
A Melan-a cells were treated with MLi-2 (200 nM) for 24 hours. 
Cells were fixed in 4% PFA before processing for IF. Cells were 
stained with Phalloidin-488 dye and coverslips mounted on Moviol 
supplemented with 4’,6-diamidino-2-phenylindole (DAPI). Images 
were acquired with a LSM900 confocal microscope x40 objective. 
Scale bar: 50 μm. 350 nm slice. B Phalloidin stain was used to draw 
round cells and the shape descriptors tool in FIJI was used to 
analyse cell morphology. Aspect ratio measurements were used for 
Melan-a cells. Each dot represents an individual cell. Different 
colours represent different experiments. Analysis: Unpaired t test 
(**** p<0.0001). n=3 biological replicates. Minimum 52 cells 






5.4.4. LRRK2 depletion does not affect cell proliferation in 
WM266.4 cells 
I was interested to see if LRRK2 depletion would change the rate of 
proliferation in melanoma cells. WM266.4 cells were treated with siRNA 
targeting LRRK2 for 72 hours. After 48 hours, cells were re-plated at two 
densities. The plate was then placed in an Incucyte imaging system and cells 
were imaged at regular intervals over 3 days to monitor cell growth. Images 
were then segmented, and cell density was plotted over time. Loss of LRRK2 
did not have any effect on the rate of cell growth at either density seeded 
(Figure 5.14). Depletion of Rab7 has previously been shown to be essential 
for the high proliferative potential of melanoma cells (Alonso-Curbelo et al., 
2014). Knockdown of Rab7 resulted in a decrease in cell proliferation or cell 




Figure 5.14  LRRK2 depletion has no effect on cell growth 
in WM266.4 cells 
WM266.4 cells were treated with 40 nM siRNA for 72 hours. After 
48 hours cells were replated into a new plate. After 72 hours cells 
were placed into an Incucyte live imaging system and imaged for 
72 hours. Incucyte software was used to segment cells and the 
confluency per well was calculated over time. Plot shows 
confluency normalised to confluency at T0. The average of 3 





5.4.5. Loss of LRRK2 activity decreases cell motility  
I wanted to determine if the loss of LRRK2 kinase activity would affect cell 
motility as LRRK2 expression correlated with cell invasion markers (Figure 
5.11). To do this, WM266.4 cells were seeded at a low density and treated 
with either DMSO or MLi-2 for 24 hours. Cells were then imaged live at regular 
intervals for 24 hours. Cells were then manually tracked using the CellTracker 
GUI in MATLAB. Tracks were input into Chemotaxis software which then 
generated values for each individual cell including the accumulated distance 
(Figure 5.15). Inhibition of LRRK2 resulted in a decrease in the accumulated 
distance of cells over time. This would indicate that LRRK2 activity promotes 
cell motility and may account for the higher expression of LRRK2 in highly 
invasive melanoma cell lines like the WM266.4 cells. 
 
 
Figure 5.15 Inhibition of LRRK2 decreases cell motility in 
WM266.4 cells 
WM266.4 cells were treated with LRRK2 inhibitor MLi-2 (200 nM) 
for 24 hours and then imaged live for the following 24 hours. 
Images were acquired with a Nikon Ti-Eclipse widefield 
microscope x10 objective. Cells were maintained at 5% CO2, 
37 °C throughout imaging. Manual tracks were generated using 
MATLAB CellTracker GUI and the resulting tracks were analysed 
using chemotaxis software. A Average accumulated distance per 
cell. Normalised to DMSO. n=4 biological replicates. Error bars: 
SEM. Analysis: Unpaired t test (* p<0.05) B Accumulated 
distance values for individual cells. n=4 biological replicates. 
Analysis: Unpaired t test (*** p<0.001). Different colours 
represent different biological replicates. Minimum 35 cells 





To confirm the inhibitor data, I repeated the same experiment with LRRK2 
siRNA knockdown in WM266.4 cells. Cells were treated with siRNA targeting 
LRRK2 and after 48 hours were replated at a low density. After a total of 72 
hours, cells were imaged live for a further 24 hours at regular intervals and 
manual tracking data generated as above. The accumulated distance for each 
cell was calculated and plotted (Figure 5.16). Depletion of LRRK2 confirmed 
that loss of LRRK2 kinase activity results in a decrease in the accumulated 
distance of cells. The changes seen with knockdown were more significant 
than those seen with the inhibitor treatment. I used a 72-hour knockdown, 
whereas MLi-2 treatment was for 24 hours which may indicate that this 




Figure 5.16 LRRK2 depletion decreases cell motility in 
WM266.4 cells 
WM266.4 cells were treated with 40 nM siRNA targeting LRRK2 
for 72 hours and then imaged live for the following 24 hours. 
Images were acquired with a Nikon Ti-Eclipse widefield 
microscope x10 objective. Manual tracks were generated using 
MATLAB CellTracker GUI and the resulting tracks were analysed 
using chemotaxis software. A Average accumulated distance per 
cell normalised to NT1. n=3 biological replicates. Error bars: 
SEM. Analysis: Unpaired t test (** p<0.01) B Accumulated 
distance values for individual cells. n=3 biological replicates. 
Analysis: Unpaired t test (**** p<0.0001). Different colours 
represent different biological replicates. Minimum 35 cells 






5.5. LRRK2 and pigmentation by EM 
5.5.1. LRRK2 inhibition increases the number of 
melanosomes by EM 
The lack of acidification and LAMP1 phenotypes observed in the WM266.4 
cells could suggest that the phenotypes observed in Melan-a cells and MNT1 
cells are the result of changes in the melanogenesis pathway. This would 
explain why no changes are seen in acidic organelles or LAMP1 staining in 
WM266.4 cells, as this cell line has lost its pigmentation.   
 
To confirm if inhibition of LRRK2 increases the number of melanosomes in the 
Melan-a cell line, we treated cells with LRRK2 inhibitor MLi-2 for 1 or 24 hours 
before cells were fixed, and samples processed for EM. Whole cells were 
imaged and the total number of melanosomes per cell was quantified (Figure 
5.17). Cells treated with MLi-2 for 24 hours had a clear increase in the number 
of melanosomes per cell. As well as an increase in the number of 
melanosomes, the area of melanosomes was increased at the 24-hour 






Figure 5.17 LRRK2 inhibition increases melanosomes per 
cell and the area of individual melanosomes 
A Melan-a cells were treated with MLi-2 inhibitor (200 nM) for the 
indicated time points. Cells were fixed and processed for EM and 
overview images were acquired. B The number and area of 
individual melanosomes was quantified. Error bars: Range. n=2 
biological replicates. Minimum 10 cells quantified per condition 
per repeat. Different colours represent different experiments.  
 
5.5.2. LRRK2 inhibition does not increase total levels of 
melanogenic markers 
I next checked if these changes in melanosomes were reflected in changes to 
total melanosome marker proteins by western blot. LRRK2 kinase activity was 
inhibited with MLi-2 and lysates analysed by western blot. Total protein levels 
of TYRP1 and PMEL were not changed (Figure 5.18). Melan-a cells were 
treated with siRNA against LRRK2 for 72 hours and lysates analysed by 
western blot. Following LRRK2 depletion the levels of melanosomal proteins 




To confirm, cDNA made from RNA extracted from Melan-a cells treated with 
siRNA targeting LRRK2 was analysed by RT-qPCR using primers against 
TYRP1 and tyrosinase. Neither melanosome marker showed a reproducible 
significant change following LRRK2 depletion confirming the results seen by 
western blot (Figure 5.20). 
 
 
Figure 5.18 LRRK2 inhibition does not increase the levels 
of melanosome markers 
Representative western blot from Melan-a cells treated with MLi-
2 inhibitor (200 nM) for the indicated time points probed with the 








Figure 5.19 LRRK2 depletion does not increase 
melanosome protein expression 
A Representative western blots of Melan-a cells treated with 
siRNA targeting LRRK2 for 72 hours probed for the indicated 
antibodies. B Quantification of A. Error bars: SD. n=3 biological 
replicates represented in different colours. 
 
 
Figure 5.20 LRRK2 depletion does not affect melanosome 
marker transcript levels 
Quantitative RT-qPCR reactions for TYRP1 and tyrosinase were 
performed with cDNA from Melan-a cells transfected with siRNA 
targeting LRRK2 for 72 hours. 2^-ΔΔCt values normalised to 
NT1. n=3 biological replicates. Error bars: SD. Individual repeats 





5.5.3. Acute LRRK2 inhibition changes melanosome 
morphology  
It could be possible that the acute change in acidic organelles with LRRK2 
inhibition are related to the recycling of the v-ATPase from melanosomes. 
Early melanosomes are acidic via the action of an isoform of the v-ATPase 
and are then neutralised in later stages of melanogenesis (Maxson and 
Grinstein, 2014; Tabata et al., 2008). Therefore, the v-ATPase must be 
removed from later stage melanosomes, and ion transporters act to neutralise 
melanosomes prior to transfer. Studies have shown that tubules can extend 
from melanosomes which are thought to recycle melanogenesis machinery 
and cargo (Ripoll et al., 2018). I next looked at EM samples, using a higher 
magnification, at the morphology of melanosomes with LRRK2 inhibition. 
Melanosomes were grouped into four categories: round, elongated, fibrils 
(early) or “halo” (Figure 5.21A-B). The first three categories are typical of the 
four stages of melanogenesis characterised previously (Raposo and Marks, 
2007) (Figure 1.10). I also identified a fourth category I have called the halo 
phenotype. These melanosomes presented with a loose outer membrane 
separating from the main body of the melanosome. There was an increase in 
the number of melanosomes that had the so called “halo” phenotype after 1 
hour of LRRK2 inhibition. It is important to note that these melanosomes were 
also present in the DMSO condition, but at a much lower abundance than in 
the 1 hour treated condition. The number of each phenotype was quantified 
and plotted as a percentage of the total number of melanosomes (Figure 
5.21C). There was an increase in the percentage of melanosomes with the 
halo phenotype after 1 hour of treatment which then dropped back down at the 





Figure 5.21 Acute LRRK2 inhibition alters melanosome 
morphology 
A x720 zoom images from B showing characteristic 
melanosomes from categories 1-4 B Melanosomes from images 
of Melan-a cells treated with MLi-2 (200 nM) for 1-hour were split 
into 4 categories. Minimum 10 cells quantified per condition per 
repeat. C Categories outlined in A and B were plotted as a 
percentage of the total number of melanosomes. Different 
colours represent individual experiments. Error bars: Range. n=2 




5.5.4. Generating melanosome enriched fraction from MLi-2 
treated cells 
In order to get a better idea of what is mechanistically happening at 
melanosomes with LRRK2 inhibition, melanosome enriched fractions were 
prepared from Melan-a cells treated with LRRK2 inhibitor for 1 hour or 24 
hours. Fractions were analysed by western blot, loading PNS and 
melanosome fractions in a 5:1 ratio (Figure 5.22). LRRK2 appeared enriched 
in the melanosome enriched fraction following 24-hour treatment with inhibitor. 
Rab7 also appeared enriched in this fraction at both 1 hour and 24-hour 
treatment with LRRK2 inhibitor. The levels of TYRP1 in the melanosome 
enriched fraction was slightly increased by eye with LRRK2 inhibition. The 
level of Rab32 at this fraction after 24 hours of treatment was increased 
relative to controls but not after 1-hour of inhibition. Quantification of these 
experiments indicated that although these results followed the same trends in 
each repeat, this did not reach statistical significance. There was a high 
amount of variability between repeats of this experiment. This may reflect the 
difference in pigmentation of cells at the time of the experiment, variability in 
the signal given by the antibodies in the western blot and the tricky nature of 
preparing melanosome enriched fractions. However, by eye it was clear that 
LRRK2, Rab7 and Rab32 followed the same trends in all 3 repeats. All western 
blots for the three repeats are shown in Appendix 3.  
 
I also did total membrane fractionations of Melan-a cell treated with MLi-2 for 
1 hour or 24 hours (Figure 5.23). The level of LRRK2 and Rab7 in the total 
membrane fractions did not increase with LRRK2 inhibition. This together with 
the melanosome enriched fractions supports a model where LRRK2 is 





Figure 5.22 Generation of melanosome enriched fractions 
from Melan-a cells treated with LRRK2 inhibitor 
A Melan-a cells were treated with MLi-2 (200 nM) for the 
indicated time points. Cells were homogenised, and then 
subjected to a series of spins to collect a melanosome enriched 
fraction. Fractions were analysed by WB probing for the indicated 
antibodies. The PNS and melanosome enriched fractions were 
loaded in a 5:1 ratio. Representative blot shown. B Quantification 
for A Samples were normalised to DMSO. n=3 biological 







Figure 5.23 Total membrane fractionation with LRRK2 
inhibition 
Melan-a cells were treated with MLi-2 (200 nM) for the 
indicated time points. Cells were homogenised, and total 
membrane fractions were collected from the PNS with a 
100,000 g spin. Fractions were analysed by WB probing for the 





5.6. Inhibition of LRRK2 increases ER-mitochondrial 
contact sites  
Whilst looking at EM images of Melan-a cells treated with LRRK2 inhibitor, 
it appeared that there was a change in the number of ER- mitochondrial 
contact sites (Figure 5.24A). I therefore quantified the number of ER 
mitochondrial contact sites per mitochondria as well as the percentage of 
the total mitochondrial perimeter in a contact site (Figure 5.24B). Contact 
sites were defined as the mitochondrial membrane and ER being within 30 
nm of each other. Treatment with LRRK2 inhibitor for 1 hour increased the 
number of ER- mitochondrial contact sites, a phenotype which was further 
increased at the 24-hour time point. No change was seen in contact site 









Figure 5.24 Inhibition of LRRK2 increases the number of 
ER-mitochondria contact sites 
A Melan-a cells were treated with MLi-2 (200 nM) for the 
indicated time points. Cells were fixed and processed for EM. 
Images were acquired using a TEM microscope. Contact sites 
were counted if mitochondria and ER were within 30 nm of each 
other. B Representative images of +/- MLi-2 are shown. C 
Average ER-mitochondria contact sites per mitochondria. 
Individual points represent different experiments. D Average 
number of contact sites per mitochondria. Points represent 
individual cells. E Average percentage of mitochondrial perimeter 
in a contact site. F Average contact site length. Individual points 
represent different experiments. R1- DMSO- 10 cells, 258 
mitochondria, 178 contact sites, MLi-2 1hr- 9 cells, 465 
mitochondria, 457 contact sites, MLi-2 24 hr- 10 cells, 264 
mitochondria, 344 contact sites R2- DMSO 10 cells, 370 
mitochondria, 238 contact sites, MLi-2 1 hr- 10 cells, 441 
mitochondria, 506 contact sites, MLi-2 24 hr- 10 cells, 446 
mitochondria, 606 contact sites. Error bars: Range. n=2 




5.7.1. LRRK2 and melanogenesis 
In this chapter I show a novel link between the PD associated protein LRRK2 
and melanogenesis. In chapter 4 I showed an inverse relationship between 
LRRK2 and melanogenesis transcription factor MITF. Collectively the data 
from brightfield imaging, immunofluorescence and EM all showed that 
treatment with LRRK2 inhibitor for longer time points, and depletion of LRRK2, 
induces an increase in pigmentation. Melanosome fractionation experiments 
revealed a portion of LRRK2 is localised to the melanosome enriched fractions 
and this pool is enriched with LRRK2 inhibition. The localisation of LRRK2 to 
this organelle has not been previously reported, however, this is undoubtably 
due to the lack of studies in this specialised cell type. Rab32 was also enriched 
in this fraction following LRRK2 inhibition at 24 hours. Rab32 has been shown 
to recruit LRRK2 to endolysosomal compartments in non-pigmented cells 
(Waschbüsch et al., 2014). Therefore, in this specialised cell type, where 
Rab32 plays a role in the trafficking of melanogenesis proteins, LRRK2 may 




To consider how this could relate to the relationship between PD and 
melanoma, we must remember that in PD, LRRK2 is hyperactivated by 
pathogenic mutations. You therefore may expect that hyperactivating 
mutations in LRRK2 would result in a decrease in pigmentation. It is not clear 
how this would affect susceptibility to melanoma. A decrease in pigmentation 
would result in a decrease in the nuclear protective caps formed around cells 
in the skin epidermis which could result in increased vulnerability to DNA 
damage by UV radiation. It could also be that LRRK2 hyperactivation is key 
for the progression of melanoma to later stages of disease. Loss of 
pigmentation is a key marker for the later stages of melanoma coupled with 
an increase in invasiveness. These hypotheses assume that the 
hyperactivating mutations of LRRK2 would result in the opposite phenotype to 
the inhibitor. However, as discussed in chapter 4, this is not always the case.  
 
The EM images revealed a morphology change in melanosomes with 1 hour 
of LRRK2 inhibition. This “halo” phenotype was characterised by a loose or 
baggy outer membrane around the main body of the melanosome. The “halo” 
phenotype was enriched after 1-hour inhibition, but this was resolved by the 
24-hour time point. This phenotype followed the same temporal pattern as the 
LysoTracker and Rab7 phenotypes observed in chapter 4, which would 
support the idea that these changes relate to melanosomes. I confirmed that 
the rapid acidification phenotype was not specific to Melan-a cells by looking 
at MNT1 cells. The finding that LysoTracker labelling and LAMP1 staining 
were unchanged in WM266.4 cells, which are a non-pigmented cell line, 
further supports the assumption that the changes we see are related to 
melanosomes and not lysosomes. Additionally, I did not observe many 
structures by EM which would resemble a lysosome in any of the samples 
imaged.  
 
If we assume that the rapid acidification and halo phenotypes are related, one 
explanation may be that there is a defect in the recycling pathway from 
melanosomes. In this proposed model, acute inhibition would result in the 




It has previously been shown that melanosomes shed some of their machinery 
prior to transfer in a process which is dependent on Myosin VI (Ripoll et al., 
2018). It was shown that depletion of Myosin VI resulted in a failure of the neck 
of the tubules to constrict, leaving wide necked tubules extending from 
melanosomes which take longer to resolve. In the case of LRRK2 inhibition 
we do not see anything that resembles a tubule, but instead a more general 
detachment of the outer membrane which may indicate a failure to properly 
form tubules. LRRK2 has been linked to lysosomal tubule formation in 
response to lysosome permeabilization by LLOME (Malik et al., 2020). There 
may be a related process that occurs in melanosomes which is regulated by 
LRRK2 activity, where inhibition causes a failure in this process accounting for 
the morphology change. Previous work has also shown that LRRK2 is able to 
interact with the v-ATPase a1 subunit, and that selective LRRK2 
hyperactivating mutations result in changes in lysosomal pH (Wallings et al., 
2019b). The data in this thesis would support previous work indicating a role 
for LRRK2 in regulating acidification by the v-ATPase. This is consistent with 
previous studies linking LRRK2 activity to alterations in autophagy, as well as 
lysosomal defects in other cell types (Baptista et al., 2013; Henry et al., 2015; 
Hockey et al., 2015; Gómez-Suaga et al., 2014; Tong et al., 2010b; MacLeod 
et al., 2013).  The work in this chapter proposes a novel role for LRRK2 in 
melanogenesis where acidification by the v-ATPase and recycling of this 
machinery are disrupted with LRRK2 inhibition.  
 
Rab7 has previously been identified as a melanosome related protein 
(Jordens et al., 2006; Gomez et al., 2001). Rab7 was enriched at the 
melanosome enriched fraction following 1-hour and 24-hour inhibition of 
LRRK2. This is in line with the GST-RILP pulldown data in chapter 4 showing 
an increase in GTP-bound Rab7 at both time points. One conclusion from this 
data might be that LRRK2 inhibition results in an increase in GTP-Rab7 which 
is associated with the melanosome membrane. This could explain the rapid 
increase in Rab7 positive vesicles with LRRK2 inhibition. What is still not clear, 
is whether the effects seen at 1 hour and 24 hours are the same process or 




From the melanosome fractionation experiments there’s an enrichment of 
Rab32 and Rab27A at the longer 24-hour time point. These are clear markers 
for the later stages of melanosome formation and transfer (Jordens et al., 2006; 
Raposo and Marks, 2007; Wasmeier et al., 2006; Wu et al., 2001). However, 
the acidification phenotype is related to earlier stages of melanogenesis, 
where melanosomes are not pigmented. This may indicate that there are two 
separate phenotypes- one which is an acute response and one which is seen 
with prolonged treatment. The inverse relationship between LRRK2 and MITF 
may be part of this prolonged response, as the acute phenotypic changes are 
too quick to be dependent on transcription and translation. Collectively these 
findings would be consistent with a model in which LRRK2 acts to negatively 
regulate melanogenesis. The finding that depletion of MITF results in a larger 
increase in the levels of LRRK2 suggests that MITF acts to suppress LRRK2 
expression which may act as a positive feedback mechanism to drive 
melanogenesis in melanocytes. It would be interesting to consider the 
significance of melanosome dysfunction in dopaminergic neurons and if there 
is a role for LRRK2 in the regulation of neuromelanin formation and 
maintenance.   
 
5.7.2. LRRK2 and ER-mitochondrial contact sites 
From the EM images I found that LRRK2 inhibition increases the number of 
ER-mitochondria contact sites in Melan-a cells, with no increase in contact site 
length. LRRK2 has been linked to mitophagy dysfunction by a number of 
studies- a link that is thought to be physiologically relevant to PD (Section 
1.4.11). ER-mitochondrial contact sites are also thought to be significant to 
neurodegenerative diseases. Ca2+ uptake by the mitochondria is essential for 
buffering cytosolic Ca2+. Dopaminergic neurons affected by PD are more 
vulnerable to defects in Ca2+ signalling as they are highly dependent on the 
pace-making regulated by Ca2+ handling (Lee et al., 2018). Both PINK1 loss 
and hyperactivation of LRRK2 have been shown to induce elevation in 
mitochondrial Ca2+. This indicates that Ca2+ homeostasis is generally 




recruited to and promotes ER-mitochondria contact sites (Gelmetti et al., 
2017).  
 
A previous paper looked at the effect of hyperactivating [G2019S] mutation, 
kinase dead [D1994A] mutation and LRRK2 knockout on ER-mitochondria 
contact sites (Toyofuku et al., 2020). They found that both knockout and 
[G2019S] mutation resulted in a decrease in the number of contact sites by 
EM but not the [D1994A] mutation. They also looked by proximity ligation 
assay (PLA) at ER-mito contact sites and found that the [D1994A] mutation 
increased the signal whereas [G2019S] mutation and knockout of LRRK2 
resulted in a loss of contact sites. The data from Melan-a cells would support 
a role for LRRK2 in the maintenance/resolution of ER-mitochondria contact 
sites which is dependent on its kinase activity. ER-mitochondrial contact sites 
have been reported to be significant to neurodegenerative diseases including 
PD. Other PD associated genes including Parkin and alpha synuclein have 
been linked to ER-mitochondria contact sites (Xu et al., 2020; Wilson and 
Metzakopian, 2021).  
 
5.7.3. LRRK2 and melanoma hallmarks 
In this chapter I present data which identify a role for LRRK2 in other cellular 
processes in melanoma. Unlike the negative correlation between LRRK2 
expression and pigmentation, LRRK2 positively correlated with cell invasion 
markers. Cell tracking experiments which showed that inhibition or depletion 
of LRRK2 resulted in a decrease in the accumulated distance travelled by cells, 
would support a role for LRRK2 in promoting cell invasion. Inhibition of LRRK2 
also resulted in a change in the morphology of cells, making them more 
elongated with longer projections. These results could be interpreted as these 
cells undergoing the EMT, common to later stages of cancer. However, as 
seen in Figure 5.11, these cells have already undergone this switch and 
express N-cadherin. You would also expect that if inhibition was promoting an 
EMT phenotype, there would be an increase in invasiveness. In fact, we see 




LRRK2 to promote invasion.  In normal conditions, melanocytes sit in the base 
of the skin epidermis and have elongated projections which are able to contact 
a number of keratinocytes. The change in morphology in WM266.4 cells with 
LRRK2 inhibition may be re-establishing a more characteristic melanocyte 
morphology that was lost when cells were transformed.  
 
LRRK2 depletion had no effect on the cell proliferation of WM266.4 cells. High 
proliferation is important to early-stage tumour formation in melanoma (Li et 
al., 2015). This would indicate that LRRK2 is specifically important to the later 
stages of melanoma progression. This would be consistent with the idea that 
LRRK2 is part of the phenotypic switching model of melanoma progression. 
Previous work has shown how melanoma cells can be highly dependent on 
Rab7 in the early stages of the disease, but that this is then rewired as the 
disease progresses through the later stages (Alonso-Curbelo et al., 2014). The 
cell proliferation experiments confirmed that depletion of Rab7 decreased cell 
growth in melanoma cells, which would be consistent with a role in core tumour 
formation. In melanoma tumours, MITF can act as an oncogene where its 
expression promotes cell survival and proliferation (Garraway et al., 2005). 
However, it has also been found to be key to “phenotypic switching” and found 
to be down regulated in the metastatic populations of cells in melanomas 
(Goodall et al., 2008; Hoek and Goding, 2010). Expression of MITF is 
commonly lost across metastatic melanoma immortalised cell lines, which is 
translated in the loss of pigmentation such as in WM266.4 cells (Figure 3.2). 
The data give evidence that LRRK2 is a previously unidentified marker for the 
phenotypic switch in melanoma. The inverse relationship between LRRK2 and 
MITF is consistent with MITF being a driver of the highly proliferative early-
stage melanomas and LRRK2 being a driver of the highly invasive later stages 






6. Final conclusions 
The molecular mechanisms underlying PD remain poorly understood with 
approximately 85-90% of cases regarded as idiopathic (Bandres-Ciga et al., 
2020). What is very clear from studying familial genes involved in PD is the 
mitophagy and protein homeostasis pathways are key to pathogenesis. 
Hyperactivating mutations in LRRK2 are the most common cause of familial 
PD and result in an autosomal dominant inheritance pattern. There is still much 
debate in the field around the clinically significant substrate(s) of LRRK2. It is 
important to understand the physiological function, as well as the pathogenic 
function, as many pharmaceutical companies are pursuing LRRK2 as a 
therapeutic target. One thing that remains elusive surrounding PD is the 
mechanism underpinning the higher incidence of melanoma in PD patients 
compared to the general population. The work carried out in this thesis aimed 
to gain a deeper understanding of the physiological function of LRRK2 and 
focused specifically on melanoma cells. It also aimed to build a platform which 
will enable future studies to better understand cross talk between LRRK2 and 
other PD related genes such as VPS35. 
 
6.1. LRRK2 and VPS35  
In this thesis I have generated supporting data showing that LRRK2 and 
VPS35 operate in a common pathway. Together with Katy McCarron I 
generated inducible VPS35 WT and [D620N] mutant RPE1 Flp-In cell lines. 
These were made to study the pathogenic mutation in VPS35 which causes 
autosomal dominant forms of PD. We also set up the established GST-RILP 
assay for studying Rab7 activity. Previous work has shown that VPS35 KO 
results in a “hyperactivation” of Rab7 (Jimenez - Orgaz et al., 2018). 
Additionally, hyperactivating mutations in LRRK2 were found to result in a 
decrease in GTP-bound Rab7 which would suggest LRRK2 kinase activity 
negatively regulates Rab7 (Gómez-Suaga et al., 2014). This is consistent with 
data from this thesis which showed that inhibition of LRRK2 increased the pool 




and VPS35 in regulating Rab7 are due to a common or two independent 
pathways. Previous work found VPS35 [D620N] to lie upstream of LRRK2 and 
hyperactivate kinase activity (Mir et al., 2018). Therefore, you would predict 
that induction of VPS35 [D620N] expression would result in an increase in 
LRRK2 kinase activity and a decrease in GTP-Rab7. This is part of ongoing 
work in the laboratory and the work carried out in this thesis generated and 
characterised tools which will be used in future studies to address this question. 
LRRK2 hyperactivation has been shown to result in a disruption of the TGN 
which is dependent on its kinase activity (Liu et al., 2018; Purlyte et al., 2018; 
Beilina et al., 2020). In this thesis I have confirmed that [G2019S] LRRK2 
induces disruption of the TGN and found that the VPS35 [D620N] mutation 
also induces a similar phenotype (Figure 3.16 and Figure 4.19). This is 
consistent with the VPS35 [D620N] mutation being an upstream activator of 
LRRK2 kinase activity, as it can phenocopy the hyperactive LRRK2 mutants. 
In the context of PD, disruption of trafficking from the Golgi would be predicted 
to effect anterograde and retrograde transport of essential lysosomal proteins. 
This dysregulation could lead to changes is protein homeostasis due to 
alterations in lysosomal activity which are predicted to be key factors in PD 
pathology.  
 
6.2. LRRK2 and melanogenesis  
Early work on this project identified a novel relationship between LRRK2 and 
two related transcription factors, MITF and TFEB. Many papers have 
previously indicated a role for LRRK2 in the endolysosomal system which is 
thought to be significant to the pathogenesis of PD (Baptista et al., 2013; 
Giaime et al., 2017; Henry et al., 2015; Hockey et al., 2015; Tong et al., 2012; 
Ysselstein et al., 2019). Initial results indicated that loss of LRRK2 caused 
defects in the later stages of the pathway, with late endosomal and lysosomal 
markers as well as LysoTracker staining being altered. The initial assumption 
was that these results were due to changes in late endosomes and or 
lysosomes and that this was related to the inverse relationship observed 
between LRRK2 and TFEB. However, the finding that 1 hour inhibition of 




initial response is independent of TFEB and transcription. I did not initially 
consider that many markers for the late endosome and lysosomal system, as 
well as LysoTracker dye, will also label melanosomes. In this thesis I show 
that loss of LRRK2 kinase activity results in an increase in pigmentation in 
melanocytes. This is consistent with the finding that LRRK2 expression is 
inversely related to the levels of pigmentation markers across melanoma cell 
lines. With all the data in this thesis considered, it is more likely that the 
phenotypes observed in Melan-a cells are a result of changes in the 
melanogenesis pathway rather than the endolysosomal pathway. The EM data 
in Chapter 5 confirmed that there is an increase in the number of 
melanosomes with LRRK2 inhibition at the longer time point. There was also 
a lack of structures resembling lysosomes by EM which would support that the 
changes are in the melanogenesis pathway.  Additionally, I was unable to 
recapitulate the acidification or LAMP1 phenotypes in the non-pigmented 
WM266.4 melanoma cells, whereas the pigmented MNT1 melanoma cells 
phenocopied the Melan-a melanocytes. This would further suggest changes 
are melanosome related.  
 
By EM there is a change in melanosome morphology with acute inhibition of 
LRRK2 which resolves itself by the 24-hour time point. This is distinct from the 
classical morphologies described previously for the four stages of 
melanogenesis (Raposo and Marks, 2007; Ohbayashi and Fukuda, 2020) and 
different from a previously described defect in melanosome recycling (Ripoll 
et al., 2018). It appears that LRRK2 affects melanogenesis at two stages 
(Figure 6.1). There is an initial response with acute inhibition resulting in rapid 
acidification. This could be due to an effect on the formation and pinching off 
of recycling tubules from melanosomes, or dysregulation of the melanosome 
v-ATPase. LRRK2 has previously been shown to regulate tubule formation 
from lysosomes (Bonet-Ponce et al., 2020). A failure to form tubules would 
explain the halo phenotype observed in Figure 5.21, which is resolved by the 
24-hour time point. At this longer time point there is an increase in later stage 
melanosomes which are neutralised and highly pigmented. In principle, the 




and MITF. However, there is no increase in total melanogenic enzymes 
evidenced by western blot or qPCR, which would suggest that the phenotypes 
are the result of changes in trafficking. LRRK2 has previously been shown to 
be recruited to membranes by Rab32, one of the Rab proteins responsible for 
the delivery of melanogenesis enzymes (Bonet-Ponce et al., 2020). 
Fractionation experiments revealed that LRRK2 is recruited to a melanosome 
enriched fraction in response to inhibition (Figure 5.22). This is a previously 
unreported localisation of LRRK2 which can be attributed to the lack of work 
in these specialised cells. It is possible that in pigmented cells, Rab32 can 
recruit LRRK2 to melanosomes. In non-pigmented cells Rab32 is also able to 
interact with retromer component SNX6, an interaction which was shown to 
effect trafficking of the CIMPR (Waschbüsch et al., 2019). It is unclear whether 
LRRK2’s interaction with Rab32 plays a role in this trafficking. Rab32 could 
play similar role in trafficking and recycling of melanosome components, 
where LRRK2 is recruited to the melanosome membrane. An alternative 
explanation for the accumulation of these proteins would be that acute 
inhibition halts the recycling from melanosomes. This would lead to an 
accumulation of otherwise cycling proteins at the melanosome membrane. 
Overall, the data shown suggest a novel role for LRRK2 in regulating the 
melanogenesis pathway, which may explain why LRRK2 is upregulated in 
later stage melanoma cells where loss of pigmentation is common. It is not 
clear whether the hyperactivating mutations in LRRK2 would have the 
opposite effect on melanocytes and result in a decrease in pigmentation. 
 
The data from my placement in Sheffield from iNPC derived dopaminergic 
neurons, which do not have melanosomes, are consistent with previous 
studies which have shown that changes in LRRK2 kinase activity result in 
changes in the endolysosomal system. LAMP1 staining was dramatically 
increased without a concomitant increase in lysosomal activity. Together this 
may indicate that LRRK2 has two related physiological functions. Perhaps 
LRRK2 can regulate the endolysosomal and lysosome biogenesis pathway in 







Figure 6.1 LRRK2 inhibition alters the melanogenesis 
pathway 
LRRK2 inhibition in melanocytes alters melanogenesis, 
potentially at multiple stages. Acute inhibition results in increased 
acidification. This could be due to a defect in the recycling of the 
v-ATPase. Longer time points result in an increase in the number 
of melanosomes per cell, indicating a change in the later stages 






6.3. LRRK2 and melanoma 
LRRK2 has not previously been linked to melanoma. In this project I show that 
LRRK2 has a characteristic expression pattern where levels are low in 
melanoma cell lines where pigmentation is high, and invasion is low, and that 
LRRK2 is upregulated in non-pigmented, invasive melanoma lines. This 
expression is characteristic of phenotypic switching expression patterns 
observed in melanoma related proteins, (Li et al., 2015; Hoek and Goding, 
2010) and would indicate that LRRK2 activity promotes later stage melanoma 
phenotypes. Data in this thesis showed that LRRK2 inhibition reduces cell 
motility, which suggests that LRRK2 kinase activity, and therefore 
hyperactivating mutations might promote invasion. In contrast to LRRK2, MITF 
and Rab7 have the opposite expression pattern across melanoma cells, and 
are upregulated in early-stage melanomas (Alonso-Curbelo et al., 2014; 
Garraway et al., 2005). Their expression confers advantages such as cell 
proliferation for bulk tumour formation. Loss of Rab7 was shown to result in an 
increase in invasive potential, (Alonso-Curbelo et al., 2014) further supporting 
an upregulation in early-stage melanoma and suppression in late-stage 
melanoma. I have shown that inhibition of LRRK2 increases the pool of GTP-
Rab7 which would in theory reduce cell invasion. Future experiments could 
investigate whether the effect of LRRK2 on cell invasion is dependent on its 
ability to effect Rab7 nucleotide binding status. Collectively the data in this 
thesis propose LRRK2 is a novel marker for the phenotypic switch observed 



















Validation of specificity of GST-RILP assay using GST-beads  
 
 
Appendix 1: Validation of GST-RILP assay with GST-beads 
A BL21 bacteria were transformed with pGEX-6P-1 plasmid. 
Positive colonies were picked into a starter culture which was 
used to inoculate a 1 litre maxi culture. Culture was grown to an 
OD value of 0.6. Protein expression was induced with IPTG for 4 
hours. Pre and post induction samples were taken and resolved 
by SDS-PAGE. Gel was stained with simply blue stain. GST band 
indicated by the red box. B HEK 293 Flp-In cells were lysed in 
Rab7 assay lysis buffer and an input sample was taken. 400 µg 
of protein was loaded onto either GST only or GST-RILP beads 
and spun on a wheel for 2 hours. Flow through and bound 
fractions were collected and analysed by western blotting 



















MITF transcriptionally controls Rab27A expression  
 
 
Appendix 2: MITF transcriptionally controls Rab27A levels 
in Melan-a cells 
Melan-a cells were treated with 40 nM siRNA targeting the 
indicated proteins for 72 hours. Cells were lysed and the lysates 



























All repeats of melanosome fractionations in Melan-a cells  
 
 
Appendix 3: Melanosome fractionations from Melan-a cells 
treated with MLi-2 inhibitor 
Melan-a cells were treated with MLi-2 (200 nM) for the indicated 
time points. Cells were homogenised, and then subjected to a 
series of spins to collect a melanosome enriched fraction. 
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